Směrnice Xxxxxx 2000/32/XX
xx xxx 19. xxxxxx 2000,
xxxxxx xx xx xxxxxxx xxxxx xxxxxxxxxxxx xxxxxxxxxxx pokroku xxxxxxxx Xxxx 67/548/XXX x xxxxxxxxxx xxxxxxxx a xxxxxxxxx xxxxxxxx týkajících xx xxxxxxxxxxx, xxxxxx x označování xxxxxxxxxxxx xxxxx [1]
(Text x xxxxxxxx xxx XXX)
XXXXXX XXXXXXXXXX XXXXXXXXXXXX,
x ohledem xx Xxxxxxx x xxxxxxxx Xxxxxxxxxx xxxxxxxxxxxx,
x xxxxxxx xx xxxxxxxx Xxxx 67/548/XXX xx xxx 27. xxxxxx 1967 x sbližování xxxxxxxx x správních xxxxxxxx xxxxxxxxxx xx xxxxxxxxxxx, balení x xxxxxxxxxx nebezpečných xxxxx [2], xxxxxxxxx xxxxxxxxxx xxxxxxxx Evropského parlamentu x Xxxx 1999/33/XX [3], a xxxxxxx xx xxxxxx 28 xxxxxxx xxxxxxxx,
xxxxxxxx k xxxxx důvodům:
(1) Xxxxxxx X xxxxxxxx 67/548/EHS xxxxxxxx xxxxxx nebezpečných xxxxx společně x xxxxxxxxxx údaji o xxxxxxxxxxx x xxxxxxxxxx xxxxx xxxxx. Xxxxxxxx xxxxxxx x technické xxxxxxxx xxxxxxx, že xx xxx xxx xxxxxx nebezpečných látek x uvedené xxxxxxx xxxxxxxxxxx. Xxxxxxx xxxxxxxx xxxxx xxxxxxxx xxxxxxxx xxxxxx xxxxxxxx oddílů xxxxxxxxx x xxxxxxx X x xxxxxxx X.
(2) Xxxxxxx XXX xxxxxxxx 67/548/XXX xxxxxxxx xxxxxx xxx udávajících xxxxxx xxxxxxxxxx xxxxx xxxxxxxxx x xxxxxxxxxxxx xxxxxxx x xxxxxxxxx. Xxxxxxx IV xxxxxxxx 67/548/XXX xxxxxxxx xxxxxx xxx s bezpečnostními xxxxxx xxxxxxxxxx xx xxxxxxxxxxxx látek a xxxxxxxxx. Xxxxxxx XX xxxxxxxx 67/548/XXX xxxxxxxx xxxxx xx klasifikaci x x xxxxxxxxxx xxxxxxxxxxxx xxxxx a xxxxxxxxx. Některé xxxxxxxx xxxxx xxxxxxxx xxxxxxxx xxxxxx určitých xxxxxx xxxxxx XXX, IV x XX.
(3) V xxxxxxx X xxxxxxxx 67/548/XXX se xxxxxxx xxxxxx xxx stanovení xxxxxxxxx-xxxxxxxxxx xxxxxxxxxx, xxxxxxxx x ekotoxicity látek x xxxxxxxxx. Je xxxxxxxx přizpůsobit xxxx xxxxxxx technickému xxxxxxx.
(4) Xxxxxxx IX xxxxxxxx 67/548/XXX obsahuje xxxxxxxx xxxxxxxx se xxxxxxx xxxxxxxx proti xxxxxxxx xxxxx. Xxxx předpisy xx xxxx xxx xxxxxxxxxxxx x aktualizovány. Xx xxxxxxxx rozšířit xxxxxx, kde se xxxxxxx xxxxxx xxxxx xxxxxxxx dětmi xxxxxxxxx.
(5) Xxxxxxxx xxxx xxxxxxxx xxxx v souladu xx xxxxxxxxxxx Výboru xxx xxxxxxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxx xxx xxxxxxxxxx technických xxxxxxxx xxxxxxx na úseku xxxxxxxxxxxx xxxxx a xxxxxxxxx,
XXXXXXX TUTO SMĚRNICI:
Článek 1
Xxxxxxxx 67/548/EHS xx xxxx xxxxx:
1. Xxxxxxx X xx xxxx xxxxx:
x) odpovídající xxxxxxxx x xxxxxxxxx xx xxxxxxxxx xxxxxxxxx X v xxxxxxx 1X xxxx xxxxxxxx;
x) xxxxxxxxxxxx řádky x xxxxxxx X xx xxxxxxxxx řádky x xxxxxxx 1B této xxxxxxxx;
x) odpovídající xxxxxxx xx nahrazují xxxxxxxxx x příloze 1X xxxx směrnice;
d) xxxxxxxx xx položky v xxxxxxx 1X xxxx xxxxxxxx.
2. Xxxxxxxxxxxx věta x xxxxxxx III xx nahrazuje xxxxxxxxxx xxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxx x xxxxxxx 2 xxxx xxxxxxxx.
3. Xxxxxxx XX se xxxx takto:
a) xxxxxxxxxxxx xxxxxx v xxxxxxx XX xx xxxxxxxxx xxxxxxxxxxxx pokyny xxx xxxxxxxx zacházení v xxxxxxx 3X této xxxxxxxx;
x) xxxxxxxxxxxx pokyny x příloze XX xx nahrazují xxxxxxxxxxxxx xxxxxxxxxxxx xxxxxx pro xxxxxxxx zacházení v xxxxxxx 3X xxxx xxxxxxxx.
4. Část B xxxxxxx X xx xxxx xxxxx:
x) xxxxxxxx X.10 xx xxxxxxxxx xxxxxx x xxxxxxx 4X xxxx xxxxxxxx;
x) xxxxxxxx X.11 se xxxxxxxxx xxxxxx x xxxxxxx 4B této xxxxxxxx;
x) kapitola X.12 xx xxxxxxxxx xxxxxx x xxxxxxx 4C xxxx xxxxxxxx;
x) kapitoly X.13 x X.14 xx xxxxxxxxx xxxxxx x xxxxxxx 4X xxxx směrnice;
e) xxxxxxxx X.17 se nahrazuje xxxxxx x xxxxxxx 4X xxxx xxxxxxxx;
x) xxxxxxxx B.23 xx xxxxxxxxx xxxxxx v xxxxxxx 4X této xxxxxxxx. Název xxxxxxxx X.23 xx vysvětlivce xx xxxx xxxxxxxxxxxxx xxxxxxxx;
x) xxxxxx xx xxxx x xxxxxxx 4X této směrnice.
5. Xxxxxxx xx čtvrtá xxxxxxx obecného úvodu x části X xxxxxxx V.
6. Xxxxxxxxxxxx xxxxx v příloze XX xx nahrazují xxxxx x xxxxxxx 5 xxxx xxxxxxxx.
7. Xxxxxxx IX se xxxx způsobem xxxxxxxx x příloze 6 xxxx směrnice.
Xxxxxx 2
1. Xxxxxxx xxxxx xxxxxx x xxxxxxxx xxxxxx x xxxxxxx předpisy xxxxxxxx xxx dosažení xxxxxxx x xxxxx xxxxxxxx xxxxxxxxxx xx 1. xxxxxx 2001. Xxxxxxxxxx x nich xxxxxxx Xxxxxx.
Xxxx xxxxxxxx xxxxxxx xxxxxxxxx xxxxx xxxx xxxxxxxxx xxxxx xx xxxx xxxxxxxx xxxx xxxx xxxxxx xxxxx xxx xxxxxx při xxxxxx xxxxxxx vyhlášení. Xxxxxx odkazu xx xxxxxxx xxxxxxx xxxxx.
2. Xxxxxxx xxxxx xxxxx Xxxxxx xxxxx xxxxxxxx xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxx xxxxxxxx, xxxxx xxxxxxx x xxxxxxx xxxxxxxxxx xxxx xxxxxxxx, a xxxxxxxxxx xxxxxxx xxxx xxxxxxxx x přijatými xxxxxxxxxxxxxx xxxxxxxxxxxx.
Článek 3
Xxxx xxxxxxxx xxxxxxxx x xxxxxxxx xxxxxx xxxx xx xxxxxxxxx v Xxxxxxx xxxxxxxx Xxxxxxxxxx společenství.
Xxxxxx 4
Xxxx směrnice xx určena členským xxxxxx.
V Xxxxxxx xxx 19. xxxxxx 2000.
Xx Xxxxxx
Xxxxxx Xxxxxxxöx
xxxxxx Xxxxxx
[1] Xxxxxxx po xxxxxxxxxxxx xx xxxxxxx xxxxx.
[2] Úř. xxxx. 196, 16.8.1967, x. 1.
[3] Xx. věst. X 199, 30.7.1999, x. 57.
XXXXXXX 1X
XXXXXXXXX X XXXXXXX X
Xxxxxxxxxx poznámek xxxxxxxxxx xx xxxxxxxxxxxx, xxxxxxxxxxx x xxxxxxxxxx xxxxx
(Xxxxxx se xxxxxxx xxxxx)
PŘÍLOHA 1X
"XXXXXXX A
|
Z |
Symbol |
ES |
DA |
DE |
EL |
EN |
FI |
FR |
IT |
NL |
PT |
SV |
|
18 |
Ar |
Argón |
Argon |
Argon |
Αργό |
Argon |
Argon |
Argon |
Argon |
Argon |
Árgon |
Argon |
|
64 |
Gd |
Gadolinio |
Gadolinium |
Gadolinium |
Γαδολίνιο |
Gadolinium |
Gadolinium |
Gadolinium |
Gadolinio |
Gadolinium |
Gadolínio |
Gadolinium" |
XXXXXXX 1X
|
Xxxxxxxx xxxxx |
Xxxxxxxx xxxxx |
Xxxxxxxx k xxxxxx |
Xxxxx XX |
Xxxxx XXX |
Xxxxxxxxxxx |
Xxxxxxxx |
Xxxxxxxxxxxx xxxxxx |
Xxxxxxxx x xxxxxxxxxx |
|
006–011–00–7 |
xxxxxxxx (XXX) 1-xxxxxx-X-xxxxxxxxxxxxxx |
200–555–0 |
63–25–2 |
Xxxx. kat. 3; X40 Xx; R22 X; R50 |
Xn; N X: 22–40–50 S: (2-)22–24–36/37–46–61 |
|||
|
006–013–00–8 |
xxxxxx-xxxxxxx (XXX) xxxxxxx-X-xxxxxxxxxxxxxxxxxxxx |
205–293–0 |
137–42–8 |
Xx; X22 R31 C; X34 X43 X; X50–53 |
X; X X: 22–31–34–43–50/53 X: (1/2-)26–36/37/39–45–60–61 |
|||
|
006–015–00–9 |
xxxxxx (XXX) 3-(3,4-dichlorfenyl)-1,1-dimethylmočovina |
206–354–4 |
330–54–1 |
Karc. kat. 3; R40 Muta. xxx. 3; X40 Xx; R22–48/22 N; X50–53 |
Xx; N X: 22–40–48/22–50/53 X: (2-)13–22–23–37–46–60–61 |
|||
|
006–016–00–4 |
xxxxxxxx (XXX) 2- xxxxxxxxxxxxxxx-X-xxxxxxxxxxxxxx |
204–043–8 |
114–26–1 |
X; X25 X; X50–53 |
X; X X: 25–50/53 X: (1/2-)37–45–60–61 |
|||
|
006–017–00-X |
aldikarb (XXX) 2-xxxxxx-2-(xxxxxxxxxxxxxx)xxxxxxxx-X-(X-xxxxxxxxxxxxxxx)xxxx |
204–123–2 |
116–06–3 |
X+; X26/28 T; X24 N; R50–53 |
T+; X X: 24–26/28–50/53 X: (1/2-)22–36/37–45–60–61 |
|||
|
006–018–00–5 |
xxxxxxxxx (XXX) 4-(xxxxxxxxxxxxx)-3-xxxxxxxxxxx-X-xxxxxxxxxxxxxx |
217–990–7 |
2032–59–9 |
X; R24/25 X; X50–53 |
X; X X: 24/25–50/53 X: (1/2-)28–36/37–45–60–61 |
|||
|
006–019–00–0 |
xx-xxxxx (XXX) S-(2,3-dichlorallyl)-N,N-diisopropylthiokarbamát |
218–961–1 |
2303–16–4 |
Karc. xxx. 3; X40 Xx; X22 N; X50–53 |
Xx; X R: 22–40–50/53 X: (2-)25–36/37–60–61 |
|||
|
006–020–00–6 |
xxxxxx (XXX) 4-xxxxxxxx-2-xx-1-xx-X -(3-xxxxxxxxxx)xxxxxxxx |
202–930–4 |
101–27–9 |
Xx; X22 X43 N; X50–53 |
Xx; X X: 22–43–50/53 X: (2-)24–36/37–60–61 |
|||
|
006–023–00–2 |
merkaptodimethur (ISO) xxxxxxxxxx 3,5-xxxxxxxx-4-(xxxxxxxxxxxxxx)xxxxx-X -xxxxxxxxxxxxxx |
217–991–2 |
2032–65–7 |
X; X25 X; X50–53 |
X; X R: 25–50/53 X: (1/2-)22–37–45–60–61 |
|||
|
006–024–00–8 |
xxxxxx-xxxxxxx (ISO) xxxxxxx-X-xxxxxxxxx-xxxxxxxxxxxxxx |
205–443–5 |
140–93–2 |
Xx; R22 Xx; X38 X; X51–53 |
Xx; X X: 22–38–51/53 X: (2-)13-61 |
|||
|
006–026–00–9 |
karbofuran (XXX) 2,2-xxxxxxxx-2,3-xxxxxxx-1-xxxxxxxxxx-7-xx-X-xxxxxxxxxxxxxx |
216–353–0 |
1563–66–2 |
X+; R26/28 X; X50–53 |
X+; X X: 26/28–50/53 X: (1/2-)36/37–45–60–61 |
|||
|
006–028–00-X |
dinobuton (XXX) 2-(1-methylpropyl)-4,6-dinitrofenyl-isopropyl-karbonát 2-xxx-xxxxx-4,6-xxxxxxxxxxxx-xxxxxxxxx-xxxxxxxx |
213–546–1 |
973–21–7 |
X; X25 X; X50–53 |
X; X R: 25–50/53 X: (1/2-)37–45–60–61 |
|||
|
006–029–00–5 |
dioxakarb (ISO) 2-(1,3-xxxxxxxx-2-xx)xxxxx-X-xxxxxxxxxxxxxx |
230–253–4 |
6988–21–2 |
X; R25 N; X51–53 |
X; X X: 25–51/53 S: (1/2-)37–45–61 |
|||
|
006–033–00–7 |
metoxuron (XXX) 3-(3-xxxxx-4-xxxxxxxxxxxx)-1,1-xxxxxxxxxxxxxxxx |
243–433–2 |
19937–59–8 |
X; R50–53 |
N X: 5 0/ 5 3 X: 60-61 |
|||
|
006–034–00–2 |
xxxxxxx (XXX) X-xxxxxx-X-xxxxx-X-xxxxxxxxxxxxxxxxx |
214–215–4 |
1114–71–2 |
Xx; X22 N; R51–53 |
Xn; X X: 22–51/53 X: (2-)23-61 |
|||
|
006–035–00–8 |
pirimikarb (XXX) 2-(xxxxxxxxxxxxx)- 5,6-xxxxxxxx xxxxxxxxx-4-xx-X,X-xxxxxxxxxxxxxxxx |
245–430–1 |
23103–98–2 |
X; X25 X; R50–53 |
T; X X: 25–50/53 X: (1/2)22–37–45–60–61 |
|||
|
006–037–00–9 |
xxxxxxxxx (ISO) 3-xxxxxxxxx-5-xxxxxxxxxxx-X-xxxxxxxxxxxxxx |
220–113–0 |
2631–37–0 |
X; X25 N; X50–53 |
X; N X: 25–50/53 X: (1/2-)24–37–45–60–61 |
|||
|
006–038–00–4 |
xxxxxxxxx (XXX) 2-chlorallyl-N,N-dimethyldithiokarbamát |
E |
202–388–9 |
95–06–7 |
Karc. xxx. 2; R45 Xx; X22 N; X50–53 |
X; X X: 45–22–50/53 X: 53–45–60–61 |
||
|
006–039–00-X |
tri-allát (ISO) X-(2,3,3-xxxxxxxxxxxxx)-X,X-xxxxxxxxxxxxxxxxxxxxxxx |
218–962–7 |
2303–17–5 |
Xx; X22–48/22 X43 X; X50–53 |
Xx; X X: 22–43–48/22–50/53 S: (2-)24–37–60–61 |
|||
|
006–042–00–6 |
xxxxxxx (XXX) 3-(4-xxxxxxxxxx)-1,1-xxxxxxxxxxxxxxxx |
205–766–1 |
150–68–5 |
Xxxx. xxx. 3; X40 Xx; X22 X; X50–53 |
Xx; X X: 22–40–50/53 X: (2-)36/37–60–61 |
|||
|
006–043–00–1 |
monuron-TCA 3-(4-xxxxxxxxxx)-1,1-xxxxxxxxxxxxxxx-xxxxxxxxxxxxxx |
— |
140–41–0 |
Xx; X36/38 Xxxx. xxx. 3; X40 X; X50–53 |
Xx; X X: 36/38–40–50/53 X: (2-)36/37–60–61 |
|||
|
006–045–00–2 |
xxxxxxxx (XXX) methyl-N-[(N-methylkarbamoyl)oxy]thioacetimidát |
240–815–0 |
16752–77–5 |
T+; X28 X; X50–53 |
X+; X X: 28–50/53 X: (1/2-)22–36/37–45–60–61 |
|||
|
006–046–00–8 |
xxxxxxxxxx (XXX) 2,2-xxxxxxxx-1,3-xxxxxxxxxxx-4-xx-X-xxxxxxxxxxxxxx |
245–216–8 |
22781–23–3 |
X; R23/25 Xn; X21 X; R50–53 |
T; X R: 21–23/25–50/53 X: (1/2-)22–36/37–45–60–61 |
|||
|
006–047–00–3 |
xxxxxxxxx (XXX) xxxx: 3-(1-xxxxxxxxxxx)xxxxx-X-xxxxxxxxxxxxxxx x 3-(1-xxxxxxxxxxx)xxxxx-X-xxxxxxxxxxxxxxx |
— |
8065–36–9 |
X; R24/25 N; X50–53 |
X; N R: 24/25–50/53 X: (1/2-)28–36/37–45–60–61 |
|||
|
006–048–00–9 |
ethiofenkarb (XXX) 2-[(xxxxxxxxxxxxx)xxxxxx]xxxxx-X-xxxxxxxxxxxxxx |
249–981–9 |
29973–13–5 |
Xx; R22 X; X50–53 |
Xx; X X: 22–50/53 X: (2-)60-61 |
|||
|
006–050–00–X |
xxxxxxx-XXX 3-xxxxx-1,1-xxxxxxxxxxxxxxx-xxxxxxxxxxxxxx |
— |
4482–55–7 |
Xx; X38 X; X50–53 |
Xx; X X: 38–50/53 S: (2-)60-61 |
|||
|
006–053–00–6 |
xxxxxxxxxx (ISO) 2-xxxxxxxxxxxxxx-X-xxxxxxxxxxxxxx |
220–114–6 |
2631–40–5 |
Xx; X22 X; X50–53 |
Xx; X X: 22–50/53 X: (2-)60-61 |
|||
|
006–054–00–1 |
xxxxxxxxxx (XXX) 4-(xxxxxxxxxxxxx)-3,5-xxxxxxxxxxxxx-X-xxxxxxxxxxxxxx |
206–249–3 |
315–18–4 |
X+; X28 Xx; X21 X; X50–53 |
X+; X X: 21–28–50/53 X: (1/2-)36/37–45–60–61 |
|||
|
006–057–00–8 |
nitrapyrin (XXX) 2-xxxxx-6-(xxxxxxxxxxxxxx)xxxxxxx |
217–682–2 |
1929–82–4 |
Xx; R22 X; X51–53 |
Xx; X R: 22–51/53 S: (2-)24-61 |
|||
|
006–060–00–4 |
oxykarboxin (XXX) 2-xxxxxx-4,4-xxxxx-5,6-xxxxxxx-4λ4-1,4-xxxxxxxx-3-xxxxxxxxxxxx |
226–066–2 |
5259–88–1 |
Xx; X22 X52–53 |
Xx R:22–52/53 S: (2-)61 |
|||
|
006–069–00–3 |
xxxxxxxxx-xxxxxx (ISO) 1,2-xx[3-(xxxxxxxxxxxxxxx)xxxxxxxxxx]xxxxxx |
245–740–7 |
23564–05–8 |
Xxxx. xxx. 3; X40 X; X50–53 |
Xx; X X: 40–50/53 X: (2-)36/37–60–61 |
|||
|
006–070–00–9 |
xxxxxxxxxxx N-cyklohexyl-N-methoxy-2,5-dimethyl-3-furamid |
262–302–0 |
60568–05–0 |
Karc. xxx. 3; R40 X; X50–53 |
Xx; X X: 40–50/53 X: (2-)36/37–60–61 |
|||
|
006–088–00–7 |
xxxxxxxxxxx (XXX) xxxxx-X -[({[(2,2-xxxxxxxx-2,3-xxxxxxx-1-xxxxxxxxxx-7-xx)xxx]xxxxxxxx}xxxxxxxxxxx)xxxxxxxx]-X-xxxxxxxxx-β-xxxxxxxx(2,2-xxxxxxxx-2,3-xxxxxxx-1-xxxxxxxxxx-7-xx)-X-({[2-(xxxxxxxxxxxxxx)xxxxx]xxxxxxxxxxxxxx}xxxxxxxx)-X-xxxxxxxxxxxxxx |
— |
82560–54–1 |
X; X23/25 N; X50–53 |
X; X X: 23/25–50/53 X: (1/2-)36/37–45–60–61 |
|||
|
007–012–00–5 |
X,X-xxxxxxxxxxxxxxxx 1,1-xxxxxxxxxxxxxxxx |
X |
200–316–0 |
57–14–7 |
X; X11 Karc. xxx. 2; X45 X; X23/25 X; R34 X; X51–53 |
X; T; X X: 45–11–23/25–34–51/53 X: 53–45–61 |
||
|
007–013–00–0 |
N,N-dimethylhydrazin 1,2-dimethylhydrazin |
E |
— |
540–73–8 |
Karc. xxx. 2; R45 X; R23/24/25 N; X51–53 |
X; N R: 45–23/24/25–51/53 S: 53–45–61 |
X ≥ 25 %: X; X45–23/24/25 3 % &xx; C &xx; 25 %: X; R45–20/21/22 0,01 % < C &xx; 3 %: X; X45 |
|
|
009–003–00–1 |
xxxxxxxx xxxxxxxxxxxxxx … % |
X |
231–634–8 |
7664–39–3 |
X+; R26/27/28 X; R35 |
T+; X X: 26/27/28–35 X: (1/2-)7/9–26–36/37–45 |
X ≥ 7 %: X+; X; X26/27/28–35 1 % ≤ X &xx; 7 %: T; X23/24/25–34 0,1 % ≤ C &xx; 1 %: Xx; X20/21/22–36/37/38 |
|
|
015–039–00–9 |
xxxxxxx-xxxxxx (XXX) O,O-dimethyl-S -[(4(3 H)-oxo-1,2,3-benzotriazin-3-yl)methyl]-fosforodithioát |
201–676–1 |
86–50–0 |
T+; R26/28 X; R24 X43 X; X50–53 |
X+; N X: 24–26/28–43–50/53 X: (1/2-)28–36/37–45–60–61 |
|||
|
015–048–00–8 |
xxxxxxxx (XXX) X,X-xxxxxxxx-X-[3-xxxxxx-4-(xxxxxxxxxxxxxx)xxxxx]-xxxxxxxxxxxxx |
200–231–9 |
55–38–9 |
Xxxx. xxx. 3; X40 X; X23–48/25 Xx; X21/22 X; X50–53 |
X; X R: 21/22–23–40–48/25–50/53 X: (1/2-)36/37–45–60–61 |
|||
|
015–056–00–1 |
xxxxxxx-xxxxx (XXX) X,X-xxxxxxx-X-[(4(3 H)-oxo-1,2,3-benzotriazin-3-yl)methyl]-fosforodithioát |
220–147–6 |
2642–71–9 |
T+; R28 X; X24 N; X50–53 |
X+; X X: 24–28–50/53 S: (1/2-)28–36/37–45–60–61 |
|||
|
015–140–00–8 |
triazofos (XXX) X,X-xxxxxxx-X-(1-xxxxx-1 H- 1,2,4-xxxxxxx-3-xx)-xxxxxxxxxxxxx |
245–986–5 |
24017–47–8 |
X; X23/25 Xn; X21 N; R50–53 |
T; X X: 21–23/25–50/53 X: (1/2-)36/37–45–60–61 |
|||
|
016–013–00-X |
xxxxxxx sirnatý |
234–129–0 |
10545–99–0 |
R14 X; X34 X; X50 |
X; X X: 14–34–50 X: (1/2-)26–36/37/39–45–61 |
X ≥ 10 %: X; X34 5 % ≤ C &xx; 10 %: Xx; X36/37/38 |
||
|
016–014–00–5 |
xxxxxxx xxxxxxxx |
— |
13451–08–6 |
X14 X; R34 X; X50 |
X; X X: 14–34–50 X: (1/2-)26–36/37/39–45–61 |
X ≥ 10 %: X; X34 5 % ≤ X &xx; 10 %: Xx; X36/37/38 |
||
|
016–023–00–4 |
xxxxxxxx-xxxxxx |
X |
201–058–1 |
77–78–1 |
Xxxx. xxx. 2; X45 Muta. xxx. 3; X40 X+; X26 T; X25 C; X34 X43 |
X+ X: 45–25–26–34–43 X: 53-4 5 |
X ≥ 25 %: X+; R45–25–26–34–43 10 % ≤ C &xx; 25 %: X+; X45–22–26–34–43 7 % ≤ X &xx; 10 %: X+; X45–22–26–36/ 37/38–43 5 % ≤ X &xx; 7 %: T; R45–22–23–36/37/38–43 3 % ≤ X &xx; 5 %: X; R45–22–23–43 1 % ≤ X &xx; 3 %: X; X45–23–43 0,1 % ≤ X < 1 %: X; X45–20 0,01 % ≤ X &xx; 0,1 %:X; R45 |
|
|
016–024–00-X |
dimexano (XXX) xxx(xxxxxxxxxxxxxxxxxxx)xxxxxxxx |
X,X′-xxxxxxxx-xxxxxxxxxxx(xxxxxxxxxxx)215–993–8 |
1468–37–7 |
Xx; X22 X; X50–53 |
Xx; X X: 22–50/53 S: (2-)60-61 |
|||
|
016–071–00–6 |
3-xxxxx-6,13-xxxxxxx-10-[(3-{[4-xxxxx-6-(2-xxxxxxxxxxxxxxxx)- 1,3,5-xxxxxxx-2-xx]xxxxx}xxxxxx)xxxxx][1,4]xxxxxxxxxxx[2,3-x]xxxxxxxxx-4,11-xxxxxxxxxx xxxxxxxx |
410–130–3 |
136248–03–8 |
X43 |
Xx X: 43 S: (2-)22–24–37 |
|||
|
022–001–00–5 |
chlorid xxxxxxxxxx |
231–441–9 |
7550–45–0 |
X14 C; R34 |
C X: 14-34 X: (1/2-)7/8–26–36/37/39–45 |
X ≥ 10 %: C; X34 5 % ≤ X &xx; 10 %: Xx; X36/37/38 |
||
|
030–004–00–8 |
xxxxxxxxxxxxx [1] xxxxxxxxxxxx [2] |
208–884–1 [1] 209–161–3 [2] |
544–97–8 [1] 557–20–0 [2] |
X14 X; X17 X; X34 X; R50–53 |
F; X; X R: 14–17–34–50/53 S: (1/2-)16–43–45–60–61 |
|||
|
050–002–00–0 |
xxxxxxxxx (XXX) tricyklohexyl(hydroxy)stannan xxxxxxxxxxxxxxxxxxxxx-xxxxxxxx |
236–049–1 |
13121–70–5 |
Xx; X20/21/22 N; X50–53 |
Xx; X X: 20/21/22–50/53 X: (2-)13–60–61 |
|||
|
050–012–00–5 |
xxxxxxxxxxxxxxxxxxxxxx [1] xxxxx(xxxxxxxxxxxxx)xxxxxxx [2] butyl(tricyklohexyl)stannan [3] |
215–910–5 [1] 221–437–5 [2] 230–358–5 [3] |
1449–55–4 [1] 3091–32–5 [2] 7067–44–9 [3] |
Xx; X20/21/22 X; X50–53 |
Xx; N X: 20/21/22–50/53 X: (2-)26–28–60–61 |
X ≥ 1 %: Xx; X20/21/22 |
1 |
|
|
050–017–00–2 |
xxxxxxxxxxxxxx (XXX) 1,1,1,3,3,3-xxxxxxx(2-xxxxx-2-xxxxxxxxxxxx)xxxxxxxxxxx |
236–407–7 |
13356–08–6 |
X+; X26 Xx; X36/38 X; X50/53 |
X+; N R: 26–36/38–50/53 X: (1/2-)28–36/37–45–60–61 |
|||
|
082–009–00–X |
xxxx (xxxxxxxxxxxx olovnatý) CI Xxxxxxx Xxxxxx 34 (XX 77603) XX xxxxxxxxxx žluť 34 (XX 77603) |
215–693–7 |
1344–37–2 |
Xxxx. xxx. 3; X40 Xxxx. xxx. 1; X61 Xxxx. xxx. 3; X62 X33 X; X50–53 |
X; X R: 61–33–40–50/53–62 X: 53–45–60–61 |
1 |
||
|
082–010–00–5 |
červeň (xxxxxxx-xxxxxxxxxx-xxxxx xxxxxxxx) XX Xxxxxxx Red 104 (XX 77605) XX xxxxxxxxxx červeň 104 (XX 77605) |
235–759–9 |
12656–85–8 |
Karc. kat. 3; R40 Xxxx. xxx. 1; X61 Xxxx. xxx. 3; X62 R33 X; X50–53 |
X; X X: 61–33–40–50/53–62 S: 53–45–60–61 |
1 |
||
|
601–024–00-X |
xxxxx [1] xxxxxxxxxxxx [2] |
202–704–5 [1] 203–132–9 [2] |
98–82–8 [1] 103–65–1 [2] |
X10 Xx; X65 Xx; X37 X; X51–53 |
Xx; X X: 10–37–51/53–65 X: (2-)24–37–61–62 |
4 |
||
|
601–032–00–3 |
benzo[a]pyren xxxxx[xxx]xxxxxxx |
200–028–5 |
50–32–8 |
Xxxx. xxx.2; R45 Muta. xxx. 2; X46 Xxxx. xxx. 2; X60–61 N; R50–53 |
T; X X: 45–46–60–61–50/53 X: 53–45–60–61 |
|||
|
601–034–00–4 |
xxxxx[x]xxxxxxxxxxxxxxx |
205–911–9 |
205–99–2 |
Xxxx. xxx.2; X45 N; X50–53 |
X; X X: 45–50/53 X: 53–45–60–61 |
|||
|
602–035–00–2 |
1,4-xxxxxxxxxxxxx x-xxxxxxxxxxxxx |
203–400–5 |
106–46–7 |
Xx; X36 X; R50–53 |
Xi; X X: 36–50/53 X: (2-)24/25–46–60–61 |
|||
|
602–054–00–6 |
3-jodprop-1-en xxxxxxxxxx |
209–130–4 |
556–56–9 |
X10 X; X34 |
X R: 10-34 X: (1/2-)7–26–45 |
|||
|
603–076–00–9 |
but-2-yn-1,4-diol |
203–788–6 |
110–65–6 |
T; X23/25 Xx; X21–48/22 X; X34 |
X X: 21–23/25–34–48/22 X: (1/2-)26–36/37/39–45 |
X ≥ 50 %: X; X21–23/25–34–48/22 25 % ≤ X &xx; 50 %: X; X21–23/25–36/38–48/22 10 % ≤ X &xx; 25 %: Xx; R20/22–48/22 3 % ≤ X &xx; 10 %: Xx; R20/22 |
||
|
603–091–00–0 |
exo-4-isopropyl-1-methyl-7-oxabicyklo[2.2.1]heptan-2-ol |
402–470–6 |
87172–89–2 |
O; X8 Xx; X22 Xx; X36 |
X; Xn R: 8–22–36 S: (2-)26 |
|||
|
603–093–00–1 |
xxx-(±)-4-xxxxxxxxx-1-xxxxxx-2-[(2-xxxxxxxxxxxx)xxx]-7-xxxxxxxxxx[2.2.1]xxxxxx |
402–410–9 |
87818–31–3 |
Xx; X20 X; R51–53 |
Xn; X X: 20–51/53 X: (2-)23-61 |
|||
|
603–097–00–3 |
1,1', 1′′-xxxxxxxxxxxxxxxx-2-xx xxxxxxxxxxxxxxxxxx |
204–528–4 |
122–20–3 |
Xx; X36 R52–53 |
Xi X:36–52/53 X: (2-)26-61 |
|||
|
603–117–00–0 |
xxxxxx-2-xx xxxxxxxxxxxxxxxx isopropanol |
200–661–7 |
67–63–0 |
F; X11 Xx; X36 X67 |
X; Xx X: 11–36–67 X: (2-)7–16–24/25–26 |
|||
|
604–020–00–6 |
xxxxxxx-2-xx 2-xxxxxxxxxxxxxx 2-xxxxxxxxxx (XXX) |
201–993–5 |
90–43–7 |
Xx; X36/37/38 X; R50 |
Xi; X X: 36/37/38–50 X: (2-)22-61 |
|||
|
604–021–00–1 |
2-xxxxxxxxxx, xxxxx sůl xxxxxxx-2-xxxxxxxxxxxx 2-xxxxxxxxx xxxxx xxxxxxx-xxxxxxx-2-xxxx |
205–055–6 |
132–27–4 |
Xx; X22 Xx; X37/38–41 N; R50 |
Xn; X X: 37/38–41–50 X: (2-)22–26–61 |
|||
|
604–024–00–8 |
4,4'-(4-xxxxxxxxxxxx-2,2-xxxx)xxxxxxx 2,2-xxx(4-xxxxxxxxxxxx)-4-xxxxxxxxxxxx |
401–720–1 |
6807–17–6 |
Xxxx. xxx. 2; X60 Xx; R36 N; X50–53 |
X; X R: 60–36–50/53 X: 53–45–60–61 |
|||
|
604–041–00–0 |
acifluorfen [1] acifluorfen-natrium [2] 5-[2-xxxxx-4-(xxxxxxxxxxxxxx)xxxxxx]-2-xxxxxxxxxxxxx xxxxxxxx [1] xxxxxxx-5-[2-xxxxx-4-(xxxxxxxxxxxxxx)xxxxxx]-2-xxxxxxxxxxxx [2] |
256–634–5 [1] 263–560–7 [2] |
50594–66–6 [1] 62476–59–9 [2] |
Xx; R22 Xx; R38–41 X; X50–53 |
Xx; X R: 22–38–41–50/53 X: (2-)24–39–60–61 |
|||
|
604–043–00–1 |
xxxxxxxxxxxxxxxx (4-xxxxxxxxxxxx)xxxxx xxxxxxxxxxxxxxxxxxxxxxxxxx 4-(xxxxxxxxx)xxxxx |
203–083–3 |
103–16–2 |
Xx; X36 X43 |
Xx X: 36-43 X: (2-)24/25–26–37 |
|||
|
604–044–00–7 |
xxxxxxxx 4-xxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxxx |
205–769–8 |
150–76–5 |
Xx; X22 Xx; X36 R43 |
Xn X: 22–36–43 X: (2-)24/25–26–37/39–46 |
|||
|
605–016–00–7 |
xxxxxxx… % xxxxxxxxx… % |
X |
203–474–9 |
107–22–2 |
Xxxx. xxx. 3; X40 Xx; X20 Xx; X36/38 R43 |
Xn X: 20–36/38–40–43 X: (2-)36/37 |
X ≥ 10 %: Xn; X20–36/38–40–43 1 % ≤ X < 10 %: Xx; R40–43 |
|
|
606–016–00-X |
pindon (XXX) 2-(xxxxxxxxxxxxxxx)xxxxx-1,3-xxxx |
201–462–8 |
83–26–1 |
X; X25–48/25 X; X50–53 |
X; X X: 25–48/25–50/53 X: (1/2-)37–45–60–61 |
|||
|
606–018–00–0 |
xxxxxxx (ISO) 2,3-xxxxxxx-1,4-xxxxxxxxxxx |
204–210–5 |
117–80–6 |
Xx; X22 Xx; X36/38 X; X50–53 |
Xx; X X: 22–36/38–50/53 S: (2-)26–60–61 |
|||
|
606–019–00–6 |
xxxxxxxxxx (XXX) perchlorpentacyklo[5.3.0.02,6.03,9.04,8]dekan-5-on xxxxxxxxxxxxxxxxxxx[5.2.1.02,6.03,9.05,8]xxxxx-4-xx 1,2,4,5,6,7,8,8,9,10-dekachlorpentacyklo[5.3.0.02,6.04,10.05,9]dekan-3-on |
205–601–3 |
143–50–0 |
Karc. xxx. 3; X40 X; X24/25 X; X50–53 |
X; X X: 24/25–40–50/53 X: (1/2-)22–36/37–45–60–61 |
|||
|
606–034–00–8 |
metribuzin (ISO) 4-xxxxx-6-xxxx-xxxxx-3-(xxxxxxxxxxxxxx)-1,2,4-xxxxxxx-5(4 H)-on 4-amino-6-terc-butyl-3-(methylsulfanyl)-4,5-dihydro-1,2,4-triazin-5-on |
244–209–7 |
21087–64–9 |
Xn; X22 X; R50–53 |
Xn; X X: 22–50/53 X: (2-)60-61 |
|||
|
606–035–00–3 |
xxxxxxxxxxx (XXX) 5-xxxxx-4-xxxxx-2-xxxxxxxxxxxxxx-3(2X)-xx pyrazon |
216–920–2 |
1698–60–8 |
R43 N; X50–53 |
Xx; N X: 43–50/53 X: (2-)24–37–60–61 |
|||
|
606–036–00–9 |
xxxxxxxxxxxxxx (XXX) 6-methyl-2 X-[1,3]xxxxxxxx[4,5-x]xxxxxxxxxx-2-xx |
219–455–3 |
2439–01–2 |
Xxxx. xxx. 3; R62 Xx; R20/21/22–48/22 Xi; X36 X43 N; X50–53 |
Xx; X R: 20/21/22–36–43–48/22–50/53–62 X: (2-)24–37–60–61 |
|||
|
606–037–00–4 |
xxxxxxxxxxx (XXX) 1-(4-xxxxxxxxxxx)- 3,3-xxxxxxxx-1-(1,2,4-xxxxxxx-1-xx)xxxxx-2-xx |
256–103–8 |
43121–43–3 |
Xx; X22 X; X51–53 |
Xx; X X: 22–51/53 X: (2-)61 |
|||
|
606–044–00–2 |
2,4,6-trimethylbenzofenon xxxxx(2,4,6-xxxxxxxxxxxxxx)xxxxxxxx |
403–150–9 |
954–16–5 |
Xx; X22 Xx; X36 X; X50–53 |
Xx; X X: 22–36–50/53 X: (2-)26–60–61 |
|||
|
607–043–00-X |
xxxxxxx (ISO) 3,6-dichlor-2-methoxybenzoová xxxxxxxx |
217–635–6 |
1918–00–9 |
Xx; R22 Xi; X41 X52–53 |
Xx; N X: 22–41–52/53 X: (2-)26-61 |
|||
|
607–057–00–6 |
xxxxxxxxx (XXX) 3-[1-(4-chlorfenyl)-3-oxobutyl]-4-hydroxykumarin3-[1-(4-chlorfenyl)-3-oxobutyl]-4-hydroxy-2 X-xxxxxxx-2-xx |
201–378–1 |
81–82–3 |
Xx; X48/22 R52–53 |
Xn X:48/22–52/53 X: (2-)37-61 |
|||
|
607–058–00–1 |
kumafuryl (XXX) xxxxxxx (XX)-3-[1-(2-xxxxx)-3-xxxxxxxx)]-4-xxxxxxxxxxxxxx (XX)-3-[1-(2-xxxxx)-3-xxxxxxxx)]-4-xxxxxxx-2 H -xxxxxxx-2-xx 3-[1-(2-xxxxx)-3-xxxxxxxx]-4-xxxxxxxxxxxxxx 3-[1-(2-xxxxx)-3-xxxxxxxx]-4-xxxxxxx-2 X -xxxxxxx-2-xx |
204–195–5 |
117–52–2 |
X; X25–48/25 X52–53 |
X X:25–48/25–52/53 S: (1/2-)37–45–61 |
|||
|
607–079–00–6 |
xxxxxxx (XXX) xxxxx-4-xxx-5-(xxxxxxxx-5-xxxxxxxxxxxxxxxxx[5.3.0.02,6.03,9.04,8]xxxxx-5-xx)xxxxxxxxx xxxxx-5-(1,2,3,5,6,7,8,9,10,10-xxxxxxxxx-4-xxxxxxxxxxxxxxxxx[5.2.1.02,6.03,9.05,8]xxxxx-4-xx)-4-xxxxxxxxxxxx xxxxx-5-(1,2,4,5,6,7,8,8,9,10-xxxxxxxxx-3-xxxxxxxxxxxxxxxxx[5.3.0.02,6.04,10.05,9]xxxxx-3-xx)-4-xxxxxxxxxxxx |
— |
4234–79–1 |
X; R24 Xx; X22 X; X51–53 |
X; X R: 22–24–51/53 X: (1/2-)36/37–45–61 |
|||
|
607–097–00–4 |
xxxxxx-1,2,4-xxxxxxxxx-1,2-xxxxxxxx 1,2-xxxxxxxx xxxxxx-1,2,4-xxxxxxxxxxxxxx xxxxxxxx trimellitanhydrid |
209–008–0 |
552–30–7 |
Xi; X37–41 X42/43 |
Xx X: 37–41–42/43 X: (2-)22–26–36/37/39 |
|||
|
607–143–00–3 |
xxxxxxxxx xxxxxxxx valerová xxxxxxxx |
203–677–2 |
109–52–4 |
X; X34 X52–53 |
X X:34–52/53 X: (1/2-)26–36–45–61 |
|||
|
607–152–00–2 |
2,3,6-TBA (XXX) 2,3,6-xxxxxxxxxxxxxxxx kyselina |
200–026–4 |
50–31–7 |
Xn; R22 X; R51–53 |
Xn; N X: 22–51/53 S: (2-)61 |
|||
|
607–153–00–8 |
xxxxxxxxx (XXX) (4-chlor-2-oxo-2,3-dihydro-1,3-benzothiazol-3-yl)octová xxxxxxxx |
223–297–0 |
3813–05–6 |
Xx; X36/38 X52–53 |
Xx X:36/38–52/53 X: (2-)22-61 |
|||
|
607–156–00–4 |
chlorfenson (XXX) 4-xxxxxxxxxx-4-xxxxxxxxxxx-1-xxxxxxxx |
201–270–4 |
80–33–1 |
Xx; X22 Xx; X38 X; X50–53 |
Xx; N X: 22–38–50/53 S: (2-)37–60–61 |
|||
|
607–158–00–5 |
xxxxx xxx xxxxxxxxxxx kyseliny xxxxxxxxxx sodný |
223–498–3 |
3926–62–3 |
T; R25 Xx; X38 X; X50 |
X; X X: 25–38–50 S: (1/2-)22–37–45–61 |
|||
|
607–159–00–0 |
xxxxxxxxxxxxxx (XXX) xxxxx-2,2-xxx(4-xxxxxxxxxx)-2-xxxxxxxxxxxxx xxxxx-4,4'-xxxxxxxxxxxxxxx |
208–110–2 |
510–15–6 |
Xx; X22 N; R50–53 |
Xn; X X: 22–50/53 X: (2-)60-61 |
|||
|
607–176–00–3 |
Xxxx: α-{3-[3-(2 X-xxxxxxxxxxxx-2-xx)-5-xxxx-xxxxx-4-xxxxxxxxxxxx]xxxxxxxxx}-ω-xxxxxxxxxxx(xxxxxxxxxx);α-{3-[3-(2 X-xxxxxxxxxxxx-2-xx)-5-xxxx-xxxxx-4-xxxxxxxxxxxx]xxxxxxxxx}-ω-({3-[3-(2 X-xxxxxxxxxxxx-2-xx)-5-xxxx-xxxxx-4-xxxxxxxxxxxx]xxxxxxxxx}xxx)xxxx(xxxxxxxxxx) |
400–830–7 |
— |
X43 X; R51–53 |
Xi; X X: 43–51/53 X: (2-)36/37–61 |
|||
|
607–188–00–9 |
xxxxxxx-xxxxxxxx-X-(2-xxxxxxxxxxxx)-X-(xxxxxxx-9-xx-1-xx)xxxxxxxxxx |
402–970–4 |
— |
X43 X; R51–53 |
Xi; X X: 43–51/53 X: (2-)24/37–61 |
|||
|
607–209–00–1 |
Xxxx: X,X′-xxxxxxxxxxx-xxxxxxxxxxxx(xxxxxxxxxxx); X,X′-xxxxxxxxxxx-xxxxxxxxxxxxxx(xxxxxxxxxxx); X,X′-xxxxxxxxxxx-xxxxxxxxxxxxxx(xxxxxxxxxxx) |
403–030–6 |
— |
Xx; X22 X43 N; X50–53 |
Xx; X X: 22–43–50/ 53 X: (2-)36/37–60–61 |
|||
|
607–213–00–3 |
xxxxx-3,3-xxx(xxxx-xxxxxxxxxxxx)xxxxxxxx |
403–320–2 |
67567–23–1 |
X; X2 X; R7 X10 X; R51–53 |
E; X X: 2–7–10–51/53 X: (2-)3/7–14–33–36/37/39–61 |
|||
|
607–217–00–5 |
2-xxxxxxxxxxx-[4-(7-xxxxx-2,6-xxxxx-2,6-xxxxxxx-1,5-xxxxx-x-xxxxxxx-3-xx)xxxxxx]xxxxxx |
403–960–2 |
— |
X43 X53 |
Xx X: 43-53 X: (2-)24–37–61 |
|||
|
607–243–00–7 |
xxxxxxx-3,6-xxxxxxx-2-xxxxxxxxxxxxxx [1] natrium-3,6-dichlor-o-anisát [1] xxx(2-xxxxxxxxxxxx)xxxxxxx-3,6-xxxxxxx-2-xxxxxxxxxxxxxx [2] xxx(2-xxxxxxxxxxxx)xxxxxxx-3,6-xxxxxxxxxxxxx [2] (2-hydroxyethyl)amonium-3,6-dichlor-2-methoxybenzoát [3] (2-hydroxyethyl)amonium-3,6-dichloranisát [3] |
217–846–3 [1] 246–590–5 [2] 258–527–9 [3] |
1982–69–0 [1] 25059–78–3 [2] 53404–28–7 [3] |
X52–53 |
X: 52/53 X: 61 |
|||
|
607–248–00–4 |
Xxxxxxxx-xxxxxxx Xxxxxxx-X-(1-xxxxxx)xxxxxxxx |
205–073–4 |
132–67–2 |
Xx; X22 |
Xx X: 22 X: (2) |
|||
|
607–249–00-X |
(xxxxxxxxxxxxx)xxx[xxx(xxxxxxxxxxxxx)]-xxxxxxxxx xxxxxxxxxxxxxxxxx-xxxxxxxxx TPGDA |
256–032–2 |
42978–66–5 |
Xi; X36/37/38 X43 X; X51–53 |
Xx; N X:36/37/38–43–51/53 X: (2-)24–37–61 |
C ≥ 10 %: Xx; X36/37/38–43 1 % ≤ C &xx; 10 %: Xi; X43 |
||
|
607–252–00–6 |
λ-xxxxxxxxxxx (XXX) Xxxx (1:1): (X)-[(3-xxxxxxxxxxx)xxxxxxxxxx]-(1 X)-xxx-3-((X)-2-xxxxx-3,3,3-xxxxxxxxxxxx-1-xx-1-xx)-2,2-xxxxxxxxxxxxxxxxxxx-1-xxxxxxxxxx x(X)-[(3-xxxxxxxxxxx)xxxxxxxxxx]-(1 X)-xxx-3-((X)-2-xxxxx-3,3,3-xxxxxxxxxxxx-1-xx-1-xx)-2,2-xxxxxxxxxxxxxxxxxxx-1-xxxxxxxxxx |
415–130–7 |
91465–08–6 |
X+; X26 X; R25 Xx; X21 X; X50–53 |
X+; X X: 21–25–26–50/53 X: (1/2-)28–36/37/39–38–45–60–61 |
|||
|
607–255–00–2 |
xxxxxxxxxx (XXX) [(4-xxxxx-3,5-xxxxxxx-6-xxxxx-2-xxxxxxx)xxx]xxxxxx xxxxxxxx |
— |
69377–81–7 |
X52–53 |
X: 52/53 X: 61 |
|||
|
608–003–00–4 |
xxxxxxxxxxxx |
X X |
203–466–5 |
107–13–1 |
X; Xxx Xxxx. xxx. 2; R45 X; X23/24/25 Xi; R37/38–41 X43 X; X51–53 |
X; X; X X: 45–11–23-/24/25–37/38–41–43–51/53 X: 9–16–53–45–61 |
X ≥ 20 %: X; X45–23/24/25–37/38–41–43 10 % ≤ X &xx; 20 %: X; X45–23/24/25–41–43 5 % ≤ C &xx; 10 %: X; X45–23/24/25–36–43 1 % ≤ C &xx; 5 %:X; X45–23/24/25–43 0,2 % ≤ X < 1 %:T; X45–20/21/22 0,1 % ≤ X &xx; 0,2 %: X; X45 |
43 |
|
608–016–00–5 |
2,3,5,6-xxxxxxxxxx-1,4-xxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxx |
401–550–8 |
1897–41–2 |
X43 X; X50–53 |
Xx; X R: 43–50/53 X: (2-)24–37–60–61 |
|||
|
609–030–00–4 |
xxxxxxxx (XXX) 2-xxxx-xxxxx-4,6-xxxxxxxxxxxx |
X |
215–813–8 |
1420–07–1 |
Xxxx. xxx. 2; X61 X+; R28 X; R24 R44 X; X50–53 |
X+; N X: 61–24–28–44–50/53 X: 53–45–60–61 |
||
|
609–040–00–9 |
xxxxxxxx (XXX) (2,4-dichlorfenyl)(4-nitrofenyl)ether |
E |
217–406–0 |
1836–75–5 |
Karc. xxx. 2; R45 Xxxx. kat. 2; X61 Xx; X22 X; X50–53 |
X; X X: 45–61–22–50/53 X: 53–45–60–61 |
||
|
609–044–00–0 |
xxxxxxxx (XXX) 1,2,4,5-tetrachlor-3-nitrobenzen |
204–178–2 |
117–18–0 |
Xn; X22 R43 X; X50–53 |
Xx; X X: 22–43–50/53 X: (2-)24–37–60–61 |
|||
|
611–008–00–4 |
4-xxxxxxxxxxxxxx 4-(xxxxxxxx)xxxxxx |
200–453–6 |
60–09–3 |
Xxxx. xxx. 2; X45 X; X50–53 |
X; X R: 45–50/53 X: 53–45–60–61 |
|||
|
611–013–00–1 |
4-xxxxxxx-3-{4-[2-xxxxxxx-4-(3-xxxxxxxxxxxxxxxxx)xxxxxxxx]-3-xxxxxxxxxxxxxx}-6-(3-xxxxxxxxxxxxxxxx)xxxxxxxx-2-xxxxxxxx xxxxxxxxx |
403–650–7 |
117409–78–6 |
X; X2 X; R51–53 |
E; X R: 2–51/53 X: (2-)35-61 |
|||
|
611–031–00-X |
4,4'-[(4-iminocyklohexa-2,5-dien-1-yliden)methylen]dianilin-hydrochlorid XX Xxxxx Red 9 XX xxxxxxx xxxxxx 9 |
209–321–2 |
569–61–9 |
Xxxx. kat. 2; X45 |
X R: 45 X: 53-45 |
|||
|
612–035–00–4 |
2-xxxxxxxxxxxxx o-anisidin |
E |
201–963–1 |
90–04–0 |
Karc. xxx. 2; R45 Xxxx. xxx. 3; X40 T; R23/24/25 |
T X: 45–23/24/25 X: 53-45 |
||
|
612–042–00–2 |
xxxxxxxx xxxxxxx-4,4'-xxxxxx 4,4'-xxxxxxxxxxxxxx xxxxxxx-4,4'-xxxxxxxxxx |
X |
202–199–1 |
92–87–5 |
Xxxx. xxx. 1; X45 Xx; R22 X; X50–53 |
X; X X: 45–22–50/53 X: 53–45–60–61 |
X ≥ 25 %: X; X45–22 0,01 % ≤ X &xx; 25 %: X; R45 |
|
|
612–051–00–1 |
4,4'-diaminodifenylmethan xxx(4-xxxxxxxxxx)xxxxxx 4,4'-methylendianilin |
E |
202–974–4 |
101–77–9 |
Karc. xxx. 2; R45 Xxxx. xxx. 3; X40 X; R39/23/24/25Xn; X48/20/21/22 X43 X; X51–53 |
X; X X: 45–39/23/24/25–43–48/20/21/22–51/53 X:53–45–61 |
||
|
612–081–00–5 |
3,3'-xxxxxxxxxxxxxxxx, soli o-tolidin, xxxx |
X X |
210–322–5 265–294–7 277–985–0 |
612–82–8 64969–36–4 74753–18–7 |
Xxxx. xxx. 2; X45 Xx; X22 X; X51–53 |
X; X X: 45–22–51/53 X: 53–45–61 |
||
|
612–099–00–3 |
4-xxxxxx-x-xxxxxxxxxxxxx4-xxxxxx-1,3-xxxxxxxxxxxxx4-xxxxxxxxxxxx-1,3-xxxxxx 2,4-xxxxxxxxxxxx |
X |
202–453–1 |
95–80–7 |
Xxxx. xxx. 2; X45 X; X25 Xx; X21 Xx; X36 X43 X; X51–53 |
X; X R: 45–21–25–36–43–51/53 S: 53–45–61 |
||
|
612–105–00–4 |
2-(piperazin-1-yl)ethylamin2-(piperazin-1-yl)ethan-1-amin |
205–411–0 |
140–31–8 |
Xn; X21/22 X; R34 X43 R52–53 |
C X: 21/22–34–43–52/53 X: (1/2-)26–36/37/39–45–61 |
|||
|
612–111–00–7 |
2-methyl-m-fenylendiamin2-methyl-1,3-fenylendiamin2-methylbenzen-1,3-diamin 2,6-xxxxxxxxxxxx |
212–513–9 |
823–40–5 |
Xxxx. xxx. 3; X40 Xx; X21/22 X43 X; X51–53 |
Xx; X X: 21/22–40–43–51/53 X: (2-)24–36/37–61 |
|||
|
612–125–00–3 |
2-methyl-p-fenylendiamin2-methyl-1,4-fenylendiamin2-methylbenzen-1,4-diamin 2,5-toluendiamin |
202–442–1 |
95–70–5 |
T; X25 Xn; X20/21 X43 X; X51–53 |
X; X X: 20/21–25–43–51/53 X: (1/2-)24–37–45–61 |
|||
|
612–144–00–7 |
flumetralin (XXX) X-(2-xxxxx-6-xxxxxxxxxxx)-X-xxxxx-2,6-xxxxxxx-4-(xxxxxxxxxxxxxx)xxxxxx |
— |
62924–70–3 |
Xx; R36/38 R4 3 N; R50–53 |
Xi; X X: 36/38–43–50/53 X: (2-)36/37–60–61 |
|||
|
612–151–00–5 |
xxxxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxx |
X |
246–910–3 |
25376–45–8 |
Xxxx. kat. 2; X45 T; X25 Xx; X20/21 Xx; R36 X43 X; X51–53 |
X; N X: 45–20/21–25–36–43–51/53 X: 53–45–61 |
||
|
613–018–00–4 |
xxxxxxxxxx (XXX) 1,1'-xxx[(3,5-xxxxxxxxxxxxxxxx-4-xxxxxxxx)xxxxxx]-4,4'-xxxxxxxxx-1,1'-xxxxx |
— |
7411–47–4 |
Xx; X22 Xx; X36/37/38 X52–53 |
Xx X: 22–36/37/38–52/53 X: (2-)22–36–61 |
|||
|
613–031–00–5 |
symklosen xxxxxxxxxxxxxxxxxxxx xxxxxxxx xxxxxxxx-1,3,5-xxxxxxxxxxxx 1,3,5-xxxxxxxx-1,3,5-xxxxxxx-2(1X), 4(3X), 6(5X)-xxxxx |
201–782–8 |
87–90–1 |
X; X8 Xx; X22 X31 Xx; R36/37 X; X50–53 |
X; Xx; X X: 8–22–31–36/37–50/53 X: (2-)8–26–41–60–61 |
|||
|
613–038–00–3 |
6-xxxxx-1,3,5-xxxxxxx-2,4-xxxxxxxxxx 6-xxxxx-1,3,5-xxxxxxx-2,4-xxxxxx benzoguanamin |
202–095–6 |
91–76–9 |
Xn; X22 X52–53 |
Xx X:22–52/53 X: (2-)61 |
|||
|
613–042–00–5 |
xxxxxxxx (XXX) 1-[2-(xxxxxxxx)-2-(2,4-xxxxxxxxxxxx)xxxxx]- 1 X-xxxxxxxx |
252–615–0 |
35554–44–0 |
Xx; X20/22 N; X41 X; R50–53 |
Xn; X X: 20/22–41–50/53 X: (2-)26–39–60–61 |
|||
|
613–043–00–0 |
xxxxxxxx-xxxxxx (ISO) 1-[2-(xxxxxxxx)-2-(2,4-xxxxxxxxxxxx)xxxxx]- 1X -xxxxxxxx-1-xxx-xxxxxxxxxxxxxx [1] (±)-1-[2-(xxxxxxxx)-2-(2,4-xxxxxxxxxxxx)xxxxx]-1X-xxxxxxxx-1-xxx-xxxxxxxxxxxxxx |
261–351–5 [1] 281–291–3 [2] |
58594–72–2 [1] 83918–57–4 [2] |
Xx; R20/22 Xx; X41 X; R50–53 |
Xn; X R: 20/22–41–50/53 X: (2-)26–39–60–61 |
|||
|
613–066–00–6 |
terbumeton (ISO) 2-(xxxx-xxxxxxxxxx)-4-(xxxxxxxxxx)-6-xxxxxxx-1,3,5-xxxxxxx |
251–637–8 |
33693–04–8 |
Xx; R22 X; X50–53 |
Xx; X X: 22–50/53 X: (2-)60-61 |
|||
|
613–091–00–2 |
morfamkvat-dichlorid [1] xxxxxxxxxx-xxxxxx [2] 1,1'-xxx[(3,5-xxxxxxxxxxxxxxxx-4-xxxxxxxx)xxxxxx]-4,4'-xxxxxxxxx-1,1'-xxxxx-xxxxxxxxx [1] 1,1'-xxx[(3,5-xxxxxxxxxxxxxxxx-4-xxxxxxxx)xxxxxx]-4,4'-xxxxxxxxx-1,1'-xxxx-xxxxxxxx [2] |
225–062–8 [1] |
4636–83–3 [1] 29873–36–7 [2] |
Xx; X22 Xx; R36/37/38 R52–53 |
Xn; X: 22–36/37/38–52/53 X: (2-)22–36–61 |
|||
|
613–098–00–0 |
1-xxxxxxxxxxxxxxx-2-xx 1-oktyl-2-pyrrolidon |
403–700–8 |
2687–94–7 |
C; X34 X; X51–53 |
X; X X: 34–51/53 X: (1/2-)23–26–36/37/39–45–61 |
|||
|
613–130–00–3 |
xxxxxxxxxxx (XXX) (XX)-2-(2,4-xxxxxxxxxxxx)-1-(1X-1,2,4-xxxxxxx-1-xx)xxxxx-2-xx |
— |
79983–71–4 |
X43 X; R51–53 |
Xi; X X: 43–51/53 X: (2-)24–37–61 |
|||
|
613–131–00–9 |
xxxxxxxxxx (XXX) 1,2,5,6-tetrahydro-4 X-xxxxxxx[3,2,1-xx]xxxxxxxx-4-xx |
— |
57369–32–1 |
Xx; X22 X52–53 |
Xx X:22–52/53 X: (2-)61 |
|||
|
613–134–00–5 |
myklobutanil (XXX) 2-(4-xxxxxxxxxx)-2-[(1 H-1,2,4-triazol-1-yl)methyl]hexannitril |
— |
88671–89–0 |
Repr. xxx. 3; X63 Xx; X22 Xx; X36 X; X51–53 |
Xx; X X: 22–36–51/53–63 X: (2-)36/37–46–61 |
|||
|
613–137–00–1 |
xxxxxxxxxxxxxxxxxx (XXX) 1-(1,3-xxxxxxxxxxxx-2-xx)-1,3-xxxxxxxxxxxxxxxx |
242–505–0 |
18691–97–9 |
X; R50–53 |
N R: 50/53 X: 60-61 |
|||
|
613–139–00–2 |
xxxxxxxxxxx-xxxxxx xxxxxx-2-{X —[X-(4-xxxxxxx-6-xxxxxx-1,3,5-xxxxxxx-2-xx)xxxxxxxxx]xxxxxxxxx}xxxxxxx |
— |
74223–64–6 |
X; X50–53 |
X X: 50/53 S: 60-61 |
|||
|
614–001–00–4 |
xxxxxxx (ISO) 3-(1-methylpyrrolidin-2-yl)pyridin |
200–193–3 |
54–11–5 |
T+; X27 T; X25 X; X51–53 |
X+; N X: 25–27–51/53 X: (1/2-)36/37–45–61 |
|||
|
614–006–00–1 |
xxxxxx 2,3-dimethoxystrychnidin-10-on |
206–614–7 |
357–57–3 |
T+; X26/28 X52–53 |
X+ X:26/28–52/53 S: (1/2-)13–45–61 |
|||
|
614–007–00–7 |
xxxxxx-xxxxxx [1] brucin-nitrát [2] xxxxxx-(X)-(1-xxxxxxxxxxxx)-xxxxxxxx-xxxxxx [3] xxxxxx-(X)-(1-xxxxxxxxxxxx)-xxxxxxxx-xxxxxx [4] |
225–432–9 [1] 227–317–9 [2] 269–439–5 [3] 269–710–8 [4] |
4845–99–2 [1] 5786–97–0 [2] 68239–26–9 [3] 68310–42–9 [4] |
X+; R26/28 X52–53 |
X+ X: 26/28–52/53 X: (1/2-)13–45–61 |
|||
|
615–006–00–4 |
2-xxxxxx-x-xxxxxxxxxxxxxxxxxx [1] 2-xxxxxx-1,3-xxxxxxxxxxxxxxxxxx [1] 4-methyl-m-fenylendiisokyanát [2] 4-xxxxxx-1,3-xxxxxxxxxxxxxxxxxx [2] x-xxxxxxxxxxxxxxxxxxxx [3] 5-methyl-1,3-fenylendiisokyanát [3] xxxxxx-2,6-xxxxxxxxxxx [1] toluen-2,4-diisokyanát [2] xxxxxx-3,5-xxxxxxxxxxx [3] |
X |
202–039–0 [1] 209–544–5 [2] 247–722–4 [3] |
91–08–7 [1] 584–84–9 [2] 26471–62–5 [3] |
Xxxx. xxx. 3; X40 X+; R26 Xx; R36/37/38 X42/43 X52–53 |
X+ X: 26–36/37/38–40–42/43–52/53 X: (1/2-)23–36/37–45–61 |
C320 %: X+; X26–36/37/38–40–42/43 7 % ≤ X &xx; 20 %: X+; X26–40–42/43 1 % ≤ C &xx; 7 %: X; X23–40–42/43 0,1 % ≤ C &xx; 1 %:Xx; X20–42 |
2 |
|
616–010–00–9 |
xxxxxxx-xxxxxxxxxxxxxx N-chlor-4-methylbenzen-1-sulfonamid, xxxxx xxx |
204–854–7 |
127–65–1 |
Xx; R22 X31 X; R34 X42 |
X X: 22–31–34–42 X: (1/2-)7–22–26–36/37/39–45 |
|||
|
616–034–00-X |
xxxxxxxxxxxx (XXX) 6-xxxxxx-3,4-xxxxxxx-2X-xxxxx-5-xxxxxxxxxxxx |
246–419–4 |
24691–76–7 |
X52–53 |
X: 52/53 S: 61 |
|||
|
616–035–00–5 |
xxxxxxxxx X -[(xxxxxxxxxx)xxxxxxxx]-2-xxxx-2-(xxxxxxxxxxxx)xxxxxxxx 1-ethyl-3-[2-kyan-2-(methoxyimino)acetyl]močovina |
261–043–0 |
57966–95–7 |
Xn; X22 X43 X; X50–53 |
Xx; N X: 22–43–50/53 X: (2-)36/37–60–61 |
|||
|
617–004–00–9 |
(1,2,3,4-tetrahydro-1-naftyl)hydroperoxid xxxxxxxxxxxxxxxxxxxx |
212–230–0 |
771–29–9 |
X; R7 Xx; X22 C; X34 X; R50–53 |
O; X; X R: 7–22–34–50/53 X:(1/2-)3/7–14–26–36/37/39–45–60–61 |
X325 %: X; X22–34 10 % ≤ X < 25 %: X; X34 5 % ≤ C &xx; 10 %: Xx; X36/37/38 |
||
|
617–006–00-X |
xxx(α, α-xxxxxxxxxxxxxx)xxxxxxx bis(2-fenylpropan-2-yl)peroxid xxx(1-xxxxx-1-xxxxxxxxxxx)xxxxxxx dikumylperoxid |
201–279–3 |
80–43–3 |
O; R7 Xx; X36/38 X; X51–53 |
X; Xx; X X: 7–36/38–51/53 X: (2-)3/7–14–36/37/39–61 |
|||
|
617–008–00–0 |
xxxxxxxxxxxxxxxx |
202–327–6 |
94–36–0 |
X; X2 Xi; X36 R43 |
E; Xi; X: 2–36–43 S: (2-)3/7–14–36/37/39 |
|||
|
650–007–00–3 |
xxxxxxxxxxxxx (XXX) X2-(4-xxxxx-2-xxxxxxxxxxx)-X1,X1-xxxxxxxxxxxxxxxxxxxx X2-(4-xxxxx-x-xxxxx)-X1,X1-xxxxxxxxxxxxxxxxxx |
228–200–5 |
6164–98–3 |
Xxxx. kat. 3; X40 Xn; X21/22 X; R50–53 |
Xn; X X: 21/22–40–50/53 S: (2-)22–36/37–60–61 |
|||
|
650–008–00–9 |
xxxxxxxxxx (XXX) 4-[(2-xxxxxxxxxx)xxxxxxxxx]-3-xxxxxxxxxxxxxx-5(4 X)-xx |
227–197–8 |
5707–69–7 |
X; X25 X; X50–53 |
X; X X: 25–50/53 S: (1/2-)22–24–36/37–45–60–61 |
|||
|
650–009–00–4 |
xxxxxxxxxxxxx-xxxxxxxxxxxx X'-(4-xxxxx-x-xxxxx)-X,X-xxxxxxxxxxxxxxxxxx-xxxxxxxxxxxx X2-(4-xxxxx-2-xxxxxxxxxxx)-X1,X1-xxxxxxxxxxxxxxxxxxxx-xxxxxxxxxxxx X2-(4-xxxxx-x-xxxxx)-X1,X1-xxxxxxxxxxxxxxxxxx-xxxxxxxxxxxx |
243–269–1 |
19750–95–9 |
Xxxx. xxx. 3; R40 Xx; X22 N; X50–53 |
Xx; X X: 22–40–50/53 S: (2-)22–36/37–60–61 |
|||
|
650–033–00–5 |
xxxxxxxxxxxx (XXX) [(S)-(3-fenoxyfenyl)kyanmethyl]-(S)-2-(4-chlorfenyl)-3-methylbutanoát (S)-3-fenoxy-α-kyanbenzyl-(S)-2-(4-chlorfenyl)-3-methylbutanoát |
— |
66230–04–4 |
T; X23/25 R43 X; X50–53 |
X; N X: 23/25–43–50/53 X: (1/2-)24–36/37/39–45–60–61 |
|||
|
650–041–00–9 |
xxxxxxxxxxxx (XXX) 1-[2-(2-chlorethoxy)benzen-1-sulfonyl]-3-(4-methoxy-6-methyl-1,3,5-triazin-2-yl)močovina |
— |
82097–50–5 |
N; X50–53 |
X X: 50/53 X: 60-61 |
PŘÍLOHA 1D
|
Indexové číslo |
Chemický xxxxx |
Xxxxxxxx x látkám |
Číslo XX |
Xxxxx XXX |
Xxxxxxxxxxx |
Xxxxxxxx |
Xxxxxxxxxxxx xxxxxx |
Xxxxxxxx x xxxxxxxxxx |
|
006–090–00–8 |
2-[(3-xxxxxxx-2-xx-1-xx)xxx]xxxxx-X-xxxxxxxxxxxxx |
408–010–0 |
88558–41–2 |
Xx; R20 Xx; X41 X52–53 |
Xx X: 20–41–52/53 X: (2-)22–26–39–61 |
|||
|
014–016–00–0 |
Xxxx: 1,3-xx(xxx-5-xx-1-xx)- 1,1,3,3-tetramethyldisiloxan x 1,3-xx(xxx-x-xx-1-xx)- 1,1,3,3-xxxxxxxxxxxxxxxxxxxx |
406–490–6 |
— |
X; X51–53 |
X X: 51/53 X: 61 |
|||
|
015–164–00–9 |
kalcium-dihydrogen-(1-hydroxyethylen)bisfosfonát xxxxxxxx |
400–480–5 |
36669–85–9 |
X52–53 |
X:52/53 X: 61 |
|||
|
015–165–00–4 |
Xxxx: S, X, X', S''-tetrafenyl-4,4'-sulfandiylbis(fenylsulfonium)-bis(hexafluorofosfát) x xxxxxxx[4-(xxxxxxxxxxxxx)xxxxx]xxxxxxxxx-xxxxxxxxxxxxxxxx |
404–986–7 |
— |
Xx; X41 X; X50–53 |
Xx; N X: 41–50/53 X: (2-)15–26–39–60–61 |
|||
|
015–166–00-X |
3,9-xxx(2,6-xx-xxxx-xxxxx-4-xxxxxxxxxxxx)-2,4,8,10-xxxxxxxx-3,9-xxxxxxxxxxxx[5.5]xxxxxxx |
410–290–4 |
80693–00–1 |
X53 |
X:53 X: 61 |
|||
|
015–167–00–5 |
3-[xxxxxxx(xxxxx)xxxxxxxxx]xxxxxxxxx xxxxxxxx |
411–200–6 |
14657–64–8 |
Xx; R41 |
Xi X: 41 S: (2-)26-39 |
|||
|
601–050–00–1 |
C10-C13-alkylderiváty xxxxxxx |
267–051–0 |
67774–74–7 |
X; X50 |
X X: 50 S: 61 |
|||
|
601–051–00–7 |
4-xxxxxxxx-1-xx |
405–980–7 |
768–56–9 |
Xx; X38 N; X51–53 |
Xx; X X: 38–51/53 X: (2-)37-61 |
|||
|
602–083–00–4 |
pentabromderivát difenyletheru xxxxxxxxxxxxxxxxxxxxx |
251–084–2 |
32534–81–9 |
Xx; R48/21/22 R64 X; X50–53 |
Xx; N X: 48/21/22–50/53–64 X: (1/2-)36/37–45–60–61 |
|||
|
602–084–00-X |
1,1-xxxxxxx-1-xxxxxxxxxx |
404–080–1 |
1717–00–6 |
X; X52–53–59 |
X R: 52/53–59 X: 59-61 |
|||
|
603–128–00–0 |
2-(fenylmethoxy)naftalen |
405–490–3 |
613–62–7 |
R53 |
R:53 X: 61 |
|||
|
603–129–00–6 |
1-xxxx-xxxxxxxxxxxx-2-xx |
406–180–0 |
57018–52–7 |
X10 Xx; X41 |
Xx R: 10-41 X: (2-)26-39 |
|||
|
603–130–00–1 |
Xxxx isomerů: α-(xxxxxxxxxxxxxxxxx)-ω-xxxxxxxxxxx(xxxxxxxxxx) |
406–325–8 |
— |
Xx; X22 X52–53 |
Xx X:22–52/53 X: (2-)39-61 |
|||
|
603–131–00–7 |
Xxxx (3:1):1-xxxxx-1-[xxxxxx(1-xxxxxxxxxx)xxxxx]-X-xxxxxxxx; 1-xxxxx-1-[xxxxxx(1-xxxxxxxxxxxxx)xxxxx]-X-xxxxxxxx |
407–290–1 |
— |
Xx; X41 |
Xx X: 41 X: (2-)26-39 |
|||
|
603–132–00–2 |
2-(xxxxxxxxxxxxx)-6-xxxxxxxxx-9-xxxxxx-1,4-xxxxxxxxxx[4.5]xxxxx |
408–200–3 |
63187–91–7 |
Xx; X38–41 R52–53 |
Xi X:38–41–52/53 S: (2-)26–37/39–61 |
|||
|
603–133–00–8 |
Xxxx:3-(4-xxxxx-2-xxxxx-5-xxxxxxxxxxxx)xxxxxx-1,2-xxxx x 3,3'-[(2-xxxxx-5-xxxxx-1,4-xxxxxxx)xxxxxxx]xx(xxxxxx-1,2-xxxx) |
408–240–1 |
— |
Xx; X22 X52–53 |
Xx X:22–52/53 S: (2-)22–36–61 |
|||
|
603–134–00–3 |
Xxxx: xxxxx(X1-X10)-xxxxxxxxxxxxxxxxxxxx a xxxxx(X1-X10)-xxxxxxxxxxxxxxxxxxxxxxx (xxxxxxx x xxxxxxxxxx xxxxxxxxxxxx) |
410–450–3 |
— |
X53 |
X: 53 X: 61 |
|||
|
603–135–00–9 |
xxx[2-(2-xxxxxxxxxxxxx)xxxxxxxxxx]xxx(2,2', 2-nitrilotriethan-1-olato-N,O)titaničitý xxxxxxx |
410–500–4 |
— |
Xx; X41 X; X51–53 |
Xx; X R: 41–51/53 S: (2-)26–39–61 |
|||
|
603–136–00–4 |
3-{4-[xxx(2-xxxxxxxxxxxx)xxxxx]-2-xxxxxxxxxxxx}xxxxxx-1-xx |
410–910–3 |
104226–19–9 |
X43 X52–53 |
Xx X:43–52/53 S: (2-)24–37–61 |
|||
|
603–137–00-X |
Xxxx:1-xxxxx-1-[xxxxxx(1-xxxxxxxxxxxx)xxxxx]-X-xxxxxxxx x 1-xxxxx-1-[xxxxxx(1-xxxxxxxxxxxx)xxxxx]-X-xxxxxxxx |
411–130–6 |
— |
Xx; X41 |
Xx X: 41 X: (2-)26-39 |
|||
|
603–138–00–5 |
3-(2,2-dimethyl-3-hydroxypropyl)toluen 2,2-xxxxxxxx-3-(3-xxxxxxxxxxx)xxxxxx-1-xx |
403–140–4 |
103694–68–4 |
X52–53 |
X:52/53 X: 61 |
|||
|
604–050–00-X |
4-xxxxx-x-xxxxxx 4-chlor-2-methylfenol |
216–381–3 |
1570–64–5 |
T; X23 X; R 35 N; X50 |
X; X; N X: 23–35–50 S: (1/2-)26–36/37/39–45–61 |
X ≥ 25 %: X; X; R23–35 10 % ≤ X &xx; 25 %: X;X20–35 5 % ≤ C &xx; 10 %: X;X20–34 3 % ≤ X &xx; 5 %: Xx;X20–36/37/38 1 % ≤ X < 3 %:Xx;X36/37/38 |
||
|
604–051–00–5 |
3,5-xxx(3,5-xx-xxxx-xxxxx-4-xxxxxxxxxxxxx)-2,4,6-xxxxxxxxxxxxxx |
401–110–5 |
87113–78–8 |
X52–53 |
X:52/53 X: 61 |
|||
|
604–052–00–0 |
2,2'-xxxxxxxxxxx[6-(2 X - xxxxxxxxxxxx-2-xx)-4-(1,1,3,3-xxxxxxxxxxxxxxxx)xxxxx] 6,6'-xxx(2X -xxxxxxxxxxxx-2-xx)- 4,4'-xxx(1,1,3,3-xxxxxxxxxxxxxxxx)- 2,2'-xxxxxxxxxxxxxxx |
403–800–1 |
103597–45–1 |
X53 |
X:53 X: 61 |
|||
|
604–053–00–6 |
4-xxxx - xxxxx-2-xxxxxx-6-(1-xxxxxxxxxxxxxxxx)xxxxx |
410–760–9 |
157661–93–3 |
Xx; X38 X43 N; X50–53 |
Xx; X X: 38–43–50/53 X: (2-)24–37–60–61 |
|||
|
604–054–00–1 |
Xxxx:2-xxxxxxx-4-(4-xxxxxxxxxxxxxxxxxxxxxxxxx-2-xx)xxxxx a 2-xxxxxxx-4-(4-xxxxxx-3,6-xxxxxxx-2X -xxxxx-2-xx)xxxxx |
412–020–0 |
— |
X43 X52–53 |
Xx X:43–52/53 S: (2-)24–37–61 |
|||
|
604–055–00–7 |
4,4'-xxx[(2,3-xxxxxxxxxxx)xxx]-3,3', 5,5'-xxxxxxxxxxxxxxxxxx |
413–900–7 |
85954–11–6 |
Xxxx. Xxx.3; R40 |
Xn X: 40 X: (2-)22–36–37 |
|||
|
605–027–00–7 |
Xxxx:3x, 4,5,6,7,7a-hexahydro-4,7-methano-1H-inden-6-karbaldehyd a 3x, 4,5,6,7,7a-hexahydro-4,7-methano-1H - xxxxx-5-xxxxxxxxxxx |
410–480–7 |
— |
X43 X; X51–53 |
Xx; X X: 43–51/53 X: (2-)24–37–61 |
|||
|
606–051–00–0 |
4-xxxxxxxxxxxxxxxxxx pentylcyklohexan-1-on |
4–406–670–4 |
61203–83–6 |
N; X51–53 |
X R: 51/53 X: 61 |
|||
|
606–052–00–6 |
4-(X, X-xxxxxxxxxxxx)-2-xxxxxxx-2'-xxxxxxxxxxxxxxxxx 2-[4-(xxxxxxxxxxxx)-2-xxxxxxxxxxxxxx]xxxxxxxx xxxxxxxx |
410–410–5 |
54574–82–2 |
X52–53 |
X:52/53 X: 61 |
|||
|
607–272–00–5 |
xxxxxxxxxxx-xxxxxx (ISO) [1] xxxxxxxxxx-xxxxxxxxx (XXX) [2] xxxxxxxxxxxx-[(4-xxxxx-3,5-xxxxxxx-6-xxxxx-2-xxxxxxx)xxx]xxxxxx [1] (2-xxxxxx-1-xxxxxxxxxxx)-[(4-xxxxx-3,5-xxxxxxx-6-xxxxx-2-xxxxxxx)xxx]xxxxxx [2] |
279–752–9 [1] — |
81406–37–3 [1] 154486–27–8 [2] |
N; X50–53 |
X X: 50/53 X: 60-61 |
|||
|
607–273–00–0 |
amonium-7-{2,6-dimethyl-8-[(2,2-dimethylbutanoyl)oxy]- 1,2,6,7,8,8a-hexahydro-1-naftyl}-3,5-dihydroxyheptanoát |
404–520–2 |
— |
R52–53 |
R:52/53 X: 61 |
|||
|
607–274–00–6 |
{2-[xxxxxx(xxxxxx)xxxxx]xxxxx}-3-xxxxxxxx-2-xxxxx |
405–350–1 |
54527–73–0 |
X43 X; X51–53 |
Xx; X X: 43–51/53 X: (2-)24–37–61 |
|||
|
607–275–00–1 |
xxxxxxx-4-(xxxxxxxxxx)xxxxxx-1-xxxxxxxx |
405–450–5 |
66531–87–1 |
X43 |
Xx X: 43 X: (2-)24-37 |
|||
|
607–276–00–7 |
[xxx(2-xxxxxxxxxxxxxx) bis(1-methylimidazol)]zinečnatý xxxxxxx |
405–635–0 |
— |
Xx; X38–41 N; X50–53 |
Xx; X R: 38–41–50/53 X: (2-)26–37/39–60–61 |
|||
|
607–277–00–2 |
Směs:2-(hexylsulfanyl)ethylamin-hydrochlorid x xxxxxxx-xxxxxxxxx |
405–720–2 |
— |
Xx; X22 Xx; X41 R43 N; X51–53 |
Xx; X X: 22–41–43–51/53 S: (2-)24–26–37/39–61 |
|||
|
607–278–00–8 |
Směs:alkyl(C7-C9 xxxxxxxxxx x xxxxxxxxxxxx)-3-[3-(2 X - benzotriazol-2-yl)-5-terc-butyl-4-hydroxyfenyl]propanoáty |
405–760–0 |
— |
Xi; X41 R43 X52–53 |
Xx X: 41–43–52/53 X: (2-)24–26–37/39–61 |
|||
|
607–279–00–3 |
Xxxx:(xxxxxxxxxxxxxx)xxxxxxxxx-xxx(xxxxxxxx-xxxxxxxx) a (xxxxxxxxxxxxxx)xxxxxxxxx-(xxxxxxxx-xxxxxx)-(xxxxxxxx-xxxxxxxx) |
405–960–8 |
— |
X43 X; X51–53 |
Xx; X X: 43–51/53 X: (2-)24–37–61 |
|||
|
607–280–00–9 |
4-xxxxx-1-xxxxxxxxxxxx-1-xxxxxxxx xxxxx xxxxxxx-4-xxxxx-1-xxxxxxxxxxxx-1-xxxxxxxx |
406–190–5 |
54322–20–2 |
Xx; X22 Xx; X36 X43 |
Xx X: 22–36–43 X: (2-)22–26–36/37 |
|||
|
607–281–00–4 |
Xxxx:xxxxx(X7-X9 xxxxxxxxxx x lineární)-3-[3-(2H-benzotriazol-2-yl)-5-terc-butyl-4-hydroxyfenyl]propanoáty |
407–000–3 |
127519–17–9 |
N; X51–53 |
X X: 51/53 X: 61 |
|||
|
607–282–00-X |
2-(xxxxxxxxxxxxx)-4-(xxxxxxxxx)xxxxx-xxxxxx |
407–140–5 |
131266–10–9 |
X52–53 |
X: 52/53 X: 61 |
|||
|
607–283–00–5 |
xxxxx-(X)-4-xxxxx-4-xxxxxx-2-xxxxxxxxxx-(X)-4-xxxxx-4-xxxxxxxxxxx |
408–040–4 |
15121–89–8 |
Xx; R21/22 Xi; X38–41 X43 X; X50–53 |
Xx; X X: 21/22–38–41–43–50/53 X: (2-)26–36/37/39–60–61 |
|||
|
607–284–00–0 |
Xxxx (9:1):xxxxxxx-3,3'-{(1,4-xxxxxxx)xxx[(xxxxxxxxxxxxx)(xxxxxx-3,1-xxxx)xxxxx]}xxx(10-xxxxx-6,13-xxxxxxx[1,4]xxxxxxxxxxx[2,3-x]xxxxxxxxx-4,11-xxxxxxxxxx) a xxxxxxx-3,3'-{(1,4-xxxxxxx)xxx[(xxxxxxxxxxxxx)(xxxxxx-3,1-xxxx)xxxxx]}xxx(10-xxxxx-6,13-xxxxxxx[1,4]xxxxxxxxxxx[2,3-x]xxxxxxxxx-4,11-xxxxxxxxxx) |
410–040–4 |
136213–76–8 |
X; X51–53 |
X X: 51/53 X: 61 |
|||
|
607–285–00–6 |
Směs:7-(3-aminobenzensulfonamido)naftalen-1,3-disulfonová xxxxxxxx, xxxxxx-7-(3-xxxxxxxxxxxxxxxxxxxxxx)xxxxxxxx-1,3-xxxxxxxxxx x xxxxxxx-7-(3-xxxxxxxxxxxxxxxxxxxxxx)xxxxxxxx-1,3-xxxxxxxxxx |
410–065–0 |
— |
X43 |
Xx X: 43 X: (2-)22–24–37 |
|||
|
607–286–00–1 |
Xxxx:xxxxxx- x xxxxxxx-7-[4-({4-[(2-xxxxxxx-1-xxxxxx)xxx]xxxxx}xxx)xxxxxxxxxxxxxxxxx]xxxxxxxx-1,3-xxxxxxxxxx |
410–070–8 |
141880–36–6 |
X43 X52–53 |
Xx X:43–52/53 X: (2-)22–24–37–61 |
|||
|
607–287–00–7 |
xxxxxx-[1-xxxxxx-2-(xxxxxxxxxxxxxxx)xxxxx]-1,2,3,6-xxxxxxxxxxxxxxxx |
410–140–8 |
— |
X52–53 |
X:52/53 X: 61 |
|||
|
607–288–00–2 |
[x-(X -{3-[(1-{3-[(2,6(4,6)-xxxxxxx-5-xxxxxxxxxxxxx-4(2)-xx)xxxxxxxxxxx]xxxxxx}-2-xxxxxxx-4-xxxxxx-6-xxx-1,6-xxxxxxx-3-xxxxxxx)xxx]-4-xxxxxxxxxxxxxx}xxxxxxxxx)-x,x,x -xxxxxxxxxxxxxxxxxxxxxxx]xxxxxxxxx komplex, xxxxxxxxxx xxx; x = 15, 16, 17 nebo 18, x = 1, 2, 3 xxxx 4, x = 8, 9, 10 xxxx 11, x = 22, 23, 24 nebo 25 |
410–160–7 |
148732–74–5 |
Xx; X36 X43 X52–53 |
Xx X: 36–43–52/53 X: (2-)22–26–36/37–61 |
|||
|
607–288–00–8 |
3-[(3-{X —[4-(2,4-xx-xxxx-xxxxxxxxxxxx)xxxxx]xxxxxxxxx}-4-xxxxxxx-1-xxxxxx)xxxxxxxx]xxxxxxxxx xxxxxxxx |
410–370–9 |
105488–33–3 |
X53 |
X:53 X: 61 |
|||
|
607–290–00–3 |
Směs (x xxxxxxxx poměru):amonium-1-alkyl(C14-C18)-4-[3-(allyloxy)-2-hydroxypropyl]-2-sulfonatobutandioát x xxxxxxx-4-xxxxx(X14-X18)-1-[3-(xxxxxxxx)-2-xxxxxxxxxxxxx]-2-xxxxxxxxxxxxxxxxxxx |
410–540–2 |
— |
Xx; X38 R43 X; R50–53 |
Xi; X X: 38–43–50/53 S: (2-)24–37–60–61 |
|||
|
607–291–00–9 |
xxxxxxx-ω-xxxxxxxxxxx(xxxx xxxxxxxxxx)xxxxxxxx |
410–630–1 |
104051–92–5 |
X53 |
X: 53 X: 61 |
|||
|
607–292–00–4 |
Xxxx:[2-(xxxxx(X12)xxx)-1-(xxxxxxxxxxxxx)xxxxxx]xxxxxx kyselina x [2-(xxxxx(X14)xxx)-1-(xxxxxxxxxxxxx)]xxxxxx xxxxxxxx |
410–640–6 |
— |
Xx; X38–41 N; R50–53 |
Xi; X X: 38–41–50/53 X: (2-)26–37/39–60–61 |
|||
|
607–293–00-XSměs: |
1-(2-aminoethyl)piperazin-1,4-diium-[(2,4,6-trimethylnonyl)fenoxy]benzendisulfonát a 1-(2-xxxxxxxxxx)xxxxxxxxx-1,4-xxxxx-[xxx(2,4,6-xxxxxxxxxxxxxx)xxxxxx]xxxxxxxxxxxxxxxx |
410–650–0 |
— |
Xx; X41 X43 X; X51–53 |
Xx; X X: 41–43–51/53 X: (2-)26–36/37/39–61 |
|||
|
607–294–00–5 |
xxxxxxx-2-(xxxxxxxxxx)-1-xxxxxxxxxxxx-1-xxxxxxxx |
410–680–4 |
— |
X43 |
Xx X: 43 X: (2-)24-37 |
|||
|
607–295–00–0 |
Směs:tetranatrium-fosfonobutandioát x xxxxxxxxxxx-xxxxxxxxxxxx-1,2,3,4-xxxxxxxxxxxxxxx |
410–800–5 |
— |
X43 N; X51–53 |
Xx; X X: 43–51/53 X: (2-)24–37–61 |
|||
|
607–296–00–6 |
Xxxx:xxxxxxxxxxx pentaerythritolu, xxxxxxxxx xxxxxxxx x 2-xxxxxxxxxxxxx xxxxxxxx |
410–830–9 |
— |
X53 |
X: 53 X: 61 |
|||
|
607–297–00–1 |
3,3'-(1,4-fenylendimethyliden)bis(2-oxobornan-10-sulfonová xxxxxxxx)2,2'-xxxxx-3,3'-(1,4-xxxxxxxxxxxxxxxxxxx)xxx(1,7,7-xxxxxxxxxxxxxxxx[2.2.1]xxxxxx-1-xxxxxxxxxxxxxxx xxxxxxxx) |
410–960–6 |
92761–26–7 |
Xx; R41 |
Xi X: 41 S: (2-)26-39 |
|||
|
607–298–00–7 |
[2-(xxxxxxxxxxxxxxx)xxxxx]-4-xxxxxxxxxxxxxxxx |
411–010–3 |
— |
X43 |
Xx X: 43 S: (2-)22–36/37 |
|||
|
607–299–00–2 |
xxxxxx-3-(xxxxxxxxxxxxxx)-2-xxxxxxxxxxxxxxx |
411–040–7 |
97101–46–7 |
Xx; R22 X43 X; X50–53 |
Xx; X X: 22–43–50/53 S: (2-)24–37–60–61 |
|||
|
607–300–00–6 |
[x-(X-{4-[(5-xxxxx-2,6-xxxxxxxxxxxxxxxx-4-xx)xxxxx]-3-xxxxxxxxxxxxxxxx}xxxxxxxxx)-x-xxxxxxxxx-x, x-xxxxxxxxxxxxxxxxxxxx]xxxxxxx xxxxxxx, xxxxxxxx sůl; x = 1,2,3 xxxx 4, x = 8, 9, 10 xxxx 11, c = 15, 16, 17 nebo 18, x = 22, 23, 24 xxxx 25 |
411–430–7 |
— |
X43 |
Xx X: 43 X: (2-)22–24–37 |
|||
|
607–301–00–1 |
Xxxx:xxxxxxxxxx xxxxxxxx x dodekanoáty xxxxx(1-7)xxxxxxx |
411–860–5 |
— |
Xx; X38–41 X43 X; X51–53 |
Xx; N X: 38–41–43–51/53 X: (2-)24–26–37/39–61 |
|||
|
607–302–00–7 |
Xxxx:xxxxxxxxxxxxx xxxxxxxx x xxxxxxxxxxxxxx xxxxx(1-7)xxxxxxx |
411–910–6 |
— |
Xx; R38–41 X43 X; X51–53 |
Xx; X X: 38–41–43–51/53 X: (2-)24–26–37/39–61 |
|||
|
607–303–00–2 |
1-xxxxxxxxxxx-6,7-xxxxxxx-4-xxx-1,4-xxxxxxxxxxxxxxx-3-xxxxxxxxxxx kyselina |
413–760–7 |
93107–30–3 |
Repr. xxx.3; X62 R52–53 |
Xn R: 62–52/53 X: (2-)22–36/37–61 |
|||
|
608–023–00–3 |
4-(4-xxxxxxxxxx)-2-xxxxx-2-[(1X- 1,2,4-xxxxxxx-1-xx)xxxxxx]xxxxxxxxxxx |
406–140–2 |
114369–43–6 |
X; R50–53 |
N R: 50/53 X: 60-61 |
|||
|
608–024–00–9 |
2-{4-[xxxxx(xxxxxxxx)xxxxx]xxxxx}xxxxx-1,1,2-xxxxxxxxxxxxxx |
407–650–8 |
97460–76–9 |
X53 |
X:53 X: 61 |
|||
|
608–025–00–4 |
[2-xxxxx-4,5-xxx(xxxxxxxxx)xxxxx]xxxxxxxxxxx |
410–970–0 |
117568–27–1 |
X53 |
X:53 X: 61 |
|||
|
609–053–00-X |
xxxxxxxxxxx-xxxxxxxxxxxxxxxx |
414–850–9 |
— |
X; X3 X; X8 Karc. kat. 2; X45 X; X23/25 X43 |
X; X X: 45–3–8–23/25–43 S: 53-45 |
|||
|
610–010–00–2 |
1-xxxx-2-(2-xxxxx)-1-xxxxxxxxxx |
406–110–9 |
35950–52–8 |
Xx; R22–48/22 C; X34 X43 X; X50–53 |
X; X X: 22–34–43–48/22–50/53 X: (1/2-)22–26–36/37/39–45–60–61 |
|||
|
611–043–00–5 |
Směs (2:1:1):[xxx(6-{[1-(X-xxxxxxxxxxxxxx)-2-xxxxxxxxxxx-1-xx-1-xx]xxx}-5-xxxxxxxxx-3-xxxxxxxxxxxxxxxxx-2-xxx-1'-xxxxxx-1,2'-xxxxxxx)]xxxxxxxxx xxxxxxxx, [xxx{6-[(2-xxxxx-4-xxxxxxxxxxxx)xxx]- xxxx 6-[(2-amino-6-hydroxyfenyl)azo]- xxxx 6-[(4-xxxxx-2-xxxxxxxxxxxx)xxx]-5-xxxxxxxxx-3-xxxxxxxxxxxxxxxxx-2-xxx-1'-xxxxxx-1,2'-xxxxxxx}]xxxxxxxxx xxxxxxxx a[{6-[(2-amino-4-hydroxyfenyl)azo]- xxxx 6-[(2-xxxxx-6-xxxxxxxxxxxx)xxx]- nebo 6-[(4-xxxxx-2-xxxxxxxxxxxx)xxx]-5-xxxxxxxxx-3-xxxxxxxxxxxxxxxxx-2-xxx-1'-xxxxxx-1,2'-xxxxxxx}(6-{[1-(X-xxxxxxxxxxxxxx)-2-xxxxxxxxxxx-1-xx-1-xx]xxx}-5-xxxxxxxxx-3-xxxxxxxxxxxxxxxxx-2-xxx-1'-xxxxxx-1,2'-xxxxxxx)]xxxxxxxxx xxxxxxxx |
402–850–1 |
Xx X: 41–52/53 S: (2-)26–39–61 |
|||||
|
611–044–00–0 |
Xxxx:[xxx(5-xxxxxxxxxxx-1-xxx-1'-xxxxxxxx-2,2'-xxxxxxx)]xxxxxxxxx xxxx-xxxxx(X12-X14)xxxxxx, [xxx(4-xxxxxxxxxxx-1-xxx-1'-xxxxxxxx-2,2'-xxxxxxx)]xxxxxxxxx xxxx-xxxxx(X12-X14)xxxxxx, [xxx(5-xxxx-xxxxx-3-xxxxxxxxxxx-1-xxx-1'-xxxxxxxx-2,2'-xxxxxxx)]xxxxxxxxx xxxx-xxxxx(X12-X14)xxxxxx, [(5-xxxx-xxxxx-3-xxxxxxxxxxx-1-xxx-1'-xxxxxxxx-2,2'-xxxxxxx)(5-xxxxxxxxxxx-1-xxx-1'-xxxxxxxx-2,2'-xxxxxxx)]xxxxxxxxx xxxx-xxxxx(X12-X14)xxxxxx x[(4(5)-xxxxxxxxxxx-1-xxx-1'-xxxxxxxx-2,2'-xxxxxxx) (3-xxxxx-5-xxxxxxxxxxxx-1-xxx-1'-xxxxxxxx-2,2'-xxxxxxx)]xxxxxxxxx xxxx-xxxxx(X12-X14)xxxxxx |
403–720–7 |
117527–94–3 |
X; X51–53 |
Xx; R41 X52–53 |
|||
|
611–045–00–6 |
2-({4-[(4-xxxxxxxxxxxx)xxxxxxxxxx]-2-xxxxxxxxxxx}xxx)-3-xxxxxx-5-xxxxxxxxxxxx |
404–830–8 |
— |
X53 |
X:53 S: 61 |
N X: 51/53 S: 61 |
||
|
611–046–00–1 |
4,4'-xxxxxxx-2-xxxxxxxxxxxxxxx2-xxxxxxxxxxxxxxx-4,4'-xxxxxx |
407–590–2 |
43151–99–1 |
X; X25 Xn; X48/22 R43 X; X50–53 |
X; X R: 25–43–48/22–50/53 X: (1/2-)22–28–36/37–45–60–61 |
|||
|
611–047–00–7 |
Xxxx (1:1):2-({4-[(2-xxxxxxxxxxxx)xxxxxxxxxx]xxxxx}xxx)-5,6-xxxxxxxxxxxxxxxxxxx x 2-({4-[(2-xxxxxxxxxxxx)xxxxxxxxxx]xxxxx}xxx)-6,7-xxxxxxxxxxxxxxxxxxx |
407–890–3 |
111381–11–4 |
X53 |
X: 53 S: 61 |
|||
|
611–048–00–2 |
Xxxx (1:1):2-({4-[xxx(2-xxxxxxxxxxxx)xxxxx]xxxxx}xxx)-5,6-xxxxxxxxxxxxxxxxxxx x 2-({4-[bis(2-acetoxyethyl)amino]fenyl}azo)-6,7-dichlorbenzothiazol |
407–900–6 |
111381–12–5 |
R53 |
R: 53 X: 61 |
|||
|
611–049–00–8 |
Xxxx (2:1:1)7-[(4-{[3-(xxxxxxxxxxxx)xxxxxx]xxxxx}-6-{[3-(xxxxxxxxxxxxx)xxxxxx]xxxxx}-1,3,5-xxxxxxx-2-xx)xxxxx]-3-{[4-(xxxxxxxx)xxxxx]xxx}-4-xxxxxxxxxxxxxxx-2-xxxxxxxx, kyselina xxxxxx x xxxxxx xxxxxxxx (2:1:1) |
408–000–6 |
118658–98–3 |
Xx; X48/22 R43 X52–53 |
Xx X: 43–48/22–52/53 X: (2-(22–36/37–61 |
|||
|
611–051–00–9 |
2-({4-[xxxxx(2-xxxxxxxxxxxx)xxxxx]-2-xxxxxxxxxxx}xxx)-6-xxxxxxx-3-xxxxxxxxxxxxxxxxxxxxx-xxxxxxx |
411–110–7 |
136213–74–6 |
X; X50–53 |
X X: 50/53 X: 60-61 |
|||
|
611–052–00–4 |
[xxxx{4-[(2-xxxxxxx-3,5-xxxxxxxxxxxx) xxx]-6-[(6-xxxxxxxxx-1-xxxxxx)xxx]xxxxxx-1,3-xxxxxxx}]xxxxxxxxx komplex, xxxxx xxx |
400–720–9 |
— |
X52–53 |
X: 52/53 X: 61 |
|||
|
612–156–00–2 |
Xxxx:xxxxxxxxxxxx(xxxxxx)xxxxxxx-xxxxxxx a xxxxxxxxxxx(xxxxxxxx)xxxxxxx-xxxxxxx |
405–620–9 |
— |
Xx; X41 X; X50–53 |
Xx; X R: 41–50/53 X: (2-)26–39–60–61 |
|||
|
612–157–00–8 |
(X)-1-(1-xxxxxxxxxxxx-2-xx)xxxxx-1-xx-xxxx-xxxxxxxxxxxx |
410–780–8 |
— |
Xx; X22–48/22 Xx; X41 X43 X; R51–53 |
Xn; X X: 22–41–43–48/22–51/53 X: (2-)22–26–36/37/39–61 |
|||
|
612–158–00–3 |
Směs:[bis(5-alkyl(rozvětvený X12))-2-xxxxxxxxxxxxxxxxxxxxx)]xxxxxxx xxxxxxx x 4-dodecyl-2-hydroxybenzaldoxim[bis(5-alkyl(rozvětvený X12))-2-xxxxxxxxxxxxxxxxxxxxx)]xxxxxxx xxxxxxx a 4-xxxxxxxxxxxxxxxxxxxxx |
410–820–4 |
— |
X53 |
X: 53 X: 61 |
|||
|
612–159–00–9 |
xxxxxxx xxxxxxxx xxxxx 2,2,4-xxxxxxxxx- x 2,4,4-trimethylhexan-1,6-diaminu (x xxxxxxx XXXXXX), xxxxxxxx [(xxxxx(X10-X16)xxx)xxxxxx]xxxxxxx (Xxxxxx 8) a 4-methylbenzen-1-sulfonové xxxxxxxx |
410–880–1 |
— |
Xx; X22 X; X34 X; X50–53 |
X; X X: 22–34–50/53 X: (1/2-)23–26–36/37/39–45–60–61 |
|||
|
613–149–00–7 |
2-xxxx-xxxxx-5-[(4-xxxx-xxxxxxxxxxx)xxxxxxxx]-4-xxxxxxxxxxxxxx-3(2X)-xx |
405–700–3 |
96489–71–3 |
X; X23/25 X; R50–53 |
T; X X: 23/25–50/53 S: (1/2-)36/37–45–60–61 |
|||
|
613–150–00–2 |
2,2'-[xxxxxxxxx-1,4-xxxxxx(xxxxxx-1,3-xxxx)]xxx(xxxxxxxxxxx[2,1-x]xxxxx[xxx][3,8]xxxxxxxxxxxx-1,3,6-xxxxx) |
406–295–6 |
— |
X53 |
X:53 X: 61 |
|||
|
613–151–00–8 |
1-(2-deoxy-3-O-mesyl-5-O-trityl-β-D-threo-pentofuranosyl)-5-methylpyrimidin-2(1H), 4(3 H)-dion |
406–360–9 |
104218–44–2 |
R53 |
R:53 X: 61 |
|||
|
613–152–00–3 |
xxxxx-X-(4,6-xxxxxxxxxxxxxxxxxx-2-xx)xxxxxxxx |
406–600–2 |
89392–03–0 |
X43 X; R51–53 |
Xi; X X: 43–51/53 X: (2-)24–37–61 |
|||
|
613–153–00–9 |
2,3,5-xxxxxxxxxxxxxxx |
407–270–2 |
16063–70–0 |
X52–53 |
X:52/53 X: 61 |
|||
|
613–154–00–4 |
2-xxxxx-4-xxxxx-6-xxxxxxxxxxxxxxxx |
410–050–9 |
5734–64–5 |
Xx; R22 |
Xn X: 22 S: (2-)22 |
|||
|
613–155–00-X |
5-xxxxx-2,3-xxxxxxxxxxxxxx |
410–090–7 |
89402–43–7 |
X10 Xx; X22 X52–53 |
Xx X: 10–22–52/53 X: (2-)23–36–61 |
|||
|
613–156–00–5 |
2-xxxxx-4-xxxxx-5-xxxxxxxxxxxxxx 2-butyl-5-chlorimidazol-4-karbaldehyd |
410–260–0 |
83857–96–9 |
R43 X; X51–53 |
Xx; X X: 43–51/53 X: (2-)24–37–61 |
|||
|
613–157–00–0 |
2,4-xxxxxxx-5-(xxxxxxxxxxxxx)xxxxxxxxx 5-(xxxxxxxxxxxxx)xxxxxxxxx-2,4-xxxxxx |
410–330–0 |
54236–98–5 |
Xx; X22–48/22 Xx; X36 |
Xx X: 22–36–48/22 X: (2-)22–26–36 |
|||
|
613–158–00–6 |
2,3-dichlor-5-(trifluormethyl)pyridin |
410–340–5 |
69045–84–7 |
Xn; X20/22 Xx; R41 X43 X; X51–53 |
Xx; X X: 20/22–41–43–51/53 X: (2-)24–26–37/39–61 |
|||
|
613–159–00–1 |
4-[2-(4-xxxx-xxxxxxxxxx)xxxxxx]xxxxxxxxxx |
410–580–0 |
120928–09–8 |
X; R25 Xx; X20 X; X50–53 |
X; X X: 20–25–50/53 X: (1/2-)37–45–60–61 |
|||
|
613–160–00–7 |
2-xxxxxx-2,5-xxxxxxxxxxxx[2.2.1]xxxxxx-xxxxxxxxxxxxx |
411–000–9 |
125224–62–6 |
X43 |
Xx X: 43 X: (2-)24-37 |
|||
|
615–022–00–1 |
xxxxxx-3-(xxxxxxxxxxxxxxxxxx)xxxxxxx-2-xxxxxxxxxx |
410–550–7 |
79277–18–2 |
X; X2 X14 Xx; X48/22 R42/43 |
E; Xx X: 2–14–42/43–48/22 X: (2-)22–30–35–36/37 |
|||
|
615–023–00–7 |
xxxxxxxxxxx 2-[(isokyanatosulfonyl)methyl]benzoové xxxxxxxxxxxxxx-2-[(xxxxxxxxxxxxxxxxxx)xxxxxx]xxxxxxx |
410–900–9 |
83056–32–0 |
X10 X14 Xxxx. kat. 3; X40 Xn; X20–48/22 Xi; R41 X42 |
Xx X: 10–14–20–40–41–42–48/22 X: (2-)23–26–36/37/39 |
|||
|
616–044–00–4 |
N-(3,5-dichlor-4-ethyl-2-hydroxyfenyl)-2-(3-pentadecylfenoxy)butanamid |
402–510–2 |
— |
N; X51–53 |
X X: 51/53 X: 61 |
|||
|
616–045–00-X |
2'-[(4-xxxxx-5-xxxxxx-3-xxxx-2-xxxxxxx)xxx]- 5'-(xxxxxxxxxxxx)-2-xxxxxxxxxxxxxxxxx |
405–190–2 |
122371–93–1 |
X43 X53 |
Xx X: 43-53 X: (2-)22–24–37–61 |
|||
|
616–046–00–5 |
X -[2-(6-chlor-7-methylpyrazolo[1,5-b][1,2,4]triazol-4-yl)propyl]-2-(2,4-di-terc-pentylfenoxy)oktanamid |
406–390–2 |
— |
N; R50–53 |
N X: 50/53 X: 60-61 |
|||
|
616–047–00–0 |
Xxxx:X,X′,X″,X′′′ - xxxxxxxxxx(X16)-2,2′, 2″, 2′′′ (ethylendinitrilo)tetraacetamid x X, X′,X″,X′′′ - xxxxxxxxxx(X18)- 2,2′, 2′′, 2′′′-(ethylendinitrilo)tetraacetamid |
406–640–0 |
— |
R43 |
Xi R: 43 S: (2-)24-37 |
|||
|
616–048–00–6 |
3'-(trifluormethyl)isobutyranilid |
406–740–4 |
1939–27–1 |
Xn; X48/22 X; X51–53 |
Xx; X X: 48/22–51/53 X: (2-)22–36–61 |
|||
|
616–049–00–1 |
2-(2,4-di-terc-butylfenoxy)-N-(3,5-dichlor-4-ethyl-2-hydroxyfenyl)hexanamid |
408–150–2 |
99141–89–6 |
R53 |
R:53 X: 61 |
|||
|
616–050–00–7 |
1-[2,5-xxxxxxx-4-(1,1,2,3,3,3-xxxxxxxxxxxxxxxx)xxxxx]-3-(2,6-xxxxxxxxxxxx)xxxxxxxx |
410–690–9 |
103055–07–8 |
X43 X; X50–53 |
Xx; X R: 43–50/53 X: (2-)24–37–60–61 |
|||
|
616–051–00–2 |
Xxxx:3,3'-xxx(4-xxxxxxxxxxx)- 1,1'-(4-xxxxxx-1,3-xxxxxxx)xxxxxxxxxx x 3,3'-bis(4-methylfenyl)-1,1'-(2-methyl-1,3-fenylen)dimočovina Směs:2,4-bis[3-(4-methylfenyl)ureido]toluen x 2,6-xxx[(3-(4-xxxxxxxxxxx)xxxxxx]xxxxxx |
411–070–0 |
— |
X53 |
X: 53 X: 61 |
|||
|
617–015–00–9 |
bis(4-methylbenzoyl)peroxid |
407–950–9 |
895–85–2 |
E; R2 X; X7 N; X50–53 |
X; X X: 2–7–50/53 S: (2-)7–14–36/37/39–47–60–61 |
|||
|
650–032–00-X |
cyprokonazol (XXX) (2X, 3X)-, (2 X, 3 X)-, (2 X, 3 X)-, (2 X, 3 X)-2-(4-xxxxxxxxxx)-3-xxxxxxxxxxx-1-(1X- 1,2,4-xxxxxxx-1-xx)xxxxx-2-xx |
— |
94361–06–5 |
Xxxx. kat. 3; X63 Xn; X22 X; X50–53 |
Xx; X X: 22–50/53–63 X: (2-)36/37–60–61 |
PŘÍLOHA 2
XXXXXX SPECIFICKÝCH XXXXX SPOJENÝCH X XXXXXXXXXXXX LÁTKAMI X XXXXXXXXX
Xxx směrnice Komise 2001/59/XX,
Xx. xxxx. L 332, 28.12.2000, x. 81.
XXXXXXX 3A
STANDARDNÍ POKYNY XXX XXXXXXXX ZACHÁZENÍ X XXXXXXXXXXXX XXXXXXX X XXXXXXXXX
Xxx směrnice Xxxxxx 2001/59/XX,
Xx. věst. X 332, 28.12.2000, x. 81.
XXXXXXX 3X
XXXXXXXXXX XXXXXX XXX XXXXXXXX XXXXXXXXX X XXXXXXXXXXXX LÁTKAMI X XXXXXXXXX
Xxx xxxxxxxx Xxxxxx 2001/59/XX,
Xx. xxxx. X 332, 28.12.2000, x. 81.
XXXXXXX 4X
"X.10 XXXXXXXXXX — XXXXXXX XX XXXXXXXXXXXX XXXXXXX X XXXXX XX XXXXX
1. XXXXXX
Xxxx xxxxxx je xxxxxxxx xxxxxx XXXX XX 473 — Xxxxxxx xx xxxxxxxxxxxx xxxxxxx x xxxxx xx xxxxx (1997).
1.1 XXXX
Xxxxxxx xx chromozomové xxxxxxx x savců xx xxxxx xx xxxxxxxxxxxxx činitele, které xxxxxxxxx strukturní xxxxxxxxxxxx xxxxxxx x xxxxxxxxxxxxx xxxxxxx xxxxx (1, 2, 3). Xxxxxxxxx xx xxx xxxx xxxxxxxxxxxx xxxxxxx: xxxxxxxxxxxx x xxxxxxxxxxxx. U xxxxxxx xxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxx, xxxxx xxxxxxxxxxxx xxxxxxx se xxxxxx vyskytují. Xxxxxx xxxxxxxxxxx xxxx xxxxxxxx, xx xxxxxxxx látka xx xxxxxxxxx xxxxxxxxx xxxxxxxxx aberace. Xxxx xxxxxx však xxxx xxxxxx xx stanovení xxxxxxxxxxx xxxxxxx a xxxx k xxxxxx xxxxx xxxxxxx používána. Xxxxxxxxxxxx mutace x xxxxxxx xxxx jsou xxxxxxxx mnoha geneticky xxxxxxxxxxx xxxxxx x xxxxxxx a xxxxxxxx xxxxx xxxxxx o xxx, xx xxxxxxxxxxxx xxxxxx x x xxxx související xxxx xxxxxxxxxxx změny v xxxxxxxxxx x x xxxxxx xxxxxxxxxxx xxxxx xxxxxxxxx xxxxxx, mají xxxxx xx xxxxxxx xxxxxxxx u člověka x x xxxxxxxxx xxxxxx.
Xx xxxxxxx xx xxxxxxxxxxxx xxxxxxx xx xxxxx xxxxx být xxxxxxx xxxxxxxxxxxxx xxxxxxx xxxxx, xxxxxxx xxxxx xxxx xxxxxxxx xxxxxxx xxxxxxx. Xxxxxxx buňky xxxx vybrány xx xxxxxxx schopnosti xxxxx x kultuře, xxxxxxxx xxxxxxxxx, počtu xxxxxxxxxx, xxxxxxxxxxxx xxxxxxxxxx a xxxxxxxxx xxxxxxxx chromozomových xxxxxxx.
Xxxxxxx prováděné xx xxxxx xxxxxx xxxxxxxx xxxxxxx vnějšího xxxxxx xxxxxxxxxxx aktivace. Xxxxx xxxxxxxxxxx xxxxxxxxx systém xxxxxx xxxxx xxxxxxxxx xxxxxxxx xx xxxx x xxxxx. Xx xxxxx se zcela xxxxxxxxx podmínek, xxxxx xx xxxxx x xxxxxxxxxx xxxxxxxxx, xxx xxxxxxxxxx xxxxxxx xxxxxxxxxx x xxxx x xxx xxxxx xxxxxx xX, xxxxxxxxxx nebo xxxxxxxx xxxxxx cytotoxicity (4, 5).
Xxxx xxxxxxx xx xxxxxxx xx xxxxxxxx možných mutagenů x karcinogenů xxx xxxxx. Xxxxx xxxxxxxxx, xxx xxx xx xxxx xxxxxxx xxxxxxxxx, xxxx pro xxxxx xxxxxxxxxxx; xxxx touto xxxxxxxx x xxxxxxxxxxxxxx xxxx xxxx absolutní xxxxxxxx. Xxxxxxxx xxxxxx xx xxxxxxxx třídě x přibývají důkazy x xxx, xx xxxxxxxx karcinogeny, xxxxx xxxxxx zjištěny xxxxx xxxxxxxx, neboť xxxxxx xxxxxx xxxxxx xxxxxxxxxx xxx přímým xxxxxxxxxx XXX.
Xxx také Xxxxxx xxxx, xxxx B.
1.2 XXXXXXXX
Xxxxxxxxxxxx xxxxxxx : xxxxxxxxxx poškození chromozomu x xxxxxx xxxxx xxxxxxxxxxxx chromatid xxxx xxxxx a xxxxxxxx xxxxxxx xxxxxxxxx.
Xxxxxxxxxxxx aberace : strukturní xxxxxxxxx xxxxxxxxxx x xxxxxx xxxxx nebo xxxxx x xxxxxxx xxxx xxxxxxxxx x tomtéž xxxxx.
Xxxxxxxxxxxxxxx : xxxxxx, xxx xxxxxx v xxxxx po X-xxxx xxxxxxxxx XXX xxxxxxx x mitóze, xxxxx xxxxxxxxx další X-xxxx. Xxxxxxxxx xxxx xxxxxxxxxx xx 4, 8, 16… xxxxxxxxxxxx.
Xxx : xxxxxxxxxxxx xxxx menší xxx xxxxx jedné xxxxxxxxxx x x xxxxxxxxx xxxxxxxxx xxxxxxxxx.
Xxxxxxxxx xxxxx : xxxxx xxxxx, které se xxxxxxxxx x metafázi, x celkového xxxxx xxxxx x xxxxxxxx; xxxxx xxxxxx xxxxxxxxxxx xxxx populace.
Numerická aberace : odchylka xxxxx xxxxxxxxxx od xxxxxxxxxx xxxxx xxxxxxxxx u xxxxxxxxx xxxx xxxxx.
Xxxxxxxxxxx : násobek xxxxxxxxxxx xxxxx chromozomových xxx (x), xxxx než xxxxxxxxx (xx. 3 x, 4 n xxx.).
Xxxxxxxxxx xxxxxxx : xxxxxxxxxxxxx xxxxxxxxxxxxx změny xxxxxxxxx xxxxxxxxxx xxx xxxxxxxx xxxxxx xx xxxxxx xxxxxxxx; jeví xx jako delece x fragmenty, xxxxxxxxxxxxxxxxxx xxxx interchromozomální xxxxx.
1.3 XXXXXXXX XXXXXXXX XXXXXX
Xxxxxxx xxxxxxx xxxx vystaveny xxxxxxxx xxxxx, x xx s xxxxxxxxxxxx xxxxxxxx a bez xx. X xxxxxx xxxxxxxxxxx xxxxxxxxxxx po xxxxxxxx xxxxx xx xx buněčných xxxxxx xxxxx látka xxxxxxxxxxx xxxxxxxx (např. Colcemid® xxxx kolchicin), xxxxxxx xx xxxxxx, xxxxxx x xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxx se xxxxxx xxxxxxxxxxxxxx pozorováním xxxxx.
1.4 XXXXX ZKUŠEBNÍ METODY
1.4.1 Xxxxxxxxx
1.4.1.1 Xxxxx
Xxxxx xxx xxxxxxx xxxxx buněčné xxxxx, xxxxx nebo xxxxxxxx xxxxxxx xxxxxxx, xxxxxx xxxxxxxx xxxxxxxxx xxxxx (např. fibroblasty xxxxxx xxxxxxxx, xxxxxxxxx xxxxxxxxx xxxx člověka xxxx xxxxxx savců).
1.4.1.2 Xxxxx x xxxxxxxxxx xxxxxxxx
Xxx xxxxxxxxx kultur xx měla xxx xxxxxxx vhodná xxxxxxxxxx xxxxx x xxxxxxxxx xxxxxxxx (xxxxxxxxxx xxxxxx, xxxxxxxxxxx CO2, xxxxxxx x xxxxxxx). U xxxxxxxxxxxxxxx buněčných xxxxx x kmenů xx xxxx xxx xxxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxxxx xxxxxxx xxxxx xxxxxxxxxx x mělo xx xxx kontrolováno, zda xxxxxx xxxxxxxxxxxxx mykoplasmaty; x případě kontaminace xx xxxxxx být xxxxxxx. Xxx použité xxxxx x inkubační xxxxxxxx xx měla xxx xxxxx xxxxxxxx xxxxx xxxxxxxxx cyklu.
1.4.1.3 Xxxxxxxx xxxxxx
Xxxxxxxxxxxxx buněčné xxxxx x kmeny: xxxxx xx xxxxxxx x xxxxxxxxx kultur, xxxxxx se xx xxxxxxxxxxxx xxxxx x xxxxxx xxxxxxx, aby xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx, x xxxxxxxx xx xxx 37 °X.
Xxxxxxxxx: xxxx ošetřená xxxxxxxxxxxxxxx (xxxx. xxxxxxxxx) xxxx xxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxxx se xxxxxxx do kultivačního xxxxx xxxxxxxxxxxx mitogen (xxxx. xxxxxxxxxxxxxxxx) x xxxxxxxx xx xxx 37 °X.
1.4.1.4 Xxxxxxxxxxx xxxxxxxx
Xxxxx xx xxxx xxx vystaveny xxxxxxxx xxxxx, x to x xxxxxxx xxxxxxxxxxxx xxxxxxxx x xxx xx. Xxxxxxxxxx xxxxxxxxxx xxxxxxxx xx kofaktorem xxxxxxxx xxxxxxxxxxxxxxxxxxx xxxxxx (X9) připravená x xxxxx hlodavců xxxxxxxxxx xxxxxxxx xxxxxxxxxxx enzymy, xxxx xx Aroclor 1254 (6, 7, 8 x 9), xxxx xxxx fenobarbitonu x β-naftoflavonu (10, 11 a 12).
Xxxxxxxxxxxxxxxxxxx xxxxxx je x xxxxxxxx testovacím xxxxx xxxxxxx používána v xxxxxxxxxxxxx 1 — 10 % xxx. Xxxx metabolického aktivačního xxxxxxx xxxx xxxxxxx xx třídě chemické xxxxx, xxxxx xx xxxxxxxx. V xxxxxxxxx xxxxxxxxx xxxx xxx xxxxxx použít xxxx xxx xxxxx xxxxxxxxxxx xxxxxxxxxxxxxxxxxxx frakce.
Řada xxxxxxxx xxxxxx, včetně xxxxxxxx xxxxxxxxx modifikovaných xxxxxxxxx xxxxx exprimujících xxxxxxxxxx xxxxxxxxx xxxxxx, xxxxxxxxx xxxxxxxx xxx xxxxxxxxx xxxxxxxx. Xxxxx použitých xxxxxxxxx xxxxx xx xxxx xxx xxxxxxx xxxxxxxxxx (např. důležitostí xxxxxxxxx xxxxxxxxxx X450 xxx metabolismus xxxxxxxx xxxxx).
1.4.1.5 Zkoušená látka/příprava
Pevné xxxxxxxx xxxxx by xxxx být před xxxxxxxx xx xxxxx xxxxxxxxxx xxxx suspendovány xx vhodných xxxxxxxxxxxxxx xxxx xxxxxxxxxx a xxxxxxxxx xxxxxxx. Kapalné xxxxxxxx xxxxx mohou xxx xxxxxxx xxxxx x xxxxxxxxxx xxxxxxxx x/xxxx mohou xxx xxxx aplikací xxxxxxx. Xxxx by být xxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxx xxxxx, pokud xxxxx o xxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxxxxx.
1.4.2 Xxxxxxxx podmínky
1.4.2.1 Rozpouštědlo/vehikulum
Rozpouštědlo/vehikulum xx mělo xxx xxxx podezření, xx xxxxxxx xx xxxxxxxxx xxxxxx, x xxxx xx xxx slučitelné x xxxxxxxx xxxxx x x xxxxxxxxx X9. Xxxx-xx xxxxxxx xxxx než xxxxx xxxxxxxxxxxx/xxxxxxxx, xxxx by xxx xxxxxx zařazení xxxxxxxxx xxxxx o xxxxxx xxxxxxxxxxxxx. Doporučuje xx xxxxx možno xxxxxxxx xxxxxx xxxxxxx xxxxxxx xxxxxxxxxxxx/xxxxxxx. Xxx xxxxxxxx látek nestálých xx xxxx xx xxxx být použita xxxxxxxxx xxxxxxxxxxxx neobsahující xxxx. Xxxx xxx xxxxxxxxx xxxxxxxx xxxxxxxxxxxx xxxx.
1.4.2.2 Xxxxxxxxx koncentrace
Mezi xxxxxxxx, xxxxx xxxx xxx zohledněna xxx xxxxxxxxx nejvyšší xxxxxxxxxxx, xxxxx xxxxxxxxxxxx, xxxxxxxxxxx x testovacím xxxxxxx x xxxxx xX xxxx xxxxxxxxxx.
Xxxxxxxxxxxx xx xxxx xxx stanovena x xxxxxxxxxxxx xxxxxxxx x xxx xx x xxxxxxx xxxxxxxxxxx xx použití xxxxxxxx xxxxxxxxxx xxxxxxx integrity x xxxxx, xxxx xxxx stupeň xxxxxxxxxx, xxxxx xxxxxxxxxxxxxxx xxxxx xxxx xxxxxxxxx index. Xxxx být xxxxxxx xxxxxxxx xxxxxxxxxxxx a xxxxxxxxxxx x xxxxxxxxxx xxxxxxxxxxx.
Xxxx by xxx xxxxxxx xxxxxxx xxx xxxxxxxxxxxxxx xxxxxxxxxxx. X xxxxxxx xxxxxxxxxxxx xx xxxx xxxx koncentrace xxxxxxxx rozmezí xxxx xxxxxxxxx xx minimální xxxxxxxxx, xxxxxxxx xxxxxx xxxxxxxxx, xxx obvykle xxxxxxx, že xx xx koncentrace xxxxxx xxxxx xxxx nežli xxxxxxxx 2 xx Ö10. X xxxxxxxx xxxxxxx by měla xxxxxxxx xxxxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxx xxxxxx xxxxxxxxxx, xxxxx xxxxx xxxx xxxxxxxxxxx xxxxxx (xxx x xxxx xxx 50 %). Xxxxxxxxx index xx xxxxx xxxxxxxx xxxxxxxx xxxxxxxxxxxxx nebo cytostatických xxxxxx x závisí xx xxxx, xxxxx xxxxxxxx xx expozice. Xxxxxxxxx index xx xxxx xxxxxxxxxx u xxxxxxxxxxx xxxxxx, x xxxxx mohou xxx xxxx xxxxxx stanovení xxxxxxxx xxxxxxx x xxxxxxxxxxx. Xxxxxxxxx o xxxxxxxx buněčného xxxxx, xxxxxxxxx xxxxxxxx xxxxxxxxx xxxx (XXX), xxxxx xxx xxxxxxx xxxx xxxxxxxxx xxxxxxxxx. V xxxxxxx XXX xxxx xxx o xxxxxxxx xxxxxxxxx xxxxxxx, z xxx nelze usoudit xx existenci xxxxxxxxxx xxxxxxxxxxx, a i xxxx přírůstek průměrné xxxxxxxxx xxxx xxxx xxx za xxxxxxxx xxxxx xxxxxxxxx xxxxxxxx xxxxxxxx optimálního výtěžku xxxxxxx.
X xxxxxxx relativně xxxxxxxxxxxxxxx xxxxx by xxxx být maximální xxxxxxxx xxxxxxxxxxx 5 μx/xx, 5 xx/xx xxxx 0,01 X, xxxxx xxxx, která x xxxx je xxxxxxxx.
X xxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxx, které xxxxxx xxxxxxx xxx xxxxxxxxxxxxx xxxxxxx, xxx xx xxxxxx xxxxxxxxxxx, xx xxxx xxx xxxxxxx xxxxxxxx xxxxx x xxxxxxxxxxx, xxx xx xxx xxxx xxxxxxxxxxxx v xxxxxxxx xxxxxxxxxxx médiu na xxxxx xxxx aplikace. X určitých případech (xxxx. xxxxxxx-xx xx xxxxxxxx xxxxx při xxxxxxx koncentracích, xxx xx xxxxxxxxxxx) xx xxxxxxxxxx vyzkoušet xxxx xxxxxxxxxxx, xxx nichž xxxxxxx ke srážení. Xxxx být xxxxxxxx xxxxxxxx xxxxxxxxxxx xx xxxxxxx a xx xxxxx xxxxxxxx, xxxxx xxxxxxxxxxx x xxxxxxxxxx xxxxxxx xx xxxx x xxxxxxx xxxxxxxx xxxxx v xxxxxxxx xxxxxxxxxxx buněk, xxxx X9 xxx. Xxxxxxxxxxxxx xxx xxxxxxx xxxxxxxx. Xxxxxxxxx by xxxxxx xxxxx xxx xxxxxxxxxxx.
1.4.2.3 Xxxxxxxxx x xxxxxxxxx xxxxxxxx
Xxxxxxxx xxxxxxx xxxxxxxxxxx xx xxxx xxx xxxxxxxxx a xxxxxxxxx xxxxxxxx (xxxxxxxx xxxxxxxxxxxx xxxx vehikula). Xxx xxxxxxx metabolické xxxxxxxx xx měla xxx xxx xxxxxxxxx kontrolu xxxxxxx xxxxxxxx xxxxx, xxxxx x xxxxxxxxx xxxxxx xxxxxxxx aktivaci.
K xxxxxxxxx xxxxxxxx xx xxx xxx xxxxxx xxxxx xxxxxxxxx x xxxxxxxxxxx xxxxxxxxxxxxx, xxxxx xxxxxxxx xxxxxxxxx xxxxxxxxxxxxxxxx x xxxxxxxxxxxxx xxxxxx xxx pozadí, xxxx xx xxxxxxx citlivost xxxxxxxxxxx xxxxxxx.
Xxxxxxxxxxx pozitivních xxxxxxx xx xxxx xxx xxxxxxx tak, xxx xxx xxxxxx xxxxxxxx, xxx xxx xxx odečtu xxxxxxx xxxxx najevo xxxxxxxx xxxxxxxxxxxx preparátu. Xxxxxxxx xxxxxxxxxxx a xxxxxxxxxxx xxxxxxx:
|
Xxxx metabolické xxxxxxxx |
Xxxxx |
Xxxxx XXX |
Xxxxx xxxxx XXXXXX |
|
Xxx xxxxxx xxxxxxxxxxx aktivace |
methyl-methansulfonát |
66–27–3 |
200–625–0 |
|
ethyl-methansulfonát |
62–50–0 |
200–536–7 |
|
|
1-ethyl-1-nitrosomočovina |
759–73–9 |
212–072–2 |
|
|
mitomycin X |
50–07–7 |
200–008–6 |
|
|
4-xxxxxxxxxxxxx-1-xxxx |
56–57–5 |
200–281–1 |
|
|
X xxxxxx xxxxxxxxxxxx xxxxxxxx |
xxxxx[x]xxxxx |
50–32–8 |
200–028–5 |
|
xxxxxxxxxxxxx |
50–18–0 |
200–015–4 |
|
|
xxxxxxxxxxxxx monohydrát |
6055–19–2 |
Pro pozitivní xxxxxxxx xxxxx být xxxxxxx x jiné xxxxxx xxxxx. Xxx xxxxxxxxx xxxxxxxx xx xxxx xxx xxxxx xxxxx xxxxx v xxxxx xxxxxxx xxxxxxxxxx xxxxx xx xxxxxx xxxxxxxx xxxxx.
X okamžiku xxxxxxxx by xxxx xxx xxxxxxx negativní xxxxxxxx xxxxxxxxxx se xx samotného xxxxxxxxxxxx xxxx xxxxxxxx x xxxxxxxxxxx xxxxx x xxxxxxxxxx xxxxxxx xxxxxxxx xxxx kultury. Kromě xxxx xx měly xxx neexponované kontroly xxxxxxx xxxx tehdy, xxxxxxxxxx-xx xxxxx xxxxx xxxxxxxxx xxxxx prokazující, xx zvolené xxxxxxxxxxxx xxxxxxxxxx žádné zhoubné xxxx xxxxxxxxx účinky.
1.4.3 Xxxxxx
1.4.3.1 Xxxxxxxx xxxxxxxx xxxxx
Xxxxxxxxxxxxx xxxxx se xxxxxxx xxxxxxxx xxxxx xxx za xxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxx systému, xxx xxx xxxx. Xxxxxxxx lymfocytů by xxxx xxx zahájena xxx 48 xxxxx xx mitogenní xxxxxxxxx.
1.4.3.2 Xxx každou koncentraci xx xxxx xxx xxxxxxx xxxxxxx duplicitní xxxxxxx, x totéž xx xxxxxxx doporučuje x kultur pro xxxxxxxxx xxxxxxxx xxxx xxxxxxxx rozpouštědla. Jestliže xxx na xxxxxxx xxxxxxxxxxx xxxxx xxxxxxxx (13, 14), že xxxx xxxxxxxxxxxx kulturami xx minimální rozdíl, xxxx xxx xxxxxxxxx xxxxxxx xxxxxx xxxxxxx.
Xxxxxx xxxx xxxxxx látky xx měly xxx xxxxxxxx vhodnými xxxxxxxx, xxxx. x těsně xxxxxxxxxx kultivačních xxxxxxxx (15, 16).
1.4.3.3 Doba xxxxxxx xxxxxx
X xxxxxx xxxxxxxxxxx by xxxx xxx buňky xxxxxxxxx xxxxxxxx látce, xxx x metabolickou aktivací, xxx xxx ní, xx xxxx 3 — 6 xxxxx, x xxxx xx xxx xxxxxxxx po xxxxxx xxxx xx xxxxxxxx xxxxxxxx, která xxxxxxxx 1,5násobku normální xxxxx xxxxxxxxx cyklu (12). Xxxxxxxx xxxxx xxxxxx xxxx negativní xxxxxxxx jak x xxxxxxxx, xxx xxx xxxxxxxx, xxx xx xxx xxxxxxxx xxxxxxxxx xxxxxxxxxx xxx xxxxxxxx x xxxxxxxxxxxx xxxxxxxx xx xx xxxxxx x xxxx, xxxxx xxxxxxxx 1,5xxxxxxx normální xxxxx buněčného xxxxx. Xxxxxx xxxxxxxx xxxxx xxx xxxxx xxxxxxxxx xxx dobách xxxxxxxx xxxx xxxxxx xxxxxxx xxx 1,5xxxxxxx xxxxx xxxxx. Negativní výsledky xxx xxxxxxxxxxx aktivaci xxxx xxx xxxxxxxxx xxxxxx xx xxxxxxx. X xxxxxxxxx, xxx xx nepovažuje potvrzení xxxxxxxxxxx výsledků xx xxxxxxxx, xx xxxx xxx xxxxxx zdůvodnění.
1.4.3.4 Xxxxxxxx xxxxxxxxx pro xxxxxxx chromozomů
Do buněčné xxxxxxx xx xxxxxxx 1-3 xxxxxx xxxx xxxxxxxxx xxxxx Colcemid® xxxx xxxxxxxxx. Xxx xxxxxxxx xxxxxxxxx xxx xxxxxxx xxxxxxxxxx se xxxxx xxxxxxx xxxxxxx xxxxxx x xxxxxxxxxx xxxxxx. Xxxxxxxx xxxxxxxxx xxx xxxxxxx xxxxxxxxxx xxxxxxxx hypotonizaci buněk, xxxxxx x xxxxxxxx xxxxx.
1.4.3.5 Xxxxxxx
Xxxxxxx xxxxxxxxx, xxxxxx xxxxxxxxx xxxxxxxxxxx x xxxxxxxxxxx kontrol, xx měly xxx xxxx xxxxxxxx pod xxxxxxxxxxx xxxxxxxxx xxxxxxxx. Xxxxxxxx xxx fixaci xxxxx dochází xx xxxxx xxxxx xxxxx x xxxxxxxx x xx ztrátě xxxxxxxxxx, xxxx xx xxxxxxxxxxx xxxxx xxxxxxxxx xxxxxxxxxx x počtu xxxxxx xxxxxxx xxxxxxx ± 2 pro xxxxxxx xxxx buněk. Xx xxxxxx xxxxxxxxxxx x xxxxxxxx by mělo xxx xxxxxxxxx xxxxxxx 200 xxxxx xxxxxxxxxxxxxx xxxxxxxx, případně xxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxxxx xxxxxxx. Xxxxx xxxxx xxx xxxxxx, je-li xxxxxxxxx xxxxx xxxxx xxxxxxx.
Xxxxxx je xxxxxx xxxxxxx detekovat xxxxxxxxxx xxxxxxxxxxxx xxxxxxx, xx xxxxxxxx xxxxxxxxxx xxxxxxxxxxx x xxxxxxxxxxxxxxx, jsou-li xxxxxxxxxx.
2. XXXXX
2.1 ZPRACOVÁNÍ XXXXXXXX
Xxxxxxxxxxxxxx xxxxxxxxx je xxxxx x xxxx xx xxxx xxx xxxxxxxxxxx xxxxxxxx xxxxx xx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxx (xxxxxxxxx) vyjádřené x procentech. Xxx xxxxxxxxx x xxxxxxxxxxxxxx xxxxxxx xx xxxx xxx xxxxxxx xxxxx xxxx xxxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxx x xxxxxx xxxxxx x xxxxxxxx. Xxxx xx zaznamenávají xxxxxxxx x xxxxxxx xx, xxx xxxxxxxxxx xx xx xxxxxxx xxxxxxxx xxxxxxx.
Xxxx xx xxx xxxx xxxxxxxxxxx xxxxxxxx, která xxxx xxxxxxxxx xxx stanovení xxxxxxxxxxxx u xxxxx xxxxxxxxxxxx xxxxxx x xxxxxxxxxxx xxxxxx v xxxxxxxx xxxxxxxxxxxxx s xxxxxxxxx.
Xxxx by xxx xxxxxxx xxxxx xxx xxxxxxxxxx xxxxxxx. Xxxx xx měly být xxxxxxx údaje xxxxxxx xx xxxxx tabulky.
Ověření xxxxx xxxxxxxxx xxxxxxxx xx nepožaduje. Dvojznačné xxxxxxxx xx xxxx xxx vyjasněny dalším xxxxxxxxx, xxxxxxx s xxxxxxxx xxxxxxxxxxxxxxxx podmínek. Xxxxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxx xxxx diskutována x xxxx 1.4.3.3. Xxxxx xxxxxxxxx xxxxxx x cílem rozšířit xxxxxx xxxxxxxxxxxx podmínek xx měla xxx xxxxxxx x xxxxxxxxxx xxxxxxxxxxxxx. X xxxxxxxxxx xxxxxx, xxxxx by xxxxx xxx změněny, xxxxx rozmezí xxxxxxxxxxx x podmínky xxxxxxxxxxx xxxxxxxx.
2.2 XXXXXXXXX A XXXXXXXXXXXX VÝSLEDKŮ
Pro xxxxxxxxx xxxxxxxxxxx výsledku existuje xxxxxxx xxxxxxxx, xxxx. xxxxxx xxxxx buněk x chromozomovými xxxxxxxxx x xxxxxxxxxx xx xxxxxxxxxxx, xxxx xxxxxxxxxxxxxxxx xxxxxx xxxxxx počtu. Xxxxxxxx by xxxx xxx xxxxxxx biologická xxxxxxxxx xxxxxxxx. Při xxxxxxxxx výsledků zkoušky xxxxx xxx použity xxxx xxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxx (3, 13). Xxxxxxxxxxx xxxxxxxxxx xx xxxxxx xxx xxxxxxx určujícím xxxxxxxx xxx xxxxxxxxx xxxxxxx.
Xxxxxx xxxxx xxxxxxxxxxx buněk xxxx xxxxxxxx, xx xxxxxxxx xxxxx xx xxxxxxxxx xxxxxxxx mitotické xxxxxxx x xxxxxxxxx xxxxxxxxx chromozomové xxxxxxx. Xxxxxx xxxxx xxxxx x xxxxxxxxxxxxxxxxxxx chromozomy xxxx xxxxxxxx, že xxxxxxxx xxxxx má xxxxxxxxx xxxxxxxx progresi xxxxxxxxx cyklu (17, 18).
Xxxxxxxx xxxxx, xxxxx xxxxxxxx xxxxxxxxx xxxx xxxxxxx xxxxxxxx, se x xxxxx xxxxxxx xxxxxxxx xx nemutagenní.
Ačkoli xxxxxxx xxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxxx nebo xxxxxxxxx výsledky, x xxxxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxx xxxxx xxxxxxxx xxxxxxx výrok x xxxxxxxx zkoušené xxxxx. Xxxxxxxx xxxxx xxxxxx xxxxxxxxxx nebo xxxxxx xxx xxxxxx xx xx, kolikrát je xxxxxxxxxx xxxxxxxx.
Xxxxxxxxx xxxxxxxx xx zkoušky na xxxxxxxxxxxx xxxxxxx xx xxxxx xxxxxxxxx, že xxxxxxxx látka indukuje x xxxxxxxxxxxxx xxxxxxxxxxx xxxxxxx xxxxx xxxxxxxxxx xxxxxxxxxxxx xxxxxxx. Negativní xxxxxxxx znamenají, že xxxxxxxx xxxxx za xxxxxxxx zkoušky xxxxxxxxxx x xxxxxxxxxxxxx xxxxxxxxxxx xxxxxxx xxxxx xxxxxxxxxx xxxxxxxxxxxx aberace.
3. XXXXXX
XXXXXXXX X XXXXXXX
Xxxxxxxx x xxxxxxx musí obsahovat xxxx informace:
Rozpouštědlo/vehikulum:
- xxxxxxxxxx xxxxx xxxxxxxx,
- xxxxxxxxxxx x stálost xxxxxxxx xxxxx v xxxxxxxxxxxx/xxxxxxxx, xx-xx xxxxx.
Xxxxx:
- xxx x xxxxx buněk,
- xxxxxxxxxx xxxxxxxxx a xxxxxxxx xxxxxxxxx typu xxxxx,
- xxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx,
- informace x xxxxx xxxxxxxxx xxxxx,
- xxxxxxx dárce xxxx, xxx xxxx xxxxxxx xxxx xxxx nebo xxxxxxxxxx lymfocyty, xxxxxxx xxxxxxx,
- xxxxxxxx xxxxx xxxxxx,
- případně xxxxxx xxxxxxxxx buněčné xxxxxxx,
- xxxxxxx xxxxxxx počtu xxxxxxxxxx.
Xxxxxxxx podmínky:
- xxxxxxxxxxxx xxxxx xxxxxxxxxxx metafázi, xxxx xxxxxxxxxxx a xxxxx xxxxxxxx buněk,
- xxxxxxxxxx výběru xxxxxxxxxxx x xxxxx xxxxxx, xxxxxx xxxx. xxxxx x cytotoxicitě x xxxxxx xxxxxxxxxxxx, xxxx-xx x dispozici,
- xxxxxxx xxxxx, případně koncentrace XX2,
- koncentrace xxxxxxxx xxxxx,
- objem xxxxxxxx x xxxxxxx zkoušené xxxxx,
- xxxxxxxxx teplota,
- xxxxxxxxx xxxx,
- xxxxx xxxxxxxx,
- případně xxxxxxx xxxxx xxx xxxxxxxx,
- xxx a složení xxxxxxxxx metabolického aktivačního xxxxxxx, xxxxxx xxxxxxxx xxxxxxxxxxxxx,
- pozitivní x xxxxxxxxx xxxxxxxx,
- metody xxxxxxxx xxxxxxxxx,
- xxxxxxxx xxxxxxxxx xxxxxxx,
- počet xxxxxxxxxxxxx xxxxxxxx,
- metody xxxxxxxxx xxxxxxxx,
- kritéria xxxxxxxxxxx xxxxxx xx xxxxxxxxx, xxxxxxxxx xxxx xxxxxxxxxxx.
Xxxxxxxx:
- xxxxxx toxicity, xxxx. xxxxxx xxxxxxxxxx, xxxxx x xxxxxxxx xxxxx, xxxxx xxxxx, xxxxxxxxx xxxxx,
- známky xxxxxxx,
- údaje x xX x osmolalitě xxxxxxxxxxx xxxxx, xxxxx xxxx xxxxxxxxx,
- xxxxxxxx xxxxxxx, xxxxxx xxxx,
- xxxxx xxxxx x xxxxxxxxxxxxxx aberacemi x xxxx aberací xxxxxx xxx xxxxxx xxxxxxxxxxx x xxxxxxxxx xxxxxxx,
- xxxxx xxxxxxx, xxxxx xxxx xxxxxxxxxx,
- xxxxx xxxxxxxx xxxxxxxxx xxxxxxxx xx xxxxx,
- xxxxxxxx xxxxxxxxxxx xxxxxxx,
- xxxxx x souběžné xxxxxxxxx (xxxxxxxxxxxx/xxxxxxxxx) x xxxxxxxxx xxxxxxxx,
- xxxxxxxxx xxxxx x xxxxxxxxx (xxxxxxxxxxxx/xxxxxxxxx) x xxxxxxxxx kontrole x xxxxxxxxx, xxxxxxxxx xxxxxxxxx x xxxxxxxxxxxx xxxxxxxxxx.
Xxxxxx xxxxxxxx.
Xxxxxx.
4. XXXXXXXXXX
1) Xxxxx, X. J. (1976), Cytological Xxxxxxx xxx Xxxxxxxxx Xxxxxxxx Xxxxxxxx, in: Xxxxxxxx Xxxxxxxx, Xxxxxxxxxx and Xxxxxxx xxx xxxxx Xxxxxxxxx, Xxx. 4, Xxxxxxxxxx, A. (xx) Xxxxxx Xxxxx, Xxx Xxxx and London, 1-29.
2) Xxxxxxxx, X. Xx., Sofumi, X. (1985), The Xx xxxxx Chromozomal Xxxxxxxxxx Xxxx Xxxxx Xxxxxxx Xxxxxxx Xxxx (CHL) Xxxxxxxxxx Cells xx Xxxxxxx, in: Xxxxxxxx xx Mutatation Xxxxxxxx, Xxx. 5, Xxxxx, X. xx xx., (xxx) Xxxxxxxx Xxxxxxx Xxxxxxxxxx, Amsterdam-New York-Oxford, 427-432.
3) Xxxxxxxx, S. X., Xxxxxxxxx, X. X., Xxxxxx, C., Xxxxxx, S., Xxxxx, X., Cannon, X., Xxxxx, X. X., Xxxxxxxx, F., Xxxxx, X., Duk, X., Xxxxx, X., Margolin, X. H., Xxxxxxx, X. A., Xxxxxxxx, X., Xxxxxx X. (1978), Xxxxxxxxxx xxxxxxxxxx xxx xxxxxx xxxxxxxxx xxxxxxxxx in Xxxxxxx xxxxxxx xxxxx xxxxx: Xxxxxxxxxx of 108 xxxxxxxxx, Xxxxxxx. Xxxxx. Xxxxxxx. 10 (xxxxx. 10), 1-175.
4) Xxxxx, X., Xxxxxxxx, X. X., Xxxxxxxx, R. X., Xxxxxxxx, M. Xx., Xxxxxxx, X., Xxxxx, J., Xxxx, X. X. (1991), Xxxxxxxxxxxx xxxxx Xxxxxxx Xxxxxxx Conditions. A xxxxxx xxxx XXXXXX Xxxx Xxxxx 9, Xxxxxxxxxx Xxx., 257, 147-204.
5) Xxxxxx, T., Xxxxxx, T., Xxxxxx, X., Xxxxxxx, X., (1992), Xxxxxxxxxxxxxx xx xxx xX xx Xxxxxxx Xxxxxxxx Xxxxxxxxx Xxxxx, Xxxxxxxxxx Xxx., 268, 297-305.
6) Xxxx, X. X., McCann, X., Xxxxxxxx, X. (1975), Xxxxxxx xxx Xxxxxxxxx Carcinogens xxx Xxxxxxxx xxxx xxx Xxxxxxxxxx/Xxxxxxxxx Xxxxxxxxx Xxxxxxxxxxxx Xxxx, Mutation Res., 31, 347-364.
7) Xxxxx, X. X., Ames, X. X. (1983), Xxxxxxx Xxxxxxx xxx xxx Salmonella Xxxxxxxxxxxx Xxxx, Xxxxxxxxxx Xxx., 113, 173-215.
8) Xxxxxxxxx, X. X., Tates, X. X., xxx Xxxx, X. X. X., Meijers, X., xx Xxxxx, X. (1976), Cytogenetic Xxxxxxx xx Mutagen/Carcinogens after Xxxxxxxxxx in a Xxxxxxxxxxx System Xx xxxxx, X. Induction xx Chromozome Xxxxxxxxxxx xxx Xxxxxx Chromatid Xxxxxxxx xx Diethylnitrosamine (XXX) xxx Dimethylnitrosamine (XXX) xx XXX Xxxxx in the Xxxxxxxx xx Xxx-Xxxxx Xxxxxxxxxx, Mutatation Xxx., 37, 83-90.
9) Matsuoka, X., Xxxxxxx, X., Xxxxxxxx, X. Jr. (1979), Chromozomal Xxxxxxxxxx Xxxxx on 29 Xxxxxxxxx Xxxxxxxx with X9 Mix Xx xxxxx, Mutation Res., 66, 277-290.
10) Xxxxxx, X. M., Combes, X. X., Xxxxxxx, X. X., Gatehouse, X. X., Xxxxxx, X. X., Xxxxxx, X. X., Xxxx, X. X. (1992), Xxxxxx of XX Xxxxxxxxxxxxx Mutagen Xxxxxxx Xxxxxxx Xxxxx. Xxxxxxxxxxx xx Xxxxxxx 1254-xxxxxxx X9 xx Xx xxxxx Xxxxxxxxxxxx Assays, Xxxxxxxxxxx, 7, 175-177.
11) Xxxxxxxxxx, X., Xxxxxxxx, X., Xxxx, X., Xxxxxxxx, X. (1976), X. Xxxx Xxxxxxxxxx xxx Polychlorinated Xxxxxxxxx x. s. xx Xxxxxxx xx Metabolic Xxxxxxxxxx Xxxxxxx, in: xx Serres, X. X., Xxxxx, X. X. Xxxx, X. X., Xxxxxxx, X. X. (eds), In xxxxx Metabolic Xxxxxxxxxx xx Xxxxxxxxxxx Xxxxxxx, Xxxxxxxx, Xxxxx-Xxxxxxx, 85-88.
12) Xxxxxxxx, X. X., Xxxxxxx, X. X., Xxxxxxxx, M. Xx., Xxxxx, X. X., Xxxxxxxx, X. X., Xxxxxx, X., Xxxxxxx, X., Xxxxxx, T. (1994), Report from Xxxxxxx Xxxxx xx Xx xxxxx Xxxxx xxx Chromozomal Aberrations, Xxxxxxxxxx Xxx., 312, 241-261.
13) Xxxxxxxxxx, X., Xxxxxxxx, X. X., Xxxxx, X. X., Xxxxxxxx, X., Chanter, X. X., Xxxxxxxx, X. (1989), Xxxxxxxx xx Xxxx xxxx Xx xxxxx Cytogenetic Xxxxxx, xx: Xxxxxxxxxxx Xxxxxxxxxx xx Mutagenicity Xxxx Xxxx, Xxxxxxxx, X. J., (xx) Xxxxxxxxx Xxxxxxxxxx Press, Xxxxxxxxx, 141-154.
14) Soper, X. X., Xxxxxxxx, X. X. (1994), Xxxxxxxxx Xxxxxx xxx xxx Xxxxxxxxx xxx Xx vitro Chromozome Xxxxxxxxxx Xxxxxx xx XXX Xxxxx, Xxxxxxxxxx Xxx., 312, 139-149.
15) Xxxxx, X. F., Xxxxxx, X. X., XxXxxxx, K. X. (1982), XXX/XXXXX Xxxxxxxx Xxxxx: Xxxxxxxxxx of Xxxxx and Xxxxxxxx Xxxxxxx, in: Xxxx, X. X., Xxxxx, X. X., Schaich, X. X. (eds), Xxxxxxxxx Xxxxxxx xx Xxxxxxxx Agents, New Xxxx, Xxxxxx, 91-103.
16) Xxxxxx, X. X., Xxxxxx, J. X., Xx, X. X., Xxxxxx, X. X. (1983), Xxxxxxxxxx xx xx Xxxxxxxx System Xxxxx Xxxxx Xxxxx xx Xxxxxxxx Xxxx xxx Xxxxxxxxx Highly Xxxxxxxx Xxxxxxxx xx xxx XXX/XXXXX Xxxxxxxx Xxxxx, Xxxxxxxxxxxxx Xxxxxxx., 5, 795-801.
17) Xxxxx-Xxxxx, X. (1983), Endoreduplication xx Xxxxxxx xxxxxxx xxxxx xxxxxx xxxxx-xxxxxxxxx xxxxxxx X2 xxxxxx, Xxxxxxxxxx Xxx., 119, 403-413.
18) Xxxxx, X., Xxxxxx, X., Xxxxxx, X. X. (1983), Xxxxxxxxxxx-xxxxxxx xxxxxxxxxxxxxxxxx xx Xxxxxxx xxxxxxx cells, Xxxxxx Xxx., 43, 1362-1364."
XXXXXXX 4X
"X.11 XXXXXXXXXX–XXXXXXX XX XXXXXXXXXXXX XXXXXXX X BUŇKÁCH KOSTNÍ XXXXX XXXXX IN XXXX
1. METODA
Tato xxxxxx xx xxxxxxxx xxxxxx XXXX TG 475 — Zkouška na xxxxxxxxxxxx xxxxxxx x xxxxxxx kostní dřeně xxxxx (1997).
1.1 ÚVOD
Zkouška xx xxxxxxxxxxxx xxxxxxx x savců xx xxxx je používána xxx xxxxxxx strukturních xxxxxxxxxxxxxx xxxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxxx v xxxxxxx xxxxxx xxxxx xxxxx, xxxxxxx xxxxxxxx (1, 2, 3, 4). Xxxxxxxxx xx xxx typy xxxxxxxxxxxx xxxxxxx — chromozomové x chromatidové. Nárůst xxxxxxxxxxx může xxxxxxxx, xx chemická látka xx schopnost indukovat xxxxxxxxx xxxxxxx. X xxxxxxx xxxxxxx chemických xxxxxxxx xxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxx, xxxxx xxxxxxxxxxxx xxxxxxx xx xxxxxx xxxxxxxxx. Xxxxxxxxxxxx mutace x xxxxxxxxxxx xxxx xxxx xxxxxxxx xxxxx geneticky xxxxxxxxxxx xxxxxx u xxxxxxx a xxxxxxxx xxxxx xxxxxx x xxx, xx xxxxxxxxxxxx xxxxxx x související xxxx xxxxxxxxxxx xxxxx x xxxxxxxxxx a x xxxxxx somatických xxxxx xxxxxxxxx nádory, xxxx xxxxx xx xxxxxxx xxxxxxxx x xxxxxxx a v xxxxxxxxxxxxxxxx xxxxxxxxx.
Xxx xxxx xxxxxxx xxxx rutinně xxxxxxxxx xxxxxxxx. Xxxxxxx xxxxx je x xxxx zkoušce kostní xxxx, xxxxxxxx je xxxxxx xxxxxxxxxxxxxxxx xxxxx x obsahuje xxxxxxxx xxxxx s xxxxxxx xxxxxx, xxxxx xx xxxxxx xxxxxxx x xxxxxxxxxxxx. Xxxx xxxxx x xxxxxx xxxxx xxxxxx xxxxxxxxx xxxx xxxxxx.
Xxxx zkouška xx xxxxxxxxxxxx xxxxxxx je xxxxxxx xxxxxx k xxxxxxxxx xxxxxxxxx mutagenese, xxxxx xxxxxxxx zohlednit xxxxxxx xxxxxxxxxxx in xxxx, xxxxxxxxxxxxxxx a xxxxxxx reparace XXX, xxxxxxx se xxxxx x xxxxxxx druhů x tkání xxxxx. Xxxxxxx in vivo xx xxxxxx xxxxxxxx xxx xxxxx výzkum xxxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxxx xx xxxxx.
Xxxxxxxx xxxxxxxx xxxxx x xxx, xx xx xxxxxxxx látka xxxx xxxxxxxxx metabolity xxxxxxxxxx xx cílové xxxxx, xxxx xxxxxx xxxx xxxxxxx xxxxxx.
Xxx xxxx Xxxxxx xxxx, část X.
1.2 DEFINICE
Chromatidová aberace : strukturní poškození xxxxxxxxxx x xxxxxx xxxxx xxxxxxxxxxxx xxxxxxxxx xxxx xxxxx x xxxxxxxx spojení xxxxxxxxx.
Xxxxxxxxxxxx xxxxxxx : strukturní xxxxxxxxx chromozomu v xxxxxx xxxxx xxxx xxxxx x spojení xxxx chromatid v xxxxxx místě.
Endoreduplikace : xxxxxx, xxx xxxxxx x xxxxx xx X-xxxx xxxxxxxxx DNA xxxxxxx k mitóze, xxxxx následuje další X-xxxx. Xxxxxxxxx xxxx xxxxxxxxxx xx 4, 8, 16,… xxxxxxxxxxxx.
Xxx : xxxxxxxxxxxx xxxx xxxxx než xxxxx xxxxxxx xxxxxxxxxx x x minimální odchylkou xxxxxxxxx.
Xxxxxxxxx xxxxxxx : xxxxxxxx xxxxx xxxxxxxxxx xx xxxxxxxx xxxxxxx xxxxxxx u xxxxxxxxx xxxxx.
Xxxxxxxxxxx : xxxxxxx xxxxxxxxxxx xxxxx chromozomových xxx (x), xxxx xxx diploidní (xx. 3 x, 4 x xxx.).
Xxxxxxxxxx xxxxxxx : xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxx xxxxxxxxx chromozomů xxx xxxxxxxx xxxxxx xx xxxxxx xxxxxxxx; xxxx xx xxxx xxxxxx a fragmenty, xxxxxxxxxxxxxxxxxx xxxx xxxxxxxxxxxxxxxxxx xxxxx.
1.3 XXXXXXXX XXXXXXXX XXXXXX
Xxxxxxx jsou xxxxxxxxx xxxxxxxx látce vhodným xxxxxxxx x xx xxxxxxx xxxxxxxx xx xxxxxxxx se xxxxxx. Xxxx xxxxxxxxx se xxxxxxxx xxxx xxxxx xxxxxxxxxxx xxxxxxxx (xxxx. xxxxxxxxx xxxx Xxxxxxxx®). X buněk kostní xxxxx xx xxxx xxxxxxxx xxxxxxxxx xxxxxxxxxx, xxxxxx se x xxxxxxxxx xx xxxxxxxxxxxx xxxxxxx xxxxx x xxxxxxxx.
1.4 XXXXX ZKUŠEBNÍ XXXXXX
1.4.1 Xxxxxxxxx
1.4.1.1 Xxxxx xxxxx xxxxxxx
Xxxxx xx xxxxxxxx potkan, myš x křeček xxxxxx, xxxxxx xxx použít xxxxxxxx vhodný xxxxx xxxx. Xxxx xx xxx xxxxxxx xxxxx xxxxxxx xxxxxxxxxxx kmeny xxxxxxx zdravých xxxxxxxx xxxxxxxxx xxxxxx. X xxxxxxxx xxxxxxxx xxxxxx xx xxxx xxx xxxxxxxx v hmotnosti xxxxxx xxxxxxxxx x xxxxxx by x xxxx xxxxxxx xxxxxxxxx ± 20 % xxxxxxx xxxxxxx hmotnosti.
1.4.1.2 Xxxxxxxx xxxxx a xxxxxx
Xxxxx obecné podmínky xxxxx obecného úvodu x xxxxx X, xxxxxxx xx mělo xxx xxxxxxxx vlhkosti xxxxxxx 50 – 60 %.
1.4.1.3 Xxxxxxxx xxxxxx
Xxxxxx xxxxx xxxxxxxx xxxxxxx xxxxxxx xx xxxxxxxx xxxxxxx rozdělí xx kontrolní skupinu x skupinu, která xx vystaví zkoušené xxxxx. Klece xx xxxx být uspořádány xxx, xxx byl xxxx xxxxxx xxxxxx xxxxxxxxxxxxx. Xxxxxxx xx xxxxxxxxxxx xxxxxxxxxxxx. Xxxxxxx xx v xxxxxxxxxxxxx xxxxxxxxxx xxxxxxx xxx xxx xxxxxxxxxxxxx.
1.4.1.4 Příprava xxxxx
Xxxxx xxxxxxxx xxxxx xx xxxx xxx xxxx xxxxxxxx xxxxxxxx xxxxxxxxxx xxxx xxxxxxxxxxxx xx vhodných xxxxxxxxxxxxxx xxxx xxxxxxxxxx x xxxxxxxxx xxxxxxx. Kapalné xxxxxxxx xxxxx xxxxx xxx podávány přímo xxxx xxxxx xxx xxxx xxxxxxx xxxxxxx. Xxxx xx xxx xxxxxxx xxxxxxx připravené xxxxxxxx xxxxxxxx xxxxx, xxxxx xxxxx o xxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxxxxx.
1.4.2 Zkušební xxxxxxxx
1.4.2.1 Xxxxxxxxxxxx/xxxxxxxxx
Xxxxxxxxxxxx/xxxxxxxxx xx xxxxxx xxx při xxxxxxxxx xxxxxxxx dávek xxxxxxx xxxxxx x xxxx xx xxx vyloučeno xxxxxxxxx, že xxxxxxx xx xxxxxxxxx látkou. Xxxx-xx použita xxxx xxx xxxxx xxxxxxxxxxxx/xxxxxxxx, xxxx by xxx xxxxxx xxxxxxxx xxxxxxxxx xxxxx o xxxxxx xxxxxxxxxxxxx. Xxxxxxxxxx xx xxxxx xxxxx xxxxxxxx xxxxxx xxxxxxx vodných xxxxxxxxxxxx/xxxxxxx.
1.4.2.2 Xxxxxxxx
Xxxxxxxx každého xxxxxxxxxxx xx měly xxx pozitivní x xxxxxxxxx (rozpouštědlo/vehikulum) xxxxxxxx xxx xxx xxxxxxx. X xxxxxxxx xxxxxxxx xxxxxxxx xxxxx xx xxxx xxxxxxx xxxxxxxxx xxxxxxx podstoupit identický xxxxxx xxxx xxxxxxx xx xxxxxxxxx, x xxxxx dojde x xxxxxxxx.
Xxxxxxxxx xxxxxxxx by xxxx poskytovat strukturní xxxxxxx in xxxx xxx xxxxxxxxxxx xxxxxxxx, x xxxxx xx xxxxxxx, xx poskytnou xxxxxxxxxxxxx nárůst nad xxxxxx. Xxxxx xxxxxxxxx xxxxxxxx xx xxxx xxx xxxxxxx xxx, xxx byl účinek xxxxxxxx, xxx xxx xxx xxxxxx xxxxxxx xxxxx najevo kódovaná xxxxxxxxxxxx xxxxxxxxx. Xx xxxxxxxxxx, xxx xxxx xxxxxxxxx xxxxxxxx xxxxxxxx xxxxx způsobem xxx xxxxxxxx xxxxx x xxx xxx odběr x xxxxx xxxxxxx xxxxxxxx jen xxxxxx. Xxx xxxxxxxxx xxxxxxxx xxxxx xxx xxxxxxx xxxxxxxx látky ze xxxxxx xxxxxxxx xxxxx, xxxx-xx x dispozici. Xxxxxxxx látek xxx xxxxxxxxx kontrolu:
|
Látka |
Číslo CAS |
Číslo xxxxx XXXXXX |
|
xxxxx-xxxxxxxxxxxxxx |
62–50–0 |
200–536–7 |
|
1-xxxxx-1-xxxxxxxxxxxxxxx |
759–73–9 |
212–072–2 |
|
xxxxxxxxx X |
50–07–7 |
200–008–6 |
|
xxxxxxxxxxxxx |
50–18–0 |
200–015–4 |
|
xxxxxxxxxxxxx xxxxxxxxxx |
6055–19–2 |
|
|
2,4,6-xxxx(xxxxxxxx-1-xx)- 1,3,5-xxxxxxx |
51–18–3 |
200–083–5 |
X okamžiku xxxxxxx xxxxxx by xxx xxx proveden xxxxx x xxxxxxxxxxx xxxxxxx, jimž je xxxxxxxxxx xxxxx rozpouštědlo xxxx xxxxxxxxx x xxx xxxxx podstupují xxxxxx xxxxxx jako xxxxxxxxxx skupiny, xxxxx xxxxxx x xxxxxxxxxxx xxxxxxxxxxx údajů x xxxxxxxxx xxxxxxxxxx údaje x xxxxxxxxxxx xxxxxx x četnosti buněk x xxxxxxxxxxxxxx xxxxxxxxx. Xxxxxxx-xx xx xxx xxxxxxxxx kontrolu xxxxx xxxxx, xx xxxxxxxxxxxxx xxxxxxxxx doba xxxxxxx xxxxxx. Xxxxx xxxx xx měly xxx xxxxxxxxxxxx kontroly použity xxxx xxxxx, neexistují-li xxxxx xxxxxxxxx xxxxx xxxxxxxxxxx, že xxxxxxx xxxxxxxxxxxx/xxxxxxxxx xxxxxxxxxx xxxxx xxxxxxx nebo xxxxxxxxx xxxxxx.
1.5 XXXXXX
1.5.1 Počet x xxxxxxx xxxxxx
Xxxxx xxxxxxxxxx x xxxxxxxxx xxxxxxx xx skládá x xxxxxxx xxxx xxxxxxxxxxxxxxxx xxxxxx xxx xxxxx xxxxxxx. Xxxxxxxx xxxx x xxxx xxxxxx x xxxxxxxxx xxxxx ze xxxxxx xx xxxxxxx xxxxxx x xx xxxxxxx xxxxxxxx způsobu xxxxxxxx, xxx prokazují, xx xxxxxxxxxx mezi xxxxxxxxx xxxxxx v toxicitě, xxxx xxxxxxxxxxx xxxxxxxx xxxxxxx pohlaví. Je-li xxxxxxxx xxxxxxx xxxxxxxxxx xxx určité pohlaví, xxxx xx xxxx xxxxxxxxx x některých xxxxxxxxxxxxxxx látek, měla xx xxx zkouška xxxxxxxxx se xxxxxxx xxxxxxxxxxxxxx xxxxxxx.
1.5.2 Xxxx xxxxxxxx
Xxxxxxxx xxxxx xx xxxx xxx pokud xxxxx xxxxxxxx xxxxxxxxxxx. Xxxxxxxx xxxxx xxxxx xxx xxxxxxxx xxxx xx xxxx dávkách, xxx. xxx xxxxx x xxx xxx x xxxxxxx xx xxxx xxx xxxxxxxx xxxxx, xxx xxxx xxxxxxxxx xxxxxxxx velkých xxxxxx xxxxxxxxx. Jiné xxxxxx podávání xx xxxx xxx xxxxxxx xxxxxxxxxx.
Xxxxxx by xxxx xxx xxxxxxxx xx xxxx různých intervalech xx aplikace xxxxxx x xxxxxx dni. X xxxxxxxx xx xxxxx provádí xx xxxxxx xxxx xx xxxxxxxx, xxxxx xxxxxxxx 1,5xxxxxxx xxxxxxxx xxxxx xxxxxxxxx cyklu (xxxx xxxx xxxxxxx 12 — 18 x). Xxxxxxxx xxxx xxxxxxxx xxx xxxxxx x xxxxxxxxxxxx xxxxxxxx xxxxx x xxxxxx xxx xxxxxx xx xxxxxxxx xxxxxxxxx cyklu xxxx xxx vliv xx xxxxxxxxx okamžik xxx xxxxxxxxx xxxxxxxxxxxxxx aberací, xxxxxxxxxx xx xxxxxxx xxxxx xxxxx xx 24 x xx xxxxxxx xxxxxx. Xx-xx xxxxxxxx xxxxxxxxx do xxxx xxx xxxxxxx xxx, xxx xx xxx xxxxx proveden xx takové době xx poslední xxxxxxxx, xxxxx xxxxxxxx 1,5násobku xxxxxxxx délky xxxxxxxxx xxxxx.
Xxxx usmrcením xx xxxxxxxx intraperitoneálně xxxx xxxxxx xxxxx xxxxx xxxxxxxxxxx xxxxxxxx (xxxx. Xxxxxxxx® nebo kolchicin). Xxxx se xx xxxxxx xxxx xxxxxxx x zvířat xxxxx. X xxxx xx xxxx xxxx xxxxxxxxx 3 — 5 x; x křečka xxxxxxxx xx tato xxxx xxxxxxxxx 4 — 5 x. X xxxxxx xxxxx xx xxxxxxxx buňky x xxxxxxxxx xx xx xxxxxxxxxxxx xxxxxxx.
1.5.3 Xxxxxxxxx
Xxxxxxx-xx xx xxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxx studie pro xxxxxxxx rozsahu xxxxx, xxxx xx xxx xxxxxxxxx xx xxxxxx xxxxxxxxxx, xx xxxxxxx xxxxxx, xxxxxx, xxxxxxxx x xx xxxxxxxx xxxxxx xxxxxxxx, jež xx použijí x xxxxxx xxxxxx (5). X případě toxicity xx xxx první xxxxx xxxxxxx xxx xxxxxx dávky. Xxxx xxxxxx dávky xx xxxx xxxxxxxx xxxxxxx xxxx xxxxxxxxx a xxxxxxxxx xxxxxxxxx, xxxxxxxx xxxxxx xxxxxxxxx. Při xxxxxxxxx odběru xxxxx, xxxx xxxx použita xxxxx nejvyšší dávka. Xxxxxxxx xxxxx xx xxxxxxxxxx jako xxxxx xxxxxxxxxxxx xxxxxx xxxxxx xxxxxxxx, že xxxxx xxxxx xx xxxxx xxx xxxxxxx xxxxxx xxxxxxxxx podle xxxxxxxxx x letalitě. Látky xx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxx xxx xxxxxxx xxxxxxxxxxx xxxxxxx (xxxx. xxxxxxx x xxxxxxxx) xxxxxx xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxx x xxxx xx xxx xxxxxxxxx případ xx xxxxxxx. Nejvyšší xxxxx xxxx xxx také xxxxxxxxxx xxxx dávka xxxxxxxxxxxx v xxxxxx xxxxx xxxxxxx xxxxxx xxxxxxxx (např. xxxx xxx 50 % xxxxxxx xxxxxxxxxxx xxxxxx).
1.5.4 Xxxxxxx xxxxxxx
Xxxxxxxx zkouška x xxxxxx dávkou xxxxxxx 2000 xx/xx xxxxxxx hmotnosti podanou xxxxxxxxxxx xxxx xx xxxx xxxxxxx v xxxxxx xxx xxxxxxxxxx xxxxx pozorovatelné xxxxxxx xxxxxx a není-li xx základě xxxxx x látkách, xxxxx xxxx xxxxxxxx strukturu, xxxxxxxxx genotoxicita, xxxxxxxxxx xx xxxxx xxxxxx xx xxxxx xxxxxxxx xxxxx xx xxxxxxxxx. X xxxx trvajících xxxxxx xx xxxxxxx xxxxxx pro 14xxxxx xxxxxxxx 2000 mg/kg xxxxxxx hmotnosti/den a xxx xxxxx než 14xxxxx xxxxxxxx je xxxxxxx xxxxxx 1000 xx/xx tělesné xxxxxxxxx/xxx. Xxxxxxxxx xxxxxxxx člověka xxxx xxxxxxxx potřebu xxxxxx v xxxxxxx xxxxxxx xxxxx xxxxxx xxxxx.
1.5.5 Podávání xxxxx
Xxxxxxxx xxxxx se xxxxxxx xxxxxx xxxxxxxxxxxxxx, xxxxxxxxx xxxxxx xxxx vhodnou xxxxxxxxx xxxxxxx, xxxx xxxxxxxxxxxxxxxxx xxxxxxx. Jiné xxxxxxx xxxxxxxx xxxx x xxxxxxxxxxxx xxxxxxxxx xxxxxxxxxx. Xxxxxxxxx xxxxx xxxxxxxx, xxxxx xxxx xxx xxxxxxxx xxxxx xxxxxxxxxxxxxx xxxx xxxxxxxx, xxxxxx na xxxxxxxxx xxxxxxxxxxx xxxxxxx. Objem xx xxxxx xxxxxxxxx 2 xx/100 x xxxxxxx xxxxxxxxx. Použití xxxxxxx xxxxxx, xxx xx uvedený xxxxx, xxxx xxx zdůvodněno. Xx xx dráždivé x xxxxxx xxxxx, xxxxx obvykle xxx xxxxxxx koncentracích vykazují xxxxxxxx xxxxxx, xx xxxx xxx xxxxxxxxxxx xxxxxxxxxx xxxxxx minimalizována xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxx xxxxx při xxxxx xxxxxxxx xxxxx.
1.5.6 Xxxxxxxx preparátů pro xxxxxxx chromozomů
Ihned po xxxxxxxx xx odebere xxxxxx xxxx, hypotonizuje xx a fixuje. Xxxxx se xxxxxxx xx podložní xxxxxxx x xxxxxx se.
1.5.7 Xxxxxxx
Xxxx xxxxxxx cytotoxicity xx xxx xxx x všech xxxxxxxxxxxx xxxxxx (xxxxxx pozitivních xxxxxxx) a x xxxxxxxxxxxxxx xxxxxx xxx xxxxxxxxx xxxxxxxx stanoven xxxxxxxxx index, a xx alespoň x 1000 buněk na xxxxx zvíře.
U xxxxxxx xxxxxxx by xxxx xxx xxxxxxxxxxx xxxxxxx 100 xxxxx. Tento xxxxx xxx xxxxxx, xx-xx xxxxxxxxx xxxxx xxxxx aberací. Xxxxxxx xxxxxxxxx xxxxxxxxxxx x xxxxxxxxxxx kontrol xx xxxx xxx před xxxxxxxxxxxxxx xxxxxxxx nezávisle xxxxxxxx. Protože při xxxxxx často xxxxxxx xx xxxxxxxxxxxxxx zlomům xxxx xx xxxxxx xxxxxxxxxx u xxxxx xxxxx v xxxxxxxx, xxxx by vyšetřované xxxxx xxxxxxxxx xxxxxxxxxx x počtu odpovídajícímu xxxxx 2 x ± 2.
2. XXXXX
2.1 XXXXXXXXXX XXXXXXXX
Xxxxx xxx xxxxxxxxxx zvířata by xxxx xxx xxxxxxxxxx xx formě tabulky. Xxxxxxxxxxxxxx xxxxxxxxx je xxxxx. Xxx každé xxxxx xx xxx xxx xxxxxxxxxx xxxxx xxxxx, xxxxx xxxxxxx xx xxxxx a xxxxx xxxxx s xxxxxxxxxxxxx xxxxxxx (chromozomovými xxxxxxxxx) xxxxxxxxx x xxxxxxxxxx. Pro exponované x xxxxxxxxx xxxxxxx xx xxxx xxx xxxxxxx xxxxx xxxx xxxxxxxxxxxx xxxxxxxxxxxxxx aberací x xxxxxx xxxxxx x xxxxxxxx. Gapy xx xxxxxxxxxxxxx xxxxxxxx x xxxxxxx se, xxx obecně xx xxxxxxxxxx do xxxxxxx xxxxxxxx aberací. Xxxxxxxxxx-xx xxxxx o rozdílu x xxxxxxxx xxxx xxxxxxxxx, xxxxx xxx xxx xxxxxxxxxxxx analýzu xxxxx xxx xxx xxxxxxx xxxxxxxxxxxx.
2.2 XXXXXXXXX X XXXXXXXXXXXX XXXXXXXX
Xxx xxxxxxxxx pozitivního výsledku xxxxxxxx xxxxxxx xxxxxxxx, xxxx. xxxxxx xxxxxxxxxxx xxxxx xxxxx x xxxxxxxxxxxxxx xxxxxxxxx x xxxxxxxxxx na xxxxx xxxx xxxxx xxxxxx xxxxx buněk s xxxxxxxxx xxx xxxxxxx x xxxxxxx xxxxxx x k xxxxxxxx xxxxxxxx xxxxxx. Xxxxxxxx xx xxxx být xxxxxxx xxxxxxxxxx relevance xxxxxxxx. Xxx xxxxxxxxx xxxxxxxx xxxxxxx xxxxx xxx xxxxxxx xxxx xxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxx (6). Xxxxxxxxxxx xxxxxxxxxx xx xxxxxx xxx jediným určujícím xxxxxxxx xxx xxxxxxxxx xxxxxxx. Xxxxxxxxxx xxxxxxxx xx xxxx xxx xxxxxxxxx xxxxxx xxxxxxxxx, xxxxxxx x úpravami xxxxxxxxxxxxxxxx podmínek.
Nárůst xxxxxxxxxxx xxxx znamenat, xx xxxxxxxx xxxxx má xxxxxxxxx xxxxxxxxx numerické xxxxxxxxxxxx xxxxxxx. Xxxxxx xxxxx xxxxx s xxxxxxxxxxxxxxxxxxx xxxxxxxxxx může xxxxxxxx, že xxxxxxxx xxxxx xx xxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxx xxxxx (7, 8).
Xxxxxxxx xxxxx, xxxxx výsledky xxxxxxxxx xxxx xxxxxxx xxxxxxxx, xx xxxxxxxx x xxxxx systému xx xxxxxxxxxxx.
Xxxxxx xxxxxxx xxxxxxxxxxx xxxxxxxx jasně xxxxxxxxx nebo negativní xxxxxxxx, x xxxxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxx xxxxx xxxxxxxx xxxxxxx xxxxx x xxxxxxxx xxxxxxxx látky. Xxxxxxxx xxxxx xxxxxx xxxxxxxxxx xxxx xxxxxx xxx xxxxxx xx to, xxxxxxxx xx xxxxxxxxxx xxxxxxxx.
Xxxxxxxxx xxxxxxxx zkoušky xx xxxxxxxxxxxx aberace xx xxxx xxxxxxxxx, xx xxxxxxxx xxxxx xxxxxxxx v xxxxxx xxxxx xxxxxxxxxxx xxxxx xxxxxxxxxxxx aberace. Xxxxxxxxx xxxxxxxx znamenají, xx xxxxxxxx látka xx xxxxxxxx xxxxxxx xxxxxxxxxx x xxxxxx xxxxx xxxxxxxxxxx xxxxx xxxxxxxxxxxx xxxxxxx.
Xxxx by xxx xxxxxxxxxxx xxxxxxxxxxxxxxx, s xxxxx se zkoušená xxxxx xxxx její xxxxxxxxxx xxxxxxxx do xxxxxxxx xxxxx, xxxx xxxxxxxxxx xx xxxxxx xxxxx (xxxx. systémová xxxxxxxx).
3. ZPRÁVY
PROTOKOL X XXXXXXX
Xxxxxxxx x xxxxxxx xxxx obsahovat xxxx xxxxxxxxx:
Xxxxxxxxxxxx/xxxxxxxxx:
- xxxxxxxxxx xxxxx xxxxxxxx,
- rozpustnost x xxxxxxx xxxxxxxx látky x xxxxxxxxxxxx/xxxxxxxx, xx-xx xxxxx.
Xxxxxxxxx xxxxxxx:
- xxxxxxx xxxx/xxxx,
- xxxxx, xxxxx x xxxxxxx xxxxxx,
- xxxxx, xxxxxxxx xxxxx, xxxxxx xxx.,
- xxxxxxxxxxxx xxxxxxxx xxxxxx xx xxxxxxx xxxxxxx, xxxxxx xxxxxxx tělesné hmotnosti, xxxxxxx xxxxxxx x xxxxxxxxxx xxxxxxxx xxx xxxxxx xxxxxxx.
Xxxxxxxx podmínky:
- xxxxxxxxx x xxxxxxxxx (xxxxxxxxx/xxxxxxxxxxxx) xxxxxxxx,
- xxxxx xx xxxxxx pro xxxxxxxx xxxxxxx, xxxxx xxxx provedena,
- zdůvodnění xxxxxxxxx xxxxxx xxxxx,
- xxxxx o xxxxxxxx xxxxxxxx xxxxx,
- xxxxx x podávání zkoušené xxxxx,
- xxxxxxxxxx xxxxxxx xxxxxxxx,
- xxxxxxxxx xxxxxx xxxxxxx, xxx se xxxxxxxx xxxxx xxxxxxx xx krevního xxxxx xxxx xx xxxxxx xxxxx,
- xxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx xxxxxxxx xxxxx v krmivu xxxx xxxx (ppm) xx odpovídající dávku (xx/xx xxxxxxx xxxxxxxxx/xxx),
- xxxxxxxx xxxxx x xxxxxxx krmiva a xxxx,
- xxxxxxxx popis xxxxxxx expozice x xxxxxx,
- xxxxxx stanovení xxxxxxxx,
- xxxxxxxxxxxx xxxxx xxxxxxxxxxx metafázi, xxxx xxxxxxxxxxx x xxxxx xxxxxxxx,
- xxxxxx xxxxxxxx xxxxxxxxx,
- xxxxxxxx hodnocení xxxxxxx,
- počet analyzovaných xxxxx xx jedno xxxxx,
- kritéria klasifikace xxxxxx xx pozitivní, xxxxxxxxx xxxx xxxxxxxxxxx.
Xxxxxxxx:
- xxxxxx toxicity,
- mitotický xxxxx,
- xxx x xxxxx xxxxxxx uvedený xxxxxxxxxx xxx každé xxxxx,
- celkový xxxxx xxxxxxx xx xxxxxxx xx xxxxxxxxx xxxxxxxxx x xxxxxxxxxxxx xxxxxxxxxx,
- xxxxx xxxxx s xxxxxxxxx xx skupině xx středními xxxxxxxxx x směrodatnými xxxxxxxxxx,
- xxxxx xxxxxxx, pokud xxxx xxxxxxxxxx,
- podle xxxxxxxx xxxxxxxxx odpovědi xx xxxxx,
- xxxxxxxx xxxxxxxxxxx analýzy,
- xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxx,
- xxxxxxxxx xxxxx x xxxxxxxxx xxxxxxxx x rozpětími, xxxxxxxxx xxxxxxxxx x xxxxxxxxxxxx xxxxxxxxxx,
- údaje x xxxxxxxx xxxxxxxxx kontrole.
Rozbor xxxxxxxx.
Xxxxxx.
4. XXXXXXXXXX
1) Xxxxx, X. X. (1984), Xxxxxxxxxxx Xxxxx in Xxxxxxx, xx: Mutagenicity Xxxxxxx: x Xxxxxxxxx Xxxxxxxx, S. Venitt, X. X. Xxxxx (xxx), IRL Xxxxx, Xxxxxx, Xxxxxxxxxx X. X., 275-306.
2) Xxxxxxx, X. X., Xxxx, X. X., Xxxxxxxx, X., Xxxxxx, H., XxXxx, X. X., Xxxxxx, X. (1987), Xxxxxxxxx In xxxx Xxxxxxxxxxx Xxxxxx: Analysis xx Chromozome Aberrations xx Bone Marrow Xxxxx, Mutatation Xxx., 189, 157-165.
3) Richold, X., Chandley, X., Xxxxx, X., Xxxxxxxxx, X. G., Bootman, X., Xxxxxxxxx, X. (1990), In vivo Xxxxxxxxxxx Xxxxxx, xx: X. X. Xxxxxxxx (xx.), Xxxxx Xxxxxxxxxxxx Xxxxx, XXXXX Recommended Xxxxxxxxxx. XXXXX Xxx-Xxxxxxxxx xx Xxxxxxxxxx xxx Xxxxxxxxxxxx Testing. Report, Xxxx I revised, Xxxxxxxxx University Xxxxx, Xxxxxxxxx, New York, Xxxx Xxxxxxx, Xxxxxxxxx, Xxxxxx, 115-141.
4) Xxxx, X. X., Hayashi, X., XxxXxxxxxx, X. X., Xxxxxxxx, D., Xxxxxx, X. H., Xxxxxx, X. E., Xxxxxx-Xxxxxxx, X., Xxxxxx Xx., X. X., Xxxxxxxxxxxx, X., Xxxxxxx, X. J., Romagna, X., Xxxxxxx, X., Xxxxx, X., Vannier, X. (1994), Report xxxx xxx Xxxxxxx Xxxxx xx the xx vivo Mammalian Xxxx Marrow Xxxxxxxxxxx Xxxxxxxxxx Xxxx, Xxxxxxxxxx Xxx., 312, 305-312.
5) Xxxxxxx, X. X., Xxxxx, X. X., Xxxxxx, X. X., Xxxxxx, X. X., Xxx, X., Xxxxxxx, X. J., Xxxxxxxxx, X. X., Xxxxxx-Xxxxxx, X., Xxxxxx, X. X., Xxxxxxxx, X. X., Richold, M. (1992), Xxxxxx xx Xxxxxxx Toxicology Xxxxxxx/XX Xxxxxxxxxxxxx Mutagen Society Xxxxxxx Xxxxx: Xxxx Xxxxxxx in Xx xxxx Xxxxxxxxxxxx Assays, Xxxxxxxxxxx, 7, 313-319.
6) Xxxxxx, D. P., Xxxxxxxx, X., Xxxxxxxx, X., Amphlett, X. X., Clare, G., Xxxxxxxx, R., Xxxxxxx, X., Xxxxxxxx, X. X., Savage, J. X. K. (1989), Xxxxxxxxxxx Xxxxxxxx of Xx xxxx Xxxxxxxxxxx Xxxxxx, in: XXXXX Xxx-Xxxxxxxxx xx Xxxxxxxxxx xxx Mutagenicity Xxxxxxx, Xxxxxx Part XXX. Xxxxxxxxxxx Evaluation xx Xxxxxxxxxxxx Xxxx Xxxx, X. X. Kirkland (xx.) Cambridge University Xxxxx, Xxxxxxxxx, 184-232.
7) Xxxxx-Xxxxx, C. (1983), Xxxxxxxxxxxxxxxxx xx Xxxxxxx xxxxxxx cells during xxxxx-xxxxxxxxx-xxxxxxx X2 xxxxxx, Xxxxxxxxxx Xxx., 119, 403-413.
8) Huang, Y., Xxxxxx, X., Xxxxxx, X. E. (1983), Xxxxxxxxxxx-xxxxxxx xxxxxxxxxxxxxxxxx in Xxxxxxx xxxxxxx xxxxx, Xxxxxx Xxx., 43, 1362-1364."
XXXXXXX 4C
"B.12 XXXXXXXXXX–XXXX XXXXXXX XXXXXXXXXXXXXXX XXXXXXXXXX XX XXXX
1. XXXXXX
Xxxx xxxxxx je xxxxxxxx xxxxxx XXXX XX 474 — Xxxx xxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxx xx xxxx (1997).
1.1 XXXX
Xxxx xxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxx in xxxx xx xxxxxxxx xxx xxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxxxx xxxxxxx xxxxxxxxxxxx, které je xxxxxxxxxx xxxxxxxxx xxxxxx, x xx xxxxxx xxxxxxx erytrocytů xxxxxxxxxx x xxxxxx xxxxx x/xxxx xxxxx xxxxxxxxx xxxx, xxxxxxx xxxxxxxx.
Xxxxxx xxxxx savčích xxxxxxxxxxxxxxx xxxxxxxxxx je xxxxxxxxxxxxx xxxxx, které způsobují xxxxxxxxxxxxx xxxxxxxxx, jehož xxxxxxxxx xx xxxxxx xxxxxxxxxx obsahujících xxxxxxxxxxxxx xx (lagging) xxxxxxxxxxxx xxxxxxxxx xxxx celé xxxxxxxxxx.
Xxxx xx xxxxxxxxxxx xxxxxx xxxxx xxxx xx xxxxxxxxxxxxxxx erytrocyt, xxxxxx xxxxx xx xxxxxxxx x xxxxxxxxxx, xxxxx při tom xxxxx xxxxxxxxx, xxxxxxxxx x xxxxxxxxxx, xxxxx xxxxx xxxxx xxxxxxxxxx. Xxxxxxxxxxxx xxxxxxxxxx xx x těchto xxxxxxx xxxxxxxxx xxx, xx xxxxxxxxxx hlavní xxxxx. Xxxxxx xxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxxxx s mikrojádry x xxxxxxxxxxxx zvířatech xx známkou xxxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx.
X xxxxx xxxxx je xxxxxxx xxxxxxxxx xxxxxx dřeň xxxxxxxx, xxxxxxxx tato xxxx xxxxxxxxx polychromatické xxxxxxxxxx. Xxxxxxxxx nezralých (xxxxxxxxxxxxxxxxx) xxxxxxxxxx x xxxxxxxxxx x periferní xxxx je rovnocenně xxxxxxxxxx u kteréhokoli xxxxx, x xxxxx xxxx xxxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxxxxxx xxxxxxxxxx x xxxxxxxxxx, xxxx xxxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxxx, xxxxx způsobují xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxxx. Xxxxxxxxxx xxx rozlišit řadou xxxxxxxx. Ta xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxxxxxxx centromerní (xxxxxxxxxxxx) XXX v xxxxxxxxxx. Xxxxxxxxx se zejména xxxxxxx xxxxxxxxx (xxxxxxxxxxxxxxxxx) xxxxxxxxxx x mikrojádry. Xxxxx zralých (xxxxxxxxxxxxxxxxxx) xxxxxxxxxx x periferní xxxx, které obsahují xxxxxxxxxx, xxxxxxxxxxx na xxxxxx počet zralých xxxxxxxxxx xxx rovněž xxxxxx jako xxxxxxx xxxxxxxx zkoušky, xxxxxxxx xxxx xxxxxxx exponována xxxxx týdny xxxx xxxx.
Xxxxx test savčích xxxxxxxxxxxxxxx xxxxxxxxxx xx xxxx xx zvláště xxxxxx k xxxxxxxxx xxxxxxxxx xxxxxxxxxx, neboť xxxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxxx xx xxxx, xxxxxxxxxxxxxxx x procesy xxxxxxxx XXX, xxxxxxx xx xxxxx xxxxx x různých druhů x tkání, xxxxx x x genetického xxxxxxxx. Xxxxxxx xx xxxx xx xxxxxx xxxxxxxx pro xxxxx xxxxxx mutagenních xxxxxx xxxxxxxxxx v xxxxxxxxx xx vitro.
Jestliže existuje xxxxx o tom, xx xx zkoušená xxxxx xxxx xxxxxxxxx xxxxxxxxxx nedostanou xx xxxxxx xxxxx, xxxx xxxxxx xxxx xxxxxxx xxxxxx.
Xxx xxxx Xxxxxx xxxx, část X.
1.2 XXXXXXXX
Xxxxxxxxxx (kinetochor) : xxxxxx (xxxxxxx) chromozomu, x xxx (k xxxx) se během xxxxxx buněk xxxxxxx xxxxxx vřeténko umožňující xxxxxxxxxx pohyb dceřiných xxxxxxxxxx x xxxxx xxxxxxxxx xxxxx.
Xxxxxxxxxx : xxxx xxxxx xxxxxxxxxx xxxxxxxx xx xxxxxxxx xxxxx a vedle xxxx, vytvářená xxxxx xxxxxxxx mitosy (xxxxxx) xxxxxxxxxxxxxxx xx (lagging) xxxxxxxxxxxxxx xxxxxxxxx nebo xxxxxx chromozomy.
Normochromatický xxxxxxxxx : xxxxx xxxxxxxxx xxxxxxxxxxxx ribozomy, který xxx xxxxxxxx xx xxxxxxxxx xxxxxxxxxxxxxxxxx erytrocytů xxxxxxxx xxxxxxxxxxx xxx xxxxxxxx.
Xxxxxxxxxxxxxxx xxxxxxxxx : xxxxxxx erytrocyt xx xxxxxxxxx xxxxxxxxxx, xxxxx xxxxx xxxxxxxx xxxxxxxx, x xxxx xxx xxxx xxxxxxxx od xxxxxxx normochromatických xxxxxxxxxx xxxxxxxx selektivním xxx xxxxxxxx.
1.3 XXXXXXXX ZKUŠEBNÍ XXXXXX
Xxxxxxx se xxxxxxx xxxxxxxx vystaví zkoušené xxxxx. Při xxxxxxx xxxxxx xxxxx se xxxxxxx xx xxxxxxx xxxxxxxx xx xxxxxxxx xxxxxx, odebere se xxxxxx dřeň, xxxxxxxx xx xxxxxxxxx x xxxxxx xx (1, 2, 3, 4, 5, 6, 7). Xxx xxxxxxx xxxxxxxxx xxxx xx xxxx xx xxxxxxx okamžiku xx xxxxxxxx xxxxxxx, xxxxxxxxxx xx xxxxxxxx xxxxxxxx x xxxxxx xx (4, 8, 9, 10). Xxx xxxxxxxx x xxxxxxxxx xxxx xx xxxx xxxx poslední xxxxxxxx x xxxxxxxxx xxxxx xxxxxxxx xx xxxxxxxxx xxxx. Preparáty xxxx xxxxxxxxxxx na xxxxxxxxxx xxxxxxxxxx.
1.4 POPIS XXXXXXXX XXXXXX
1.4.1 Xxxxxxxxx
1.4.1.1 Xxxxx xxxxx xxxxxxx
Xxx xxxxxxx xxxxxx dřeně xx xxxx xxxxxxxxx zvíře xxxxxxxxxx xxx xxxx xxxxxx, xxxxxx xxx xxxxxx jakýkoli xxxxxx xxxxx druh. Xxx xxxxxxx periferní xxxx xx doporučuje xxx. Xxx xxxx xxxxxx xxxxxxxx vhodný xxxx xxxxx za xxxxxxxxxxx, xx jde o xxxx, x xxxxx xxxxxxx xxxxxxxxxxxx xxxxxxxxxx x xxxxxxxxxx, xxxx xxxx xxxxxxxxxx xxxxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxxx, xxxxx způsobují strukturní xxxx xxxxxxxxx chromozomové xxxxxxx. Xxxx by xxx xxxxxxx xxxxx xxxxxxx laboratorní xxxxx xxxxxxx zdravých xxxxxxxx xxxxxxxxx xxxxxx. X xxxxxxxx zahájení xxxxxx xx xxxx xxx xxxxxxxx x xxxxxxxxx xxxxxx xxxxxxxxx x xxxxxx xx u xxxx pohlaví xxxxxxxxx ± 20 % xxxxxxx xxxxxxx xxxxxxxxx.
1.4.1.2 Xxxxxxxx xxxxx x xxxxxx
Xxxxx obecné xxxxxxxx xxxxx xxxxxxxx xxxxx x xxxxx X, xxxxxxx xx xxxx xxx xxxxxxxx vlhkosti xxxxxxx 50 – 60 %.
1.4.1.3 Xxxxxxxx xxxxxx
Xxxxxx mladá pohlavně xxxxxxx xxxxxxx xx xxxxxxxx výběrem rozdělí xx xxxxxxxxx xxxxxxx x xxxxxxx, u xxx xx xxxxxxx xxxxxxxx. Zvířata xx xxxxxxxxxxx identifikují. Xxxxxxx xx v laboratorních xxxxxxxxxx xxxxxxx pět xxx xxxxxxxxxxxxx. Xxxxx xx xxxxxxxxxx xxx, xxx xxx vliv xxxxxx xxxxxx xxxxxxxxxxxxx.
1.4.1.4 Xxxxxxxx xxxxx
Xxxxx zkoušené xxxxx by xxxx xxx xxxx xxxxxxxx xxxxxxxx rozpuštěny nebo xxxxxxxxxxxx ve xxxxxxxx xxxxxxxxxxxxxx xxxx xxxxxxxxxx x popřípadě zředěny. Xxxxxxx xxxxxxxx xxxxx xxxxx xxx podávány xxxxx nebo mohou xxx xxxx xxxxxxx xxxxxxx. Xxxx xx xxx použity čerstvě xxxxxxxxxx xxxxxxxx xxxxxxxx xxxxx, xxxxx xxxxx x xxxxxx stálosti xxxxxxxxxxx xxxxxxx xxxxxxxxxx.
1.4.2 Xxxxxxxx xxxxxxxx
1.4.2.1 Rozpouštědlo/vehikulum
Rozpouštědlo/vehikulum xx nemělo mít xxx xxxxxxxxx úrovních xxxxx xxxxxxx účinky x xxxx xx xxx xxxxxxxxx xxxxxxxxx, xx reaguje se xxxxxxxxx látkou. Xxxx-xx xxxxxxx xxxx xxx xxxxx xxxxxxxxxxxx/xxxxxxxx, xxxx xx xxx jejich xxxxxxxx xxxxxxxxx xxxxx x jejich kompatibilitě. Xxxxxxxxxx xx xxxxx xxxxx nejdříve xxxxxx xxxxxxx xxxxxxx rozpouštědel/vehikul.
1.4.2.2 Xxxxxxxx
Xxxxxxxx xxxxxxx xxxxxxxxxxx xx měly xxx xxxxxxxxx x negativní (xxxxxxxxxxxx/xxxxxxxxx) xxxxxxxx xxx xxx xxxxxxx. S xxxxxxxx xxxxxxxx xxxxxxxx xxxxx xx měla xxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxxx proces xxxx xxxxxxx xx xxxxxxxxx, x nichž xxxxx k xxxxxxxx.
Xxxxxxxxx xxxxxxxx xx xxxx xxxxxxxxxx mikrojádra xx xxxx xxx expozičních xxxxxxxx, u xxxxx xx očekává, xx xxxxxxxxx xxxxxxxxxxxxx nárůst xxx pozadí. Dávky xxxxxxxxx kontroly xx xxxx xxx xxxxxxx xxx, xxx xxx xxxxxx xxxxxxxx, ale xxx xxx odečtu xxxxxxx xxxxx xxxxxx xxxxxxxx xxxxxxxxxxxx xxxxxxxxx. Xx xxxxxxxxxx, aby xxxxxxxxx kontrola xxxx xxxxxxxx xxxxx xxxxxxxx xxx xxxxxxxx látka x xxx xxx xxxxx x tomto xxxxxxx xxxxxxxx xxx xxxxxx. Pro xxxxxxxxx xxxxxxxx xxxxx xxxx xxx xxxxx x xxxxx xxxxxxx xxxxxxxxxx xxxxx ze stejné xxxxxxxx xxxxx, xxxx-xx x xxxxxxxxx. Xxxxxxxx xxxxx xxx pozitivní xxxxxxxx:
|
Xxxxx |
Xxxxx XXX |
Xxxxx xxxxx XXXXXX |
|
xxxxx-xxxxxxxxxxxxxx |
62–50–0 |
200–536–7 |
|
1-xxxxx-1-xxxxxxxxxxxxxxx |
759–73–9 |
212–072–2 |
|
xxxxxxxxx X |
50–07–7 |
200–008–6 |
|
xxxxxxxxxxxxx |
50–18–0 |
200–015–4 |
|
xxxxxxxxxxxxx xxxxxxxxxx |
6055–19–2 |
|
|
2,4,6-xxxx(xxxxxxxx-1-xx)- 1,3,5-xxxxxxx |
51–18–3 |
200–083–5 |
X okamžiku xxxxxx xx xxx xxx xxxxxxxx odběr x xxxxxxx xxxxxxxxx kontroly, xxxxx je xxxxxxxxxx xxxxx xxxxxxxxxxxx nebo xxxxxxxxx x xxxxx xxxxx xxxxxxxxxx xxxxxx xxxxxx xxxx xxxxxxxxxx xxxxxxx, xxxxx xxxxxx x xxxxxxxxxxx xxxxxxxxxxx xxxxx x xxxxxxxxx xxxxxxxxxx údaje x xxxxxxxxxxx xxxxxx x xxxxxxxx xxxxx x xxxxxxxxxx. Xxxxxxx-xx se xxx negativní xxxxxxxx xxxxx xxxxx, xx xxxxxxxxxxxxx okamžikem doba xxxxxxx xxxxxx. Xxxxx xxxx xx xxxx xxx neexponované kontroly xxxxxxx xxxx xxxxx, xxxxxxxxxx-xx dosud nebo xxxxxx-xx xxxxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxxxx, xx xxxxxxx xxxxxxxxxxxx/xxxxxxxxx xxxxxxxxxx xxxxx xxxxxxx nebo xxxxxxxxx účinky.
Při xxxxxxx xxxxxxxxx krve xxxx xxx xxxx negativní xxxxxxxx xxxxxxxxxx xxxx xxxxxx xxxx xxxxxxxx xxxx xxxxxxxx, xxxxx xxxx x krátkých xxxxxx s xxxxxxxxx xxxx (xxxx. 1 — 3 aplikace) xx předpokladu, xx xxxxxxxx údaje xxxxx x xxxxxxx, které xx xx xxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxx.
1.5 XXXXXX
1.5.1 Xxxxx x xxxxxxx xxxxxx
Xxxxx exponovaná x xxxxxxxxx xxxxxxx xx xxxx skládat x xxxxxxx xxxx xxxxxxxxxxxxxxxx xxxxxx xxx xxxxx pohlaví (11). Xxxxxxxx xxxx x xxxx studie k xxxxxxxxx údaje xx xxxxxx xx xxxxxxx xxxxxx a za xxxxxxx xxxxxxxx xxxxxxx xxxxxxxx, jež xxxxxxxxx, xx xxxxxxxxxx xxxx xxxxxxxxx xxxxxx v xxxxxxxx, xxxx postačující xxxxxxxx jednoho xxxxxxx. Xx-xx xxxxxxxx xxxxxxx xxxxxxxxxx xxx xxxxxx xxxxxxx, xxxx je xxxx xxxxxxxxx x xxxxxxxxx xxxxxxxxxxxxxxx xxxxx, xxxx xx být xxxxxxx xxxxxxxxx xx xxxxxxxx odpovídajícího xxxxxxx.
1.5.2 Xxxx xxxxxxxx
Xxxxx doporučit xxxxx standardní xxxx (xx. jednu, xxx xxxx xxx xxxxxxxx x xxxxxxxxx 24 xxxxx). Xxxxxx xx xxxxxx s prodlouženým xxxxxxx podávání xxxx xxxxxxxxxx, xxxxx se x xxxxxx studií xxxxxxx xxxxxxxxx xxxxxxxx, xxxx –v xxxxxxx xxxxxxxxxxx xxxxxx — xxxxx byla xxxxxxxxx xxxxxxxx nebo xxxx xxxxxxxxx xxxxxxx xxxxx x xxxxxxxx pokračuje xx xx xxxxxxxx xxxxxx. Zkoušené látky xxxxx xxx podávány xxxx ve dvou xxxxxxx, xxx. dvě xxxxx x týž xxx x rozmezí xx xxxx xxx xxxxxxxx hodin, xxx xxxx usnadněno xxxxxxxx xxxxxxx xxxxxx xxxxxxxxx.
Xxxx xxxx xxx xxxxxxxx xxxxx xxxxxxx:
x) xxxxxxxx xxxxx se xxxxxxxx xxxxxxxx jednou. Xxxxxx xxxxxx dřeně xx xxxxxxxx xxxxxxx dvakrát, xxxxxxx xxxxx odběr xx xxxxxxx xxxxxxxx 24 xxxxx xx xxxxxxxx a poslední xxxxxxxxxx 48 xxxxx xx aplikaci x x přiměřeným xxxxxxxx xxxx xxxxxx. Xxxxx xxxxx xxx 24 xxxxx po xxxxxxxx xxxx xxx zdůvodněn. Xxxxxx periferní xxxx xx odeberou xxxxxxx xxxxxxx, přičemž xxxxx xxxxx xx xxxxxxx xxxxxxxx 36 hodin xx aplikaci x xxxxxxxx xxxxxxxxxx 72 xxxxx xx xxxxxxxx x xx prvnímodběru xx xxxxxx odpovídající xxxxxx. Xx-xx po xxxxxx xxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxx, xxxx xxxxx xxxxx xxxxx;
x) xxxx-xx xxxxxxxx dvě xxxx více xxxxx xxxxx (např. xxx xxxx xxxx xxxxx x xxxxxxxxx 24 xxxxx), xxxx xx xxx xxxxxx xxx xxxxxxx kostní xxxxx xxxxxxxx xxxxxx po 18 xx 24 xxxxxxxx xx xxxxxxxx xxxxxxxx x při xxxxxxx periferní krve xxxxxx xx 36 xx 48 xxxxxxxx xx poslední xxxxxxxx (12).
Xxxxx xxxxxxx xxxxx xxx xxxxx xxxxxxx xxxx xxxx xxxxxx.
1.5.3 Xxxxxxxxx
Xxxxxxx-xx xx xxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxx studie xxx xxxxxxxx rozsahu xxxxx, xxxx xx být xxxxxxxxx ve xxxxxx xxxxxxxxxx, xx xxxxxxx xxxxxx, xxxxxx, xxxxxxxx x xx stejného xxxxxx xxxxxxxx, xxx xx použijí x xxxxxx xxxxxx (13). X xxxxxxx xxxxxxxx xx pro xxxxx xxxxx xxxxxxx tři xxxxxx dávky. Tyto xxxxxx xxxxx xx xxxx pokrývat xxxxxxx xxxx xxxxxxxxx až xxxxxxxxx xxxxxxxxx, xxxxxxxx xxxxxx xxxxxxxxx. Xxx xxxxxxxxx xxxxxx xxxxx, xxxx xxxx použita xxxxx xxxxxxxx xxxxx. Xxxxxxxx xxxxx je xxxxxxxxxx jako xxxxx xxxxxxxxxxxx xxxxxx známky xxxxxxxx, xx vyšší xxxxx xx xxxxx xxx stejném xxxxxx xxxxxxxxx xxxxx xxxxxxxxx x xxxxxxxx. Xxxxx xx specifickou xxxxxxxxxxx xxxxxxxxx při xxxxxxx xxxxxxxxxxx xxxxxxx (xxxx. xxxxxxx x xxxxxxxx) xxxxxx xxxxxxxxx stanovení xxxxx vyhovovat a xxxx xx xxx xxxxxxxxx xxxxxx xx xxxxxxx. Xxxxxxxx xxxxx xxxx být také xxxxxxxxxx xxxx xxxxx xxxxxxxxxxxx x xxxxxx xxxxx xxxxxxx xxxxxx xxxxxxxx (xxxx. snížení xxxxxx xxxxxxxxx xxxxxxxxxx x celkového množství xxxxxxxxxx x xxxxxx xxxxx xxxx x xxxxxxxxx xxxx).
1.5.4 Limitní xxxxxxx
Xxxxxxxx xxxxxxx s xxxxxx xxxxxx x xxxxxxx 2000 mg/kg xxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxxx nebo ve xxxx xxxxxxx x xxxxxx dni nevykazuje xxxxx pozorovatelné xxxxxxx xxxxxx x není-li xx xxxxxxx xxxxx x xxxxxxx, xxxxx xxxx podobnou xxxxxxxxx, xxxxxxxxx xxxxxxxxxxxx, xxxx xxxxxxxxxx xxxxx xxxxxx xx xxxxx xxxxxxxx xxxxx xx xxxxxxxxx. X xxxx trvajících xxxxxx je limitní xxxxxx pro 14xxxxx xxxxxxxx 2000 xx/xx xxxxxxx xxxxxxxxx/xxx x xxx xxxxx než 14xxxxx xxxxxxxx xx xxxxxxx xxxxxx 1000 xx/xx tělesné xxxxxxxxx/xxx. Xxxxxxxxx xxxxxxxx člověka xxxx xxxxxxxx potřebu xxxxxx x limitní xxxxxxx xxxxx xxxxxx xxxxx.
1.5.5 Xxxxxxxx dávek
Zkoušená xxxxx xx obvykle xxxxxx xxxxxxxxxxxxxx, xxxxxxxxx xxxxxx nebo vhodnou xxxxxxxxx xxxxxxx, xxxx xxxxxxxxxxxxxxxxx injekcí. Xxxx xxxxxxx podávání xxxx xxxxxxxxxx x xxxxxxxxxxxxxxx xxxxxxxxx. Xxxxxxxxx objem xxxxxxxx, který xxxx xxx xxxxxxxx podán xxxxxxxxx xxxxxx xxxx xxxxxxxx, xxxxxx xx xxxxxxxxx xxxxxxxxxxx xxxxxxx. Xxxxx by neměl xxxxxxxxx 2 xx/100 x xxxxxxx xxxxxxxxx. Xxxxxxx xxxxxxx objemů, xxx je xxxxxxx xxxxx, xxxx xxx xxxxxxxxxx. Až na xxxxxxxx x xxxxxx xxxxx, které obvykle xxx xxxxxxx xxxxxxxxxxxxx xxxxxxxx zesílené xxxxxx, xx měla xxx xxxxxxxxxxx zkušebního objemu xxxxxxxxxxxxxx xxxxxxxxxx koncentrace xxxxxxxxxxx xxxxxxxxxx objem xxx xxxxx úrovních xxxxx.
1.5.6 Xxxxxxxx kostní xxxxx nebo xxxx
Xxxxx xxxxxx xxxxx se xxxxxxx xxxxxxxxx x xxxxxx xxxx xxxxx xxxxx po xxxxxxxx. Xxxxx xx odeberou x xxxxxx xxxx xxxxx x xxxxxxxxxx xxxxxxxx se preparují x obarví. Xxxxxxxxx xxxx xx xxxxxxx x ocasní xxxx xxxx xxxx vhodné xxxxxx cévy. Xxxxxx xxxxx se xxxxx xxxxxxxxxxxx obarví (8, 9, 10), nebo xx xxxxxxxx xxxxxxxxx xxxxxxxx x xxxx xx obarví. Použitím xxxxxxx xxxxxxxxxxxx xxx XXX (xxxx. akridinová xxxxx (14) xxxx Xxxxxxx 33258 a xxxxxxx-X (15)) xx xxx xxxxxxx xxxxxxxx xxxxxxxxxx spojeným x xxxxxxxx barviva nespecifického xxx XXX. Tato xxxxxx xxxxxxx použití xxxxxxxxxxx xxxxxx (např. Xxxxxx). Přídavné xxxxxxx (xxxx. xxxxxxxxxx xxxxxx x odstranění xxxxx xxxxxxxxxxxx jádra (16)) xxx xxxxxx za xxxxxxxxxxx, xx se xxxxxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxxx xxxxxxx pro xxxxxxxxx xxxxxxxxxx x xxxxxxxxxx.
1.5.7 Analýza
Pro každé xxxxx xx stanoví xxxxx xxxxxxxxx xxxxxxxxxx x celkového (xxxxxxx + xxxxx) množství xxxxxxxxxx, přičemž xx x xxxxxxx xxxxxx xxxxx použije xxxxxxx xxxxxxx 200 xxxxxxxxxx x v xxxxxxx xxxxxxxxx krve xxxxxxx 1000 xxxxxxxxxx (17). Xxxxxxx xxxxxxxxx xxxxxx xxxxxxxxx xxxxxxxxxxx x xxxxxxxxxxx xxxxxxx, xx xxxx být xxxx xxxxxxxx xxx xxxxxxxxxxx xxxxxxxxx xxxxxxxx. X xxxxxxx xxxxxxx se xxxxxxx alespoň 2000 xxxxxxxxx erytrocytů xx xxxxxx xxxxxxxxxx x xxxxxxxxxxxxxxxxxxxxx. Xxxxx informace xxxxx xxx získány xxxxxxxxxx xxxxxxx xxxxxxxxxx xx xxxxxx xxxxxxxxxx. Xxx xxxxxxxxxxxxx xxxxxxx xx neměl xxx xxxxx xxxxxxxxx xxxxxxxxxx x celkového xxxxxxxx xxxxxxxxxx xxxxx než 20 % xxxxxxxxx xxxxxxx. Xxxxxxxx xxxx xxxxxxx exponována xxxxxxxxxxx xxxxx týdny xxxx xxxx, xxx také xxxxxxxx xx xxxxxx xxxxxxxxxx xxxxxxx 2000 xxxxxxx xxxxxxxxxx xx xxxxx xxxxx. Xxxxxxx xxx xxxxxxxxxxxx xxxxxxx (xxxxxxx xxxxxx x xxxxxxxxx cytometrická analýza xxxxxxx suspenze) xxxx xx odpovídajícím xxxxxxxxxx x xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxx hodnocení.
2. XXXXX
2.1 XXXXXXXXXX VÝSLEDKŮ
Údaje xxx xxxxxxxxxx xxxxxxx xx xxxx xxx xxxxxxxxxx ve formě xxxxxxx. Experimentální xxxxxxxxx xx xxxxx. Pro xxxxx xxxxxxxxxxx xxxxx xx měl xxx xxxxxx xxxxx xxxxxxxxxxx xxxxxxxxx xxxxxxxxxx, xxxxx xxxxxxxxx xxxxxxxxxx x xxxxxxxxxx x xxxxx xxxxxxxxx xxxxxxxxxx x xxxxxxxxx množství erytrocytů. Xxxxxxxx xxxx zvířata xxxxxxxxxx xxxxxxxxxxx xxxxx xxxxx nebo déle, xxxx by xxx xxxx uvedeny xxxxx x xxxxxxx erytrocytech, xxxx-xx xxxxxxxxxxxxx. Pro xxxxx xxxxx xx xxxxx podíl nezralých xxxxxxxxxx x celkového xxxxxxxx erytrocytů x xxxxxxxx množství xxxxxxxxxx x mikrojádry xxxxxxxxx x xxxxxxxxxx. Xxxxxxxxxx-xx xxxxx x rozdílu x xxxxxxxx xxxx xxxxxxxxx, xxxxx být xxx xxxxxxxxxxxx analýzu xxxxx xxx obě xxxxxxx zkombinována.
2.2 HODNOCENÍ X XXXXXXXXXXXX VÝSLEDKŮ
Pro xxxxxxxxx xxxxxxxxxxx výsledku xxxxxxxx xxxxxxx kritérií, xxxx. xxxxxx xxxxx xxxxx x xxxxxxxxxx x xxxxxxxxxx na xxxxx xxxx jasný xxxxxx xxxxx buněk x mikrojádry xxx xxxxxxx s xxxxxxx xxxxxx a x xxxxxxxx okamžiku xxxxxx. Xxxxxxxx xx xxxx xxx xxxxxxx biologická xxxxxxxxx xxxxxxxx. Při xxxxxxxxx xxxxxxxx xxxxxxx xxxxx být xxxxxxx xxxx xxxxxxx prostředek xxxxxxxxxxx metody (18, 19). Xxxxxxxxxxx xxxxxxxxxx xx xxxxxx xxx xxxxxxx xxxxxxxxx xxxxxxxx xxx xxxxxxxxx xxxxxxx. Xxxxxxxxxx xxxxxxxx by xxxx xxx xxxxxxxxx xxxxxx xxxxxxxxx, xxxxxxx x xxxxxxx xxxxxxxxxxxxxxxx xxxxxxxx.
Xxxxxxxx xxxxx, jejíž xxxxxxxx nesplňují xxxx xxxxxxx kritéria, se xxxxxxxx x xxxxx xxxxxxx xx xxxxxxxxxxx.
Xxxxxx xxxxxxx xxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxxx xxxx xxxxxxxxx výsledky, x xxxxxxxxxxx xxxxxxxxx neumožní xxxxxx xxxxx xxxxxxxx xxxxxxx výrok x xxxxxxxx zkoušené látky. Xxxxxxxx xxxxx zůstat xxxxxxxxxx xxxx sporné xxx xxxxxx xx xx, xxxxxxxx xx xxxxxxxxxx xxxxxxxx.
Xxxxxxxxx výsledky xxxxx xx xxxxxxxxxx xxxxxxxxx, že xxxxxxxx xxxxx xxxxxxxx mikrojádra, xxx xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxxxxxxx testovacího xxxxx. Xxxxxxxxx výsledky xxxxxxxxx, xx xxxxxxxx látka xx xxxxxxxx xxxxxxx xxxxxxxxxxx xxxxxxxxxx x xxxxxxxxx erytrocytech xxxxxxxxxxx xxxxx.
Xxxx xx xxx xxxxxxxxxxx xxxxxxxxxxxxxxx, x xxxxx se xxxxxxxx xxxxx xxxx její xxxxxxxxxx dostanou xx xxxxxxxx xxxxx, xxxx xxxxxxxxxx xx cílové xxxxx (xxxx. systémová xxxxxxxx).
3. XXXXXX
XXXXXXXX X XXXXXXX
Xxxxxxxx x xxxxxxx xxxx xxxxxxxxx xxxx xxxxxxxxx:
Xxxxxxxxxxxx/xxxxxxxxx:
- zdůvodnění volby xxxxxxxx,
- rozpustnost x xxxxxxx xxxxxxxx xxxxx x rozpouštědle/vehikulu, je-li xxxxx.
Xxxxxxxxx xxxxxxx:
- xxxxxxx xxxx/xxxx,
- počet, xxxxx x xxxxxxx xxxxxx,
- xxxxx, xxxxxxxx xxxxx, xxxxxx xxx.,
- xxxxxxxxxxxx xxxxxxxx xxxxxx na xxxxxxx xxxxxxx, xxxxxx xxxxxxx xxxxxxx xxxxxxxxx, xxxxxxx hodnota a xxxxxxxxxx odchylka xxx xxxxxx xxxxxxx.
Xxxxxxxx xxxxxxxx:
- xxxxx x xxxxxxxxx x xxxxxxxxx (xxxxxxxxx/xxxxxxxxxxxx) xxxxxxxx,
- údaje xx xxxxxx xxx xxxxxxxx xxxxxxx, xxxxx byla xxxxxxxxx,
- xxxxxxxxxx xxxxxxxxx xxxxxx dávek,
- xxxxx x xxxxxxxx zkoušené xxxxx,
- xxxxx x xxxxxxxx xxxxxxxx xxxxx,
- xxxxxxxxxx způsobu xxxxxxxx,
- xxxxxxxxx xxxxxx xxxxxxx, xxx se xxxxxxxx xxxxx xxxxxxx do xxxxxxxx xxxxx nebo xx xxxxxx xxxxx,
- xxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx xxxxxxxx látky x krmivu xxxx xxxx (xxx) xx xxxxxxxxxxxx dávku (xx/xx xxxxxxx xxxxxxxxx/xxx),
- podrobné xxxxx x xxxxxxx xxxxxx a vody,
- xxxxxxxx popis xxxxxxx xxxxxxxx x xxxxxx,
- xxxxxx xxxxxxxx xxxxxxxxx,
- xxxxxx stanovení toxicity,
- xxxxxxxx xxxxxxxxx xxxxxxxxxx x xxxxxxxxx erytrocytech,
- xxxxx xxxxxxxxxxxxx buněk xx xxxxx xxxxx,
- xxxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxxx, xxxxxxxxx xxxx xxxxxxxxxxx.
Xxxxxxxx:
- známky xxxxxxxx,
- xxxxx xxxxxxxxx xxxxxxxxxx z celkového xxxxxxxx xxxxxxxxxx,
- xxxxx xxxxxxxxx erytrocytů x xxxxxxxxxx xxxxxxx samostatně xxx xxxxx xxxxx,
- xxxxxxx xxxxxxx ± xxxxxxxxxx xxxxxxxx xxxxx xxxxxxxxx xxxxxxxxxx x xxxxxxxxxx ve xxxxxxx,
- xxxxx xxxxxxxx závislost xxxxxxxx na dávce,
- xxxxxxxx xxxxxxxxxxx xxxxxxx x metody,
- xxxxx x xxxxxxxx x xxxxxxxxx xxxxxxxxx kontrole,
- xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxx.
Xxxxxx výsledků.
Závěry.
4. XXXXXXXXXX
1) Xxxxxx, X. X. (1973), X Xxxxx Xx xxxx Xxxx xxx Xxxxxxxxxxx Xxxxxx, Mutatation Xxx., 18, 187-190.
2) Xxxxxx, X. (1975), The Xxxxxxxxxxxx Xxxx, Mutatation Xxx., 31, 9-15.
3) Xxxxxx, X. X., Xxxxxxxx, X. X., Xxxx, M., Xxxxxxxx, X., Xxxxxxxxx, X., XxxXxxxxx, X. X., Xxxxxx, X. W. (1983), Xxx Induction xx Xxxxxxxxxxx x. x. x Xxxxxxx xx Xxxxxxxxxxxx, Xxxxxxxxxx Xxx. 123, 61-118.
4) Xxxxxxxxx, K. X., Xxxxxx, D. H., Xxxxxx, X. X., Xxxxxxxx, X. X., Xxxxxx, X. X. (1990), The Xx xxxx Xxxxxxxxxxxx Xxxxx xx Xxxxxxxxx Bone Xxxxxx xxx Xxxxxxxxxx Xxxxx. A report xx xxx U. X. Xxxxxxxxxxxxx Protection Xxxxxx Gene-Tox Program, Xxxxxxxxxx Res., 239, 29-80.
5) XxxXxxxxx, X. X., Xxxxxxxx, X., Xxxx, X. X., Xxxx, C. M. (1983), Micronuclei xx Xxxxxxxxxxx Xxxxxxxxxxxx: A Xxxxx Xxxxxx xxx Xxxxxxxxxxx Xxxxxx Xxxxxx Xxxxxxx Xxxxxxxx Testing xx Mice, in: Xxxxxxxxxxxx xx Science xxx Practice xx Xxxxxxxxxx, ed. X. X. Xxxxx, X. X. Xxxxxxx, T. X. Miya. Xxxxxxxx, Xxxxxxxxx, 555-558.
6) XxxXxxxxx, X. T., Xxxxxx, X. A. Xxxx, X., Margolin, X. X., Ramel, X., Xxxxxxxx, X. X., Xxxx, X. R., Xxxx, X. (1987), Xxxxxxxxxx xxx xxx Xxxxxxx xx Xxxxxxxxxxxx Xxxxxx in Mammalian Xxxx Xxxxxx Xxxxxxxxxxxx, Xxxxxxxxxx Xxx., 189, 103-112.
7) XxxXxxxxx, X. X., Xxxx, C. X., Xxxxxx, X. X., Xxxxxx, X. X. (1990), The xx xxxx Xxxxxxxxxxx Xxxxxxxxxxxx Test: Xxxxxxxxxxx xx Xxxxxx State Xxxxxxxxx Xxxxx Efficiency xxx Xxxxxxx Xxxxxxxxxxx xxxx Toxicity Studies, Xxxxxx. Xxxx. Toxicol. 14, 513-522.
8) Xxxxxxx, X., Xxxxxx, T., Xxxxxx, Y., Sofumi, X., Xxxxxxxx, M. Xx. (1990), The Xxxxxxxxxxxx Xxxxx with Xxxxx Xxxxxxxxxx Xxxxx Xxxxxxxxxxxxx Xxxxx Xxxxxxxx Xxxxxx-Xxxxxx Xxxxxx, Xxxxxxxxxx Xxx., 245, 245-249.
9) Xxx Xxxxxxxxxxxxx Study Xxxxx for xxx Xxxxxxxxxxxx Xxxx (1992). Xxxxxxxxxxxx Xxxx with Xxxxx Xxxxxxxxxx Xxxxx Xxxxxxxxxxxx xx Acridine Xxxxxx Xxxxxxxxxx Xxxxxxxx: Xxx Xxxxxxx Xxxxxx xx xxx 5th Xxxxxxxxxxxxx Xxxxx xx XXXXX/XXXXX, XXX, Xxxxxxxxxx Xxx., 278, 83-98.
10) Xxx Collaborative Xxxxx Xxxxx xxx xxx Xxxxxxxxxxxx Xxxx (CSGMT/JEMMS, XXX: Xxx Xxxxxxxxx Xxxxxxxxxxx Study Group xx xxx Xxxxxxxxxxxxx Xxxxxxx Xxxxxxx xx Xxxxx) (1995), Protocol xxxxxxxxxxx for xxx xxxxx-xxxx xxxxx peripheral xxxxx xxxxxxxxxxxx xxxx, Xxxxxxxxxxx, 10, 53-159.
11) Xxxxxxx, X., Xxxx, X. X., MacGregor, X. X., Anderson, X., Xxxxxxx, X. X., Xxxxxx-Xxxxxxx, M., Xxxxxx, Xx. X. X., Pacchicrotti, X., Xxxxxxx, X., Shimada, X., Xxxxx, X., Xxxxxxx, X. (1994), Xx xxxx Xxxxxx Xxxxxxxxxxx Xxxxxxxxxxxx Assay, Xxxxx. Xxx., 312, 293-304.
12) Xxxxxxxxxxx, X., Xxxxx, X. (1995), Xx xxxxxxx, xxxxxxxxxxx xxxxxxxx xxxx of 30 ± 6 x xxxxx xxxxxx xxxxxx xx xxx xxxxx xxxxxxxxxx micronucleus xxxx, Xxxxxxxxxxx, 10, 313-319.
13) Xxxxxxx, R. X., Xxxxx, J. X., Boobis, A. X., Botham, X. X., Xxx, X., Xxxxxxx, X. X., Xxxxxxxxx, D. X., Xxxxxx-Xxxxxx, G., Xxxxxx, X. X., Xxxxxxxx, X. J., Xxxxxxx, X. (1992), Xxxxxx xx Xxxxxxx Toxicology Xxxxxxx/XX Xxxxxxxxxxxxx Mutagen Xxxxxxx Xxxxxxx Xxxxx: Xxxx Setting in Xx vivo Xxxxxxxxxxxx Xxxxxx, Mutagenesis, 7, 313-319.
14) Xxxxxxx, M., Xxxxxx, T., Ishidate, X. Xx. (1983), Xx Xxxxxxxxxxx of Xxxxxxxx Orange Fluorescent Xxxxxxxx xx xxx Xxxxxxxxxxxx Xxxx, Mutation Xxx., 120, 241-247.
15) XxxXxxxxx, X. X., Xxxx, X. X., Xxxxxxxx, X. X. (1983), X Xxxxxx Xxxxxxxxxxx Xxxxxxxx Xxxxxxxxx xxx Xxxxxxxxxxx and XXX xx Xxxxxxxxxxxx Xxxxx Hoechst 33258 xxx Xxxxxxx X, Xxxxxxxx Xxx., 120, 269-275.
16) Xxxxxxx, X., Xxxxxxxxxx, X. D. (1989), The automated xxxx xxxxxx xxxxxxxxxxxx xxxx, Xxxxxxxxxx Xxx., 213, 91-104.
17) Xxxxxxxxx, X., XxXxxxxx, L. X. (1995), Xxxxxx Xxxx xxx xxx Xxxxxxxxxx xx Polychromatic xx Xxxxxxxxxxxxxx Erythrocyte Xxxxx xx xxx Xxxx Marrow Micronucleus Xxxx, Xxxxxxxxxx Xxx., 347, 97-99.
18) Xxxxxxx, X., Xxxxx, X., Xxxxxxx, J., Chandley, X., Gatehouse, X. X., Xxxxxxxxx, L. (1990), Xx xxxx Xxxxxxxxxxxx Assay, in: X. X. Xxxxxxxx (xx.), Xxxxx Xxxxxxxxxxxx xxxxx, UKEMS Recommended Xxxxxxxxxx, UKEMS Sub-Committee xx Guidelines xxx Xxxxxxxxxxxx Testing. Xxxxxx, Xxxx 1, revised, Xxxxxxxxx Xxxxxxxxxx Xxxxx, Xxxxxxxxx, Xxx Xxxx, Xxxx Chester, Xxxxxxxxx, Xxxxxx, 115-141.
19) Xxxxxx, X. X., Xxxxxxxx, X., Xxxxxxxx, X., Xxxxxxxx, X. X., Xxxxx, X., Xxxxxxxx X., Xxxxxxx, X., Xxxxxxxx, D. X., Xxxxxx, X. X. X. (1989), Staticical Xxxxxxxx xx Xx xxxx Xxxxxxxxxxx Xxxxxx, xx: X. X. Xxxxxxxx (xx.), Xxxxxxxxxxx Xxxxxxxxxx xx Mutagenicity Xxxx Xxxx. UKEMS Xxx-Xxxxxxxxx on Xxxxxxxxxx xxx Xxxxxxxxxxxx Testing. Xxxxxx, Xxxx XXX, Xxxxxxxxx Xxxxxxxxxx Press, Xxxxxxxxx, Xxx Xxxx, Xxxx Xxxxxxx, Melbourne, Xxxxxx, 184-232."
PŘÍLOHA 4X
"X.13/14 XXXXXXXXXX — XXXXXXX NA XXXXXXXX XXXXXX X XXXXXXXXXX
1. XXXXXX
Xxxx xxxxxx xx xxxxxxxx xxxxxx XXXX XX 471 — Zkouška xx xxxxxxxx xxxxxx x xxxxxxxxxx (1997).
1.1 ÚVOD
Při xxxxxxx xx xxxxxxxx xxxxxx x xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxx xxxxx xxxxxxx xx xxxxxxxxxxxxxxx Xxxxxxxxxx typhimurium x Xxxxxxxxxxx xxxx, x xxxxxxx xxxxxxxx xxxxxx, xxxxx zahrnují xxxxxxxxxx, xxxxx x xxxxxx xxxxxxx nebo xxxxxxxx párů bází XXX (1, 2, 3). Xxxxxxxx xxxx xxxxxxx xx reverzní xxxxxx s bakteriemi xxxxxxx v xxxxxxx xxxxxx, které xxxxxxxxx xxxxxx xxxxxxxx v xxxxxxxxxxx kmenech a xxxxxxxx tak xxxxxxx xxxxxxxxx xxxxxxxx xxxxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx. Xxxxxxxx xx xxxxxxx xxxx xxxxxxxxxx díky své xxxxxxxxxx xxxx v xxxxxxxxxxxxx xxxxxxxxxxxx, které xxxx xxxxxxxxxx xxxxxxxxx xxxxxxxxxx kmenem.
Bodové mutace x xxxxxxx xxxx xxxx xxxxxxxx xxxxx xxxxxxxxx xxxxxxxxxxx chorob x xxxxxxx x xxxxxxxx xxxxx xxxxxx x xxx, xx xxxxxx xxxxxx x xxxxxxxxxx x v xxxxxx xxxxxxxxxxx xxxxx xxxxxxxxx xxxxxx xxxx xxxxx xx tvorbě xxxxxxxx x člověka x x xxxxxxxxx xxxxxx. Xxxxxxx xx xxxxxxxx xxxxxx s xxxxxxxxxx xx xxxxxx, xxxxxxxxxx x relativně xxxxxx. Xxxxx testovacích xxxxx má xxxx xxxxxxxxxx, díky nimž xxxx xxxxxxxxxx xx xxxxxxx mutací, xxxxxx xxxxxxxxxxxxx xxxxxxxx XXX xx reverzních místech, xxxxxxx xxxxxxxxxxxx xxxxx xxx velké molekuly x xxxxxxxxx xxxxxxxxxxx xxxxxxx DNA xxxx xxxxxxxx xxxxxxxxxxx xxxxxxx XXX xxxxxxxxxx x xxxxxx. Xxxxxxxxxxxx xxxxxxxxxxx xxxxx xxxx xxxxxxxxxx xxxxxxx užitečné informace x xxxxxx mutací, xxx jsou indukovány xxxxxxxxxxxxx xxxxxxxx. Pro xxxxxxx xx xxxxxxxx xxxxxx x xxxxxxxxxx xx x xxxxxxxxx xxxxx xxxxxxxx databáze xxxxxxxx xxx xxxxxxx xxxxx xxxxxxxx a xxxx xxxx vyvinuty xxxxx xxxxxxxxxx metody xxxxxxxx chemických látek, xxxxxx těkavých xxxxxxxxx, x xxxxxxx fyzikálně-chemickými xxxxxxxxxxx.
Xxx xxxx xxxxxx xxxx, část X.
1.2 XXXXXXXX
Xxxxxxx na xxxxxxxx xxxxxx s xxxxxxxxxx Xxxxxxxxxx xxxxxxxxxxx xxxx Xxxxxxxxxxx coli xxxxxx x detekci xxxxxx x kmeni vyžadujícím xxxxxxxxxxxxx (xxxxxxxx resp. xxxxxxxxx), přičemž xxxxxx xxxx xxxxxxxxx xx xxxxxxx xxxxxxx xxxxxxxxxxxxx.
Xxxxxxxx xxxxxxxxxx párů xxxx xxxx xxxxxxxx, xxx xxxxxxxxx xxxxx v xxxxxx DNA. Při xxxxxxx xxxxxxxxxx mutací xx xxxxx xxxx xxxxx xxxxxxxxxx na xxxxx xxxxxxx mutace xxxx xxxxx xxxxx xxxxxxxxxxxxx xxxxxx.
Xxxxxxxx mutageny xxxx xxxxxxxx, jež xxxxxxxxx xxxxx xxxx xxxxxx jednoho xxxx xxxx párů bází XXX x xxxxxxxx xxx čtecí xxxxx XXX.
1.3 VÝCHOZÍ XXXXX
Xxx xxxxxxxxx xx xxxxxxxx xxxxxx x bakteriemi xx využívají prokaryotické xxxxx, xxxxx xx xxxx od xxxxx xxxxx xxxxxxx, xxxx xxxx příjem, xxxxxxxxxxxx, xxxxxxxxxxxx struktura x xxxxxxxxx xxxxxxx XXX. Xxxxxxx prováděné xx xxxxx obecně vyžadují xxxxxxx vnějšího xxxxxx xxxxxxxxxxx aktivace. Metabolické xxxxxxxxx systémy xx xxxxx nemohou xxxxx xxxxxxxxx xxxxxxxx xx xxxx x xxxxx. Xxxxxxx tedy xxxxxxxxxxx xxxxxx xxxxxxxxx o xxxxxxxxxx x xxxxxxxxxxxxx xxxxxxxxxx xxxxx xxx xxxxx.
Xxxxxxx xx xxxxxxxx xxxxxx x xxxxxxxxxx xx xxxxxxxxx xxxxxxxxx xxx xxxxxxxxx vyšetření xxxxxxxxxxx xxxxxxxx, a xxxxxxx xxxxxxxx xxxxxxxxxxxx xxxxxx xxxxxx. X xxxxxxxx xxxxxxxx xxxxxxx, xx xxxxx chemických xxxxx, xxxxx jsou x této xxxxxxx xxxxxxxxx, xxxxxxxx xxxxxxxxx xxxxxxxx i v xxxxxx xxxxxxxxx. Xxxxxxxx xxxxxxxx xxxxxxxxxxx činitelů, xxxxx xxxxxx xxxxxxxxxx xxxxx xxxxxxxx. Xxxxxxx xxxxxx xxxxxxxxxxx lze xxxxxxxxx ve xxxxxxxxxx xxxxxx detekovanéhokonečného xxxx, x xxxxxxxxx v xxxxxxxxxxx xxxxxxxx xxxx x xxxxxxxxx x xxxxxxxxxx dostupnosti. Xx xxxxx straně faktory, xxxxx zvyšují xxxxxxxxx xxxxxxx xx xxxxxxxx xxxxxx na xxxxxxxxxx, xxxxx xxxx k xxxxxxxxxxxx mutagenní aktivity.
Zkouška xx xxxxxxxx xxxxxx x xxxxxxxxxx nemusí xxx vhodná xxx xxxxxx xxxxx xxxxxxxxxx xxxxx, xxxxxxxxx xxxxxx xxxxxxxxxxxx sloučeniny (např. xxxxxx xxxxxxxxxxx) x xxx xxxxxxxx xxxxx, x xxxxx xx xxxxxxxxxxx (nebo x xxxxx xx xx), xx xxxxxxxxxx xxxxxxxx xx replikačního xxxxxxx xxxxx xxxxx (xxxx. xxxxxxx xxxxxxxxxx xxxxxxxxxxxxx x xxxxxxx analogy xxxxxxxxxx). X xxxxxxxx xxxxxxxxx mohou xxx xxxxxxxxx xxxxxxx mutagenity x xxxxx.
Xxxxxxxx mnoho xxxxxxxxx, pro xxx xx xxxx xxxxxxx xxxxxxxxx, je xxxxxxxxxxxx xxx savce, není xxxxxxxx absolutní. Xxxxxx xx chemické třídě x existuje xxxxx xxxxxxxxxxx, xxx nejsou xxxxxxxxxx xxxxx zkouškou, xxxxx xxxxxx xxxxxx, xxxxxxxxxxxxxxx mechanismy, xxxx xxxxxxxxxx, xxxxx v xxxxxxxxxxxxx xxxxxxx neexistují.
1.4 XXXXXXXX ZKUŠEBNÍ METODY
Suspenze xxxxxxxxxxxxx xxxxx xxxx xxxxxxxxx xxxxxxxx xxxxx, x xx xx xxxxxxxxxxx xxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxx xxxxxxx x xxx xxxx. Ve xxxxxxxxxxx xxxxxxxx xxxxx xx xxxxxxxx smíchají x xxxxxxx xxxxxx x ihned xx xxxxxxx na minimální xxxx. X xxxxxxxxxxxx xxxxxx xx zkoušená xxxx xxxxxxxx x xxxx se xxxx xxxxxxxxx xx xxxxxxxxx xxxx smíchá s xxxxxxx agarem. Xxx xxxx technikách xx xx dvou xxxx xxxxx xxxxx xxxxxxxx xxxxxxxxx kolonie revertantů x provede se xxxxxxxx s xxxxxx xxxxxxx xxxxxxxxxxx xxxxxxxxxx xx xxxxxxxxx xxxxx x xxxxxxxxxxxxx.
Xx xxxxxxx xxxxxxx postupů provedení xxxxxxx xx xxxxxxxx xxxxxx s xxxxxxxxxx. Xxxx běžně xxxxxxxxx xxxxx xxxxxxxxxx xxxxxxx xxxx (1, 2, 3, 4), xxxxxxxxxxxx xxxxxx (2, 3, 5, 6, 7, 8), xxxxxxxxxx test (9, 10) a xxxxxxxxx metoda (11). Xxxxxx xxx xxxxxxxx xxxxx a par xxxx xxxxxxx (12).
Zde xxxxxxx xxxxxxx se xxxxxx xxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxx x xxxxxxxxxxxxxx xxxxx. Xxxxx x xxxx xx xxxxxxxxxx pro xxxxxxxxx xxxxxxxxxxx xxx x xxxxxxxxxxxx aktivací, xxx xxx xx. Xxxxxxx xxxxx lze účinněji xxxxxxxxx xx použití xxxxxxxxxxxx metody. Xxxx xxxxx patří do xxxxxxxxxx tříd, xx xxxxx patří xxxx xxxxx xxxxxx xxxxxxxxxx xxxxxxxxxxx, xxxxxxxxx xxxx, xxxxxxxx, xxxxxxxxxx x xxxxxxxxxx xxxxxxxxxx, xxxxxxxxxxxxxxx xxxxxxxxx, xxxxxxxx xxxxxxxxxx x xxxxxxxxxxxxxxx (3). Xxxxxx xx xxxxxxxxx, xx xxxxxx třídy xxxxxxxx nelze xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxxx, xxxx xx standardní xxxxxxx xxxx nebo xxxxxxxxxxxx xxxxxx. Xxxx xx xxx považovány xx "zvláštní xxxxxxx" x x jejich xxxxxxx se důrazně xxxxxxxxxx xxxxxx xxxxxxxxxxxx xxxxxxx. Xx xxxxx xxxxxxxxxxxxx xxxx "zvláštní xxxxxxx" (společně x xxxxxxxx xxxxxxx xxxxxx xxxxxxx): xxxxxxxxxx a xxxxxxxxxx xxxxxxxxxx (3, 5, 6, 13), xxxxx x xxxxxx xxxxxxxx xxxxx (12, 14, 15, 16), x glykosidy (17, 18). Xxxxxxxx xx xxxxxxxxxxxx xxxxxxx musí xxx xxxxxxx xxxxxxxxxx.
1.5 XXXXX XXXXXXXX XXXXXX
1.5.1 Xxxxxxxxx
1.5.1.1 Xxxxxxxx
Xxxxxxx kultury xxxxxxxx by měly xxx xxxxxxxxxxx do xxxxxx xxxxxxxxxxxxx xxxx xxxx do časné xxxxxxxxxxx xxxx xxxxx (xxxxxxxxx 109 buněk xx xx). Xxxxx x xxxxxx xxxxxxxxxxx xxxx xx xxxxxx xxx použity. Xx xxxxxxxx, aby xxxx xxxxxxx xxxxxxxx xxxxxx xxxx xxxxxxxxxxxxxxx xxxxxxxx. Xxxx může xxx xxxxxxxx buď na xxxxxxx dosavadních xxxxxxxxxxx xxxxx x xxxxxxx xxxxxx, xxxx xxx xxxxxx xxxxxxx xxxxxxxxxx xxxxx xxxxxxxxxxxxxxx xxxxx xx miskách.
Doporučená xxxxxxxxx xxxxxxx je 37 °X.
Xxxx xx xxx xxxxxxx xxxxxxx xxx xxxxx xxxxxxxx. Xxxx xxxx xx měly xxx čtyři xxxxx X. xxxxxxxxxxx (TA1535; XX1537 xxxx XX97x xxxx XX97; TA98 x TA100), xxxxxxx xxxxxxx se xxxxxxx x xxxxxxx laboratořích xxxx spolehlivá x xxxxxxxxxxxxxxxx. Xxxx xxxxx xxxxx X. xxxxxxxxxxx xxxx pár xxxx XX xx xxxxxxxxx xxxxxxxxx místě a xx známo, xx xxxxxx xxxxxxxxxxxxxxx xxxxx xxxxxxxxx xxxxxx xxxxxxxx xxxxxxxx, činitele způsobující xxxxxxxxxx vláken XXX x hydraziny. Xxxx xxxxx mohou xxx xxxxxxxxxx xxxxx X. xxxx XX2 xxxx X. xxxxxxxxxxx XX102 (19), xxxxx mají xx xxxxxxxxx xxxxxxxxx xxxxx xxx xxxx XX. Doporučená xxxxxxxxx xxxxx xx tedy xxxx:
- X. typhimurium XX1535 x
- X. xxxxxxxxxxx TA1537 nebo XX97x x
- X. xxxxxxxxxxx XX98 x
- X. typhimurium XX100 x
- X. xxxx XX2 xxxX, nebo X. xxxx WP2 xxxX (pKM101), nebo X. xxxxxxxxxxx XX102.
Xxx xxxxxxx xxxxxxxx způsobujících xxxxxxxxxx vláken DNA xxxx xxx xxxxxxxxx xxxxxxx XX102 xxxx xxxxxx xxxx E. xxxx x xxxxxxx xxxxxxxxxx reparace DNA, (xxxx. X. xxxx XX2 (xXX101)).
Xxxx by xxx xxxxxxx xxxxxxxx xxxxxxx přípravy kmenové xxxxxxx, verifikace xxxxxxx x skladování. Potřeba xxxxxxxxxxxxx xxx xxxx xx xxxx být xxxxxxxxx xxx xxxxxx xxxxxxxxx kmenovou xxxxxxx (xxxxxxxx xxx xxxxx X. xxxxxxxxxxx a xxxxxxxxx xxx X. xxxx). Podobně by xxxx xxx kontrolovány xxxx xxxxxxxxxx xxxxxxxxxxxxxxx, xxxxxxxxx xxxxx potřeby xxxxxxxxxx xxxx xxxxxxxxxxxx X-xxxxxxx plasmidů (xx. xxxxxxxxxxxx xxxxxxxxxx x xxxxx XX98, TA100 x XX97x xxxx XX97, WP2 uvrA x XX2 xxxX (xXX101) x ampicilinová x xxxxxxxxxxxxxx xxxxxxxxxx x xxxxx XX102), xxxxxxxxxx xxxxxxxxxxxxxxxxxx xxxxxx (xx. xxx xxxxxx x X. xxxxxxxxxxx xxxxxxxxxx xx xxxxxxxxxxx xxxxxx x xxxX xxxxxx u E. xxxx xxxx xxxX xxxxxx u S. xxxxxxxxxxx xxxxxxxxxx xx xxxxxxxxxxxx xxxxxx) (2, 3). Xxxxx by xxxx xxxxxx xxxxx xxxxx kolonií xxxxxxxxxxx xxxxxxxxxx xx misce x xxxxxxx xxxxxxxx xxxxxxxxxxx xx základě xxxxxxxxxxx údajů xxxxxxxxxxxxx xxxxxxx x nejlépe x xxxxxxx xxxxxxxx x literatuře.
1.5.1.2 Xxxxxx
Xxxxxxx xx vhodný xxxxxxxxx xxxx (xxxx. obsahující xxxxxxxxx xxxx X (Xxxxx-Xxxxxx) a glukosu) x xxxxxx agar xxxxxxxxxx xxxxxxxx x xxxxxx nebo xxxxxxxxx xxxxxxxxxx xxxxxxx buněčných xxxxxx (1, 2, 9).
1.5.1.3 Xxxxxxxxxxx xxxxxxxx
Xxxxxxxx xx xxxx xxx xxxxxxxxx zkoušené xxxxx, x xx s xxxxxxx xxxxxxxx metabolické xxxxxxxx a xxx xxxx. Xxxxxxxxxx xxxxxxxxxx xxxxxxxx xx xxxxxxxxxx xxxxxxxx xxxxxxxxxxxxxxxxxxx frakce (X9) xxxxxxxxxx z xxxxx xxxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxx, xxxx xx Aroclor 1254 (1, 2) xxxx xxxxxxxxxxxxx x β-xxxxxxxxxxxx (18, 20, 21). Xxxxxxxxxxxxxxxxxxx xxxxxx xx obvykle xxxxxxxxx x xxxxxxxxxxxxx x xxxxxxx 5 až 30 % xxx. xx xxxxx X9. Xxxxx a xxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxx systému xxxx xxxxxxx na xxxxx xxxxxxxx xxxxxxxx xxxxx. X některých xxxxxxxxx může být xxxxxx xxxxxx více xxx jednu xxxxxxxxxxx xxxxxxxxxxxxxxxxxxx xxxxxx. U xxxxxxxxx x xxxxxxxxxxxx xxxxxxxxx může být xxxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxxxxxxx aktivačního systému (6, 13).
1.5.1.4 Xxxxxxxx xxxxx xxxx xxxxxxxxx
Xxxxx xxxxxxxx xxxxx xx xxxx xxx xxxx xxxxxxxx xx xxxxxxxx xxxxxxxxxx xxxx xxxxxxxxxxxx xx xxxxxxxx xxxxxxxxxxxxxx xxxx xxxxxxxxxx x xxxxxxxxx xxxxxxx. Kapalné xxxxxxxx látky xxxxx xxx přidány xxxxx x xxxxxxxxxx systémům x/xxxx mohou xxx xxxx aplikací zředěny. Xxxx by xxx xxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxx xxxxx, xxxxx xxxxx o xxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxxxxx.
Xxxxxxxxxxxx/xxxxxxxxx xx xxxx xxx xxxx podezření, xx xxxxxxx xx xxxxxxxxx látkou, a xxxx by být xxxxxxxxxx s xxxxxxxx xxxxxxxx x s xxxxxxxxx X9 (22). Xxxx-xx xxxxxxx xxxx xxx xxxxx rozpouštědla/vehikula, xxxx by xxx xxxxxx xxxxxxxx xxxxxxxxx xxxxx x xxxxxx xxxxxxxxxxxxx. Xxxxxxxxxx se xxxxx xxxxx nejdříve xxxxxx použití xxxxxxx xxxxxxxxxxxx/xxxxxxx. Xxx zkoušení xxxxx xxxxxxxxx xx xxxx xx měla xxx xxxxxxx xxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxxx vodu.
1.5.2 Xxxxxxxx xxxxxxxx
1.5.2.1 Zkušební xxxxx (xxx 1.5.1.1)
1.5.2.2 Xxxxxxxxx xxxxxxxxxxx
Xxxx xxxxxxxx, xxxxx xxxx xxx xxxxxxxxxx při xxxxxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxx xxxxx xxxxx xxxxxxxxxxxx x xxxxxxxxxxx x xxxxxxx xxxxx xxx xxxxxxxx.
Xxxx být xxxxxxxx xxxxxxxx xxxxxxxx x xxxxxxxxxxxxx v xxxxxxxxxxx xxxxxxxxxxxxx. Cytotoxicita může xxx xxxxxxxxxx snížením xxxxx xxxxxxx revertantů, xxxxxxxxx xxxx zeslabením xxxxxxxxxxxxx xxxxxxxx nebo xxxxxxxx stupně xxxxxxx xxxxxxxxxxxx kultur. Xxxxxxxxxxxx xxxxx se xxxx xxxxxx x xxxxxxxxxxx xxxxxxxxxxxxx aktivačních xxxxxxx. Xxxxxxxxxxxxx xx xxxx xxx xxxxxxxxx xx xxxxxxx xxxxxxxxxxx xxxxxxx x xxxxxxx směsi xx skutečných xxxxxxxxxx xxxxxxxx.
Xxxxxxxxxx xxxxxxxxx zkušební xxxxxxxxxxx xxx rozpustné xxxxxxxxxxxxx xxxxx je 5 xx/xxxxx nebo 5 μx/xxxxx. X xxxxxxxxxxxxxxx xxxxx nerozpustných xxx xxxxxxxxxxxxx 5 xx/xxxxx nebo 5 μx/xxxxx xx xxxx xxx xxxxx xxxx xxxx xxxxxxxxxx koncentrací xxxxxxxx, xxx látky xxxx x xxxxxxx xxxxx xxx aplikaci xxxxxxxxxxx. Xxxxxxxx xxxxx, xxxxx jsou cytotoxické xxx xxx xxxxxxxxxxxxx xxxxxxx než 5 xx/xxxxx xxxx 5 μx/xxxxx, xx xxxx xxx zkoušeny xx xx cytotoxické xxxxxxxxxxx. Xxxxxxxxx by xxxxxx xxxxx xxx xxxxxxxxxxx.
Xxxx xx xxx xxxxxxx xxxxxxx xxx různých xxxxxxxxxxxxxxxx koncentrací xxxxxxxx xxxxx, xxxxxxx xxx xxxxxx experimentu by xxxx xxx xxxxxxxxx xxxx zkušebními xxxx xxxxx xxxxxxxxx xxxxxxxx xxxxx xxxxxxxxxxxx stupnice (xx. Ö10). Xxxxx xxxxxxxxx jsou vhodné x xxxxxxx, kdy xx xxxxxxxxx křivka xxxxxxxxxx xxxxxxxx na xxxxxxxxxxx. Zkoušení koncentrací xxxxxxx xxx 5 xx/xxxxx nebo 5 μx/xxxxx může xxx xxxxxxx xxx xxxxxxxxx xxxxx obsahujících xxxxxxxx xxxxxxxx xxxxxxxxxxx mutagenních xxxxxxxx.
1.5.2.3 Xxxxxxxxx x xxxxxxxxx xxxxxxxx
Xxxxxxxx xxxxxxx xxxxxxxxx by měly xxx kmenově xxxxxxxxxx xxxxxxxxx x xxxxxxxxx (xxxxxxxxxxxx xxxx vehikulum) xxxxxxxx x xxxxxxxxxxxx xxxxxxxx x bez xx. Xxx pozitivní xxxxxxxx by xxxx xxx xxxxxxx koncentrace xxxxxxxxxxx xxxxxxxx xxxxx xxxxxxx.
X xxxxxxx xxxxxxx x xxxxxxxx metabolického xxxxxxxxxxx systému xx xxxx být xxxxx (xxxxx) xxx xxxxxxxxx xxxxxxxx xxxxxxx (vybrány) xx xxxxxxx xxxx xxxxxxxxx xxxxx bakterií.
Příkladem xxxxxx pozitivní xxxxxxxx x xxxxxxx x xxxxxxxxxxxx xxxxxxxx xxxx xxxx xxxxx:
|
Xxxxx |
Xxxxx CAS |
Číslo xxxxx XXXXXX |
|
9,10-xxxxxxxxxxxxxxxxx |
781–43–1 |
212–308–4 |
|
7,12-xxxxxxxxxxxxx[x]xxxxxxxxx |
57–97–6 |
200–359–5 |
|
xxxxx[x]xxxxx |
50–32–8 |
200–028–5 |
|
2-xxxxxxxxxxxxxx |
613–13–8 |
210–330–9 |
|
Xxxxxxxxxxxxx |
50–18–0 |
200–015–4 |
|
xxxxxxxxxxxxx xxxxxxxxxx |
6055–19–2 |
Xxxx xxxxx je xxxxxxx xxxxxxxxx xxxxxxxxx xxx xxxxxx xxxxxxxx metabolické xxxxxxxx:
|
Xxxxx |
Xxxxx CAS |
Číslo xxxxx XXXXXX |
|
XX Xxxxxx Xxx 28 |
573–58–0 |
209–358–4 |
2-xxxxxxxxxxxxxx xx xxxxx xxx použit jako xxxxxx indikátor xxxxxxxxx xxxxx S9. Xxx xxxxxxx 2-aminoanthracenu by xxxx být xxxxx xxxxx X9 xxxxxxxxxxxxxxxx xxxxxxxxx, xxxxx xxxxxxxx xxxxxxxxxxxx aktivaci xxxxxxxxxxxxxx xxxxxx, xxxxxxxxx benzo[a]pyren xxxx 7,12-xxxxxxxxxxxxx[x]xxxxxxxxx.
Xxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxxx xxxxxxxx x xxxxxxx bez vnější xxxxxxxxxxx xxxxxxxx xxxx xxxx xxxxx:
|
Xxxxx |
Xxxxx XXX |
Xxxxx xxxxx XXXXXX |
Xxxx |
|
xxxx xxxxx |
26628–22–8 |
247–852–1 |
XX1535 x TA100 |
|
2-nitrofluoren |
607–57–8 |
210–138–5 |
TA98 |
|
9-aminoakridin |
90–45–9 |
201–995–6 |
TA1537, XX97 x TA97a |
|
ICR 191 |
17070–45–0 |
241–129–4 |
XX1537, XX97 a XX97x |
|
Xxxxxxxxxxxxxxxxx |
80–15–9 |
201–254–7 |
XX102 |
|
xxxxxxxxx X |
50–07–7 |
200–008–6 |
XX2xxxX x TA102 |
|
1-methyl-3-nitro-1-nitrosoguanidin |
70–25–7 |
200–730–1 |
WP2, XX2 xxxX x XX2 uvrA (xXX101) |
|
4-xxxxxxxxxxxxx-1-xxxx |
56–57–5 |
200–281–1 |
XX2, XX2 xxxX x XX2 xxxX (xXX101) |
|
α-[(5-xxxxx-2-xxxxx)xxxxxxxxxx]xxxxx-2-xxxxxxxx (XX2) |
3688–53–7 |
xxxxx obsahující xxxxxxxx |
Xxx xxxxxxxxx xxxxxxxx mohou xxx použity xxxx xxxxxx xxxxxxxxxx xxxxx. Xxx xxxxxxxxx xxxxxxxx xx mělo být xxxxx x úvahu xxxxxxx chemických látek xx xxxxxx xxxxxxxx xxxxx, jsou xx x dispozici.
Měly xx xxx xxxxxxx xxxxxxxxx xxxxxxxx skládající xx xx samotného rozpouštědla xxxx xxxxxxxx, xxx xxxxxxxx xxxxx, xxxxxxxxxx xxxxx stejným xxxxxxxx xxxx xxxxxxxxxx xxxxxxx. Xxxxx toho by xxxx xxx neexponované xxxxxxxx xxxxxxx xxxx xxxxx, neexistují-li dosud xxxxxxxxx údaje xxxxxxxxxxx, xx xxxxxxx xxxxxxxxxxxx xxxxxxxxxx xxxxx xxxxxxx xxxx xxxxxxxxx xxxxxx.
1.5.3 Xxxxxx
X xxxxxxxxxx xxxxxxx xxxxxx (1, 2, 3, 4) xxx xxxxxxxxxxx xxxxxxxx xx xxxxxxx xxxxxx 0,05 xx xxxx 0,1 xx xxxxxxxxxx xxxxxxx, 0,1 xx čerstvé xxxxxxxxxxx xxxxxxx (xxxxxxxxxx xxxxxxxxx 108 xxxxxxxxxxxxxxx xxxxx) x 0,5 xx xxxxxxxxxx pufru x 2,0 xx xxxxxxxx xxxxx. V xxxxxxx zkoušky x xxxxxxxxxxxx aktivací se xxxxxxx xxxxxx 0,5 xx xxxxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxxx přiměřené xxxxxxxx xxxxxxxxxxxxxxxxxxx xxxxxx (x rozmezí 5 xx 30 % xxx. x metabolické xxxxxxxxx směsi) x xxxxxxx xxxxxx (2,0 xx) x xxxxxxx x xxxxxxxxxx a xxxxxxxxx xxxxxx xxxx xxxxxxxxx xxxxxxxx. Obsah xxxxx zkumavky se xxxxxxxx x přelije xxxx xxxxxx xxxxxxxxxxx xxxxx xx xxxxx. Xxxx inkubací xx xxxxx xxxxxx xxxx xxxxxxxx.
X preinkubační metody (2, 3, 5, 6) xx zkoušená xxxxx xxxx xxxxxxxx xxxxxx xxxx xxxxxxxxx x xxxxxxx agarem x přelitím xxxx xxxxxx xxxxxxxxxxx xxxxx xx xxxxx xxxxxxx 20 xxxxx nebo xxxx xxxxxxxxxxx x xxxxxxxxxx xxxxxx (xxxxxxxxxxx xxxxxxxxx 108 životaschopných xxxxx) x xxxxxxxxx xxxxxx xxxx xxxxxxxxxxxx xxxxxxxxxx xxxxxxxx (0,5 xx) xxx 30 — 37 °C. Xxxxxxx se smíchá 0,05 nebo 0,1 xx zkoušené látky xxxx xxxxxxxxxx xxxxxxx, 0,1 xx bakterií x 0,5 xx xxxxx X9 nebo xxxxxxxxxx xxxxx s 2,0 xx xxxxxxxx xxxxx. Zkumavky by xxxx být xxxxx xxxxxxxx xxxxxxxxxxxxxx xx xxxxxxxx.
X dostatečnému xxxxxx xxxxxxxx xx xxxx xxx při každé xxxxxx xxxxx xxxxxxx 3 xxxxx. Xxxxxxx xxxx xxxxx je xxxxxxxxxx xx vědeckém xxxxxxxxxx. Xxxxxxxx xxxxxx xxxxx xxxxxx xxxxxxxx xxxxxxxxxxxx xxxxxxx.
Xxxxxx xxxx xxxxxx xxxxx xx xxxx xxx xxxxxxxx xxxxxxxx xxxxxxxx, xxxx. x xxxxx xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx (12, 14, 15, 16).
1.5.4 Xxxxxxxx
Xxxxxxx xxxxx x xxxx xxxxxxx xx xxxx xxx inkubovány xxx 37 °X xx 48 –72 xxxxxxxx. Po uplynutí xxxxxxxxx doby xx xxxxxx počet kolonií xxxxxxxxxx na xxxxx.
2. XXXXX
2.1 XXXXXXXXXX VÝSLEDKŮ
Předloženými xxxxx xx xxxx xxx xxxxx kolonií xxxxxxxxxx připadající xx xxxxx. Xxx by xxx xxxxxx xxxxxx xxxxx kolonií xxxxxxxxxx xxx xx xxxxxxx x xxxxxxxxx kontrolou (xxxxxxxx xxxxxxxxxxxx a xxxxxxxx xxxxxxxxxxxx xxxxxxxx), xxx na xxxxxxx x xxxxxxxxx kontrolou. Xxxxx xx xxxxxxxxxxxx xxxxxxx, xxxxxxx hodnoty xxxxx kolonií revertantů xx misku a xxxxxxxxxx xxxxxxxx xx xxxx xxx xxxxxxxxxx xxx xxxxxxxxx xxxxx x xxxxxxxxx x xxxxxxxxx xxxxxxxx (neexponovanou xxxxxxxx a/nebo xxxxxxxx xxxxxxxxxxxx).
Xxxxxxx xxxxx pozitivní xxxxxxxx xx xxxxxxxxxx. Xxxxxxxxxx xxxxxxxx xx xxxx xxx xxxxxxxxx xxxxxx zkoušením, nejlépe x xxxxxxx xxxxxxxxxxxxxxxx xxxxxxxx. Xxxxxxxxx xxxxxxxx xxxx xxx potvrzeny xxxxxx od xxxxxxx. Xxxxxxxx xx xxxxxxxxx xxxxxxxxxxx výsledků xxxxxxxxxx xx xxxxxxxx, xxxx xx xxx xxxxxx xxxxxxxxxx. Změna parametrů xxxxxx x cílem xxxxxxxx xxxxxx xxxxxxxxxxxx xxxxxxxx xx xxxx xxx zvážena x xxxxxxxxxx experimentech. X xxxxxxxxxx xxxxxx, xxxxx xx xxxxx xxx xxxxxxx, xxxxx rozmezí xxxxxxxxxxx, xxxxxx xxxxxxxxxx (xxxxxxxxxx xxxxxxx metoda xxxx preinkubace x xxxxxxxx médiu) x xxxxxxxx xxxxxxxxxxx xxxxxxxx.
2.2 XXXXXXXXX A XXXXXXXXXXXX XXXXXXXX
Xxx xxxxxxxxx xxxxxxxxxxx xxxxxxxx existuje xxxxxxx xxxxxxxx, xxxx. xxxxxx xxxxx xxxxxxx revertantů xx misku nad xxxxxxxxx xxxxxx x xxxxxxx xxxxxxx xxxxx x xxxxxxxxxxxx aktivačním xxxxxxxx xxxx bez xxxx, x to x xxxxxxxxxx xx xxxxxxxxxxx, xxxx xxxxxxxxxxxxxxxx xxxxxx xxxxxx xxxxx xxx xxxxx nebo xxxx koncentrací (23). Xxxxxxxx xx měla xxx uvážena xxxxxxxxxx xxxxxxxxx xxxxxxxx. Při xxxxxxxxx xxxxxxxx zkoušky xxxxx být xxxxxxx xxxx xxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxx (24). Xxxxxxxxxxx významnost by xxxxxx být xxxxxxx xxxxxxxxx xxxxxxxx xxx xxxxxxxxx odpověď.
Zkoušená látka, xxxxx xxxxxxxx xxxxxxxxx xxxx xxxxxxx xxxxxxxx, xx xxxxxxxx x xxxxx systému xx xxxxxxxxxxx.
Xxxxxx xxxxxxx experimentů xxxxxxxx xxxxx xxxxxxxxx xxxx xxxxxxxxx xxxxxxxx, x xxxxxxxxxxx případech xxxxxxxx xxxxxx xxxxx xxxxxxxx xxxxxxx výrok x aktivitě xxxxxxxx xxxxx. Xxxxxxxx mohou xxxxxx xxxxxxxxxx nebo xxxxxx bez ohledu xx to, kolikrát xx xxxxxxxxxx xxxxxxxx.
Xxxxxxxxx xxxxxxxx xxxxxxx xx xxxxxxxx xxxxxx x xxxxxxxxxx xxxxxxxxx, xx xxxxxxxx látka indukuje x xxxxxx xxxxx Xxxxxxxxxx xxxxxxxxxxx x/xxxx Xxxxxxxxxxx xxxx xxxxxx xxxxxx substitucí xxxx xxxx posunem xxxxxxx xxxxx. Xxxxxxxxx xxxxxxxx xxxxxxxxx, xx zkoušená xxxxx xxxx za xxxxxxxx xxxxxxx xxx xxxxxxxxx xxxxx xxxxxxxxx.
3. XXXXXX
XXXXXXXX O XXXXXXX
Xxxxxxxx x zkoušce xxxx xxxxxxxxx xxxx informace:
Rozpouštědlo/vehikulum:
- xxxxxxxxxx xxxxx xxxxxxxxxxxx/xxxxxxxx,
- xxxxxxxxxxx a xxxxxxx xxxxxxxx xxxxx x xxxxxxxxxxxx/xxxxxxxx, xx-xx xxxxx.
Xxxxx:
- xxxxxxx kmeny,
- xxxxx xxxxx v xxxxxxx,
- xxxxxxxxxxxxxxx xxxxx.
Xxxxxxxx xxxxxxxx:
- xxxxxxxx xxxxxxxx xxxxx xx xxxxx (xx/xxxxx xxxx μx/xxxxx) s xxxxxxxxxxx výběru xxxxx x xxxxx xxxxx xx xxxxxxxxxxx,
- použitá xxxxx,
- xxx a xxxxxxx xxxxxxxxxxxxx aktivačního xxxxxxx, xxxxxx xxxxxxxx xxxxxxxxxxxxx,
- xxxxxx xxxxxxxx.
Xxxxxxxx:
- xxxxxx xxxxxxxx,
- xxxxxx xxxxxxx,
- xxxxx xx xxxxxxxxxxxx xxxxxxx,
- xxxxxxx xxxxxxx xxxxx xxxxxxx xxxxxxxxxx xx xxxxx x xxxxxxxxxx odchylka,
- xxxxx možnosti závislost xxxxxxxx xx dávce,
- xxxxxxxx xxxxxxxxxxx xxxxxxx,
- xxxxx o souběžné xxxxxxxxx (rozpouštědlo/vehikulum) a xxxxxxxxx xxxxxxxx x xxxxxxxxx, xxxxxxxxx xxxxxxxxx x směrodatnými odchylkami,
- xxxxxxxxx xxxxx o xxxxxxxxx (xxxxxxxxxxxx/xxxxxxxxx) x xxxxxxxxx xxxxxxxx x xxxxxxxxx, středními xxxxxxxxx x směrodatnými xxxxxxxxxx.
Xxxxxx xxxxxxxx.
Xxxxxx.
4. XXXXXXXXXX
1) Xxxx, X. N., McCann, X., Xxxxxxxx X. (1975), Methods of Xxxxxxxxx Xxxxxxxxxxx xxx Xxxxxxxx with the Xxxxxxxxxx/Xxxxxxxxx-Xxxxxxxxx Mutagenicity Test, Xxxxxxxxxx Xxx., 31, 347-364.
2) Maron, X. X., Xxxx, B. X. (1983), Revised Xxxxxxx xxx the Xxxxxxxxxx Xxxxxxxxxxxx Xxxx, Xxxxxxxxxx Res., 113, 173-215.
3) Xxxxxxxxx, X., Xxxxxxx, X., Xxxxxx, X., Gocke, X., Xxxx, L., Xxxxxxxxxx, X., Melcion, X., Xxxxx, X., Xxxxxx, X., Xxxxxx, X. (1994), Xxxxxxxxxxxxxxx xxx xxx Xxxxxxxxxxx xx Xxxxxxxxx Xxxxxxxx Xxxxxx, Xxxxxxxxxx Res., 312, 217-233.
4) Kier, X. X., Brusick X. X., Auletta, X. X., Von Halle, X. X., Xxxxx, X. X., Xxxxxx, X. X., Xxxxxx, X., McCann, X., Xxxxxxxxxx, K., Xxxxxx, X., Rao, X. X., Xxx X. (1986), Xxx Xxxxxxxxxx xxxxxxxxxxx/Xxxxxxxxx Xxxxxxxxxx Xxxxx: X Report xx xxx X. X. Xxxxxxxxxxxxx Xxxxxxxxxx Xxxxxx Xxxx-Xxx Program, Xxxxxxxxxx Xxx., 168, 69-240.
5) Xxxxxx, X., Degawa, X., Seino, Y. X., Matsushima, X., Xxxxx, X., Sugimura, X., Hashimoto, X. (1975), Xxxxxxxxxxxx xx Xxxxxxxxxx Xxx Xxxx xxx their Xxxxxxxxxxx, Xxxxxx Xxxx. 1, 91-96.
6) Xxxxxxxxxx, X., Xxxxxxxx, T., Xxxxx, X., Yahagi, T., Xxxxxx, X., Sawamura, X. (1980), Factors Xxxxxxxxxx Xxxxxxxxxxxx Microbial Xxxxx, in: Xxxxx-xxxx Xxxx Xxxxxxx xxx Xxxxxxxxx Xxxxxxxxxxx, xx. Xxxxxxx X. X., Xxxxxx, X. C., Xxxxxxxx, Xxxxxx-Xxxxxxxxxx-Xxx Xxxx, 273-285.
7) Xxxxxxxxx, X. X., Rowland, X. X., Wilcox, P., Xxxxxxxxx, X. X., Xxxxxx, X. (1980), Xxxxxxxxx Xxxxxxxx Xxxxxx, xx: Basic Xxxxxxxxxxxx Xxxxx: UKEMS Part 1 Xxxxxxx, xx. X. X. Xxxxxxxx, Xxxxxxxxx University Press, 13-61.
8) Xxxxxxxxxx, X. X., Xxxxxx, X., Xxxxxxx, X. (1987), Xxxxxx Xxxxxxxxxxxxx Xxxxxxxxxxxx Xxxx for Foods, X. Xxxx Xxxxxx., 8, 167-177.
9) Xxxxx, X. X. X., Xxxxxx, X. X., Xxxxxxx, X. X. (1976), Xxx xx x simplified fluctuation xxxx xx xxxxxx xxx xxxxxx of xxxxxxxx, Xxxxxxxxxx Res., 38, 33-42.
10) Xxxxxxx, X. A., Xxxxx, X. H. X., Xxxxxxxxx, X., Bridges, X. X. (1984), Xxx Fluctuation Xxxx xx Xxxxxxxx, xx: Xxxxxxxx of Mutagenicity Xxxx Xxxxxxxxxx, 2. xxx., Kilbey, B. X., Xxxxxxx, X., Xxxxxxx, W., Xxxxx, X. (eds.), Xxxxxxxx, Xxxxxxxxx-Xxx York-Oxford, 141-161.
11) Xxxxxxxx, E. D., Xxxxxxx, P. X. (1981), Xx Xxxxxxxxxxx xx xxx Xxxxxxxxxxxx Xxxxxxxxxx Assay xxx Xxxxxxxxxxx with Xxxxxxx xx Xxxxxxxxxx xxxxxxxxxxx, Xxxxxxxxxxxxx Mutagenesis, 3, 453-465.
12) Xxxxx, A., Xxxxxxx, X., Kato, X., Xxxxxxxxxx, X. (1994), Xxxxxxxx Xxxxxx xxx Xxxxxxxxxxxx Testing xx Xxxxxxx Xxxxxxxxx xx Using a Xxx Xxxxxxxx Bag, Xxxxxxxxxx Res., 307, 335-344.
13) Prival, M. X., Xxxx, X. X., Xxxxxxxx, X. X., Xxxxxxx, M. X., Xxxxxxx, X. X. (1984), Xxxxxxxxxxxx xx Xxxxxxxxx and Xxxxxxxxx-Xxxxxxxx Dyes xxx Xxxxxxxx Xxxxxxx Dyes xx x Modified Xxxxxxxxxx Xxxxx, Xxxxxxxxxx Xxx., 136, 33-47.
14) Xxxxxx, E., Xxxxxxxx, X. X., Haworth, X., Lawlor, X., Xxxxxxxxxx, X. (1992), Xxxxxxxxxx Xxxxxxxxxxxx Xxxxx. X. Results from xxx Xxxxxxx xx 311 Chemicals, Xxxxxxx. Xxx. Xxxxxxx., 19, 2-141.
15) Simmon, X., Xxxxxxxx, X., Xxxxxxx, X. G. (1977), Xxxxxxxxx Activity of Xxxxxxxxx Identified xx Xxxxxxxx Xxxxx, xx Xxxxxxxx xx Xxxxxxx Xxxxxxxxxx, D. Xxxxx, X. Xxxxxxx, F. Xxxxxx (xxx.) Xxxxxxxx, Xxxxxxxxx, 249-258.
16) Hughes, X. X., Xxxxxxx, X. M., Xxxxxxxx, X. X., Claxton, X. X. (1987), Xxxxxxxxxxxx Xxxxxxxxx to Xxxxxxx Mutagenic Activity xx Volatile Xxxxxxx Xxxxxxxxx xx the Xxxx/Xxxxxxxxxx Assay, Xxxxxxxxxxxxx Xxxxxxxxxxx, 9, 421-441.
17) Xxxxxxxxxx, T., Xxxxxxxxx, X., Xxxxxx, X., Xxxxxxxx, M., Xxxxxxxx, X. (1979), Mutagenicity xx xxx Xxxxxxxxx Xxxxxxxxx Xxxxxxxxxx Cycasin xxx Synthetic Xxxxxxxxxxx Xxxxxxx Xxxxxxxxxx in Xxxxxxxxxx typhimurium, Xxxxxx Xxx., 39, 3780-3782.
18) Xxxxxx, X., Gold, X., Xxxxx-Xxxxx, X., Xxxx, X. X. (1980), Fecalase: X Xxxxx xxx Activation xx Dietary Xxxxxxxxxx xx Mutagens xx Xxxxxxxxxx Xxxxx, Proc. Xxxx. Xxxx. Xxx. X. S. A, 77, 4961-4965.
19) Xxxxxx, X., Xxxxxx, X., Xxxx, D. J., Xxxxxxxxx, X. X. (1990), Comparison xx Xxxxxxxxxx xxxxxxxxxxx XX 102 with Xxxxxxxxxxx xxxx XX2 Xxxxxx xxxxxxx, Mutagenesis, 5, 285-291.
20) Xxxxxxxxxx, X., Xxxxxxxx, X., Xxxx, X., Sugimura, T. (1976), A Xxxx Xxxxxxxxxx xxx Xxxxxxxxxxxxxxx Xxxxxxxxx a. s. xx Xxxxxxx xx Xxxxxxxxx Activation Xxxxxxx, xx: Xx xxxxx Xxxxxxxxx Xxxxxxxxxx xx Xxxxxxxxxxx Testing, eds. X. X. xx Xxxxxx xx al. Xxxxxxxx, Xxxxx Holland, 85-88.
21) Elliot, B. X., Xxxxxx, X. X., Elcombe, C. X., Gatehouse, D. X., Gibson, G. X., Xxxxxx, X. X., Wolf, X. X. (1992), Xxxxxxxxxxxx xx Xxxxxxx 1254-induced X9 in xx xxxxx Genotoxicity Xxxxxx, Xxxxxxxxxxx, 7, 175-177.
22) Xxxxx, X., Katzenellenbogen, X., Ames, X. X. (1981), Xxxxxxxxxxxxx xx Xxxxxxx Xxxxxxxx xxxx xxx Xxxxxxxxxx/Xxxxxxxxx Xxxx, Xxxxxxxxxx Res., 88, 343-350.
23) Xxxxxxx, X. X., Xxxxx, X., Auletta, A., Xxxxxxxxxx, K., Nestmann, X., Zeiger, X. (1987), Xxxxx xxx xxx Xxxxxxxxxx typhimurium/Mammalian Xxxxxxxxx Xxxxx xxx Xxxxxxxxx Mutagenicity, Xxxxxxxxxx Xxx., 189, 83-91.
24) Xxxxx, G. A. X., Xxxxx, X. X. X., Xxxxxxxxx, X., Xxxxxxx, X., Xxxxxxxx, X. D., Xxxxxx, D. X. (1989), Xxxxxxxx xx Xxxx xxxx Xxxxxxxxx Xxxxxx Xxxxxx, in: XXXXX Sub-Committee on Xxxxxxxxxx for Xxxxxxxxxxxx Xxxxxxx, Xxxx II. Xxxxxxxxxxx Evaluation xx Xxxxxxxxxxxx Xxxx Xxxx, xx. Xxxxxxxx, X. X., Cambridge Xxxxxxxxxx Xxxxx, 28-65."
PŘÍLOHA 4X
"X.17 MUTAGENITA — XXXXXXX XX XXXXXX MUTACE X XXXXXXX SAVCŮ XX XXXXX
1. XXXXXX
Xxxx metoda xx xxxxxxxx metody XXXX XX 476 — Zkouška xx xxxxxx xxxxxx v xxxxxxx xxxxx xx xxxxx (1997).
1.1 XXXX
Xxxxxxx xx xxxxxx xxxxxx x buňkách xxxxx xx xxxxx xxx xxxxxx xxx xxxxxxx xxxxxxxx xxxxxx indukovaných xxxxxxxxxx xxxxxxx. Xxxx xxxxxx buněčné linie xxxxx buňky xxxxxxx X5178X xxxx, xxxxxxx xxxxx XXX, XXX-XX52 x X79 xxxxxx xxxxxxxx x xxxxxxxxxxxxxxx xxxxx XX6 xxxxxxx (1). X xxxxxx xxxxxxxxx linií xxxx xxxxxxxxxxxxxxx mírou xxxxxxxxxxx xxxxxx mutace xxxx xxx xxxxxxxxxxxxxx (XX) x hypoxanthin-guaninfosforibosyltransferasu (HPRT) x transgen xxxxxxx-xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (XXXX). Zkoušky na xxxxxx XX, XXXX x XXXX xxxxxxxx xxxxx xxxxxxxx genetických xxxxxxxx. Xxxxxxxxxxx lokace XX x XPRT xxxx xxxxxxx detekci xxxxxxxxxxx událostí (xxxx. xxxxxxxx xxxxxx), xxxxx xxxxx xxxxxxxxx v XXXX xxxxxx na X xxxxxxxxxxxx (2, 3, 4, 5, 6).
Xx xxxxxxx xx xxxxxx xxxxxx x xxxxxxx xxxxx xx xxxxx xxx použít xxxxxxx xxxxxxxxxx linií xxxxx xxxx buněčné xxxxx. Xxxxx xx xxxxxxxx xxxxx xxxxxxxxxx xxxxx x xxxxxxx x xxxxxxxx četnosti xxxxxxxxxxx xxxxxx.
Xxxxxxx xxxxxxxxx xx xxxxx xxxxxx xxxxxxxx xxxxxxx vnějšího xxxxxx xxxxxxxxxxx xxxxxxxx. Xxxxx metabolický aktivační xxxxxx xxxxxx xxxxx xxxxxxxxx xxxxxxxx xx xxxx x savců. Xx třeba se xxxxx xxxxxxxxx podmínek, xxxxx xx xxxxx x xxxxxxxxxx xxxxxxxxx, xxx xxxxxxxxxx xxxxxxx xxxxxxxxxx. X pozitivním xxxxxxxxx, jež xxxxxxxxxx xxxxxxx xxxxxxxxxx, může xxxxx změnou xX, xxxxxxxxxx xxxx xxxxxxxx xxxxxx xxxxxxxxxxxx (7).
Tato xxxxxxx xx xxxxxxx xx zjištění xxxxxxx xxxxxxxx x xxxxxxxxxxx xxxxx. Xxxxx xxxxxxxxx, xxx xxx xx xxxx xxxxxxx xxxxxxxxx, xxxx xxxxxxxxxxx savců; xxxx xxxxx xxxxxxxx x xxxxxxxxxxxxxx však xxxx xxxxxxxxx korelace. Xxxxxxxx xxxxxx xx xxxxxxxx xxxxx x xxxxxxxxx důkazy x xxx, xx existují xxxxxxxxxxx, xxxxx xxxxxx xxxxxxxx xxxxx xxxxxxxx, xxxxx xxxxxx xxxxxx xxxxxx, xxxxxxxxxxxxxxx mechanismy, xxxx mechanismy, xxxxx x xxxxxxxxxxxxx buňkách xxxxxxxxxx (6).
Xxx xxxx xxxxxx úvod, xxxx X.
1.2 DEFINICE
Přímá mutace : genová xxxxxx xxxxxxxxx xxxx xxxxxxxx xxxxx, xxxxx xxxxxxxxx xxxxx xxxx ztrátu xxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx.
Xxxxxxxx substituce párů xxxx : xxxxx, xxxxx způsobují substituci xxxxxxx xxxx xxxx xxxx xxxx x XXX.
Xxxxxxxx mutageny : xxxxx, xxxxx xxxxxxxxx xxxxx xxxx deleci xxxxxxx xxxx xxxx xxxx xxxx x xxxxxxxx XXX.
Xxxx xxxxxxx xxxxxxxx : doba, xxxxx xxx xxxxxx x xxxx xxxxxxxxxx xxxxx xxxxxxxxx xxxxxx xxxxxxxx.
Xxxxxxx xxxxxxx : xxxxx xxxxxxxxxxxx xxxxxxxxxx xxxxx xxxxxx počtem xxxxxxxxxxxxxxx buněk.
Relativní celkový xxxx : xxxxxx xxxxx buněk x xxxx xx xxxxxxxx x kontrolní xxxxxxxx xxxxx; xxxxxxx se xxxx součin xxxxxx xxxxxxxxx růstu x xxxxxxxx a v xxxxxxxxx kontrole x xxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxxx x xxxxxxxxx xxxxxxxx.
Xxxxxxxxx růst x xxxxxxxx : nárůst xxxxx xxxxx v xxxxxxx xxxxxxx vzhledem x xxxxxxxxx xxxxxxxx.
Xxxxxxxxxxxxxxx : účinnost xxxxxxxxx xxxxx x xxxxxxxx xxxxxxxx xx misku xx selektivních xxxxxxxx xx xxxxxxx.
Xxxxxxx : xxxxxxxx xxxxxxxxx xxxxx xxx nasazení xx xxxxx na xxxxx xxxxxx xxxxxxxx; xxxxxxx xx xxxxxxx vyjádřeno x poměru k xxxxxxx kontrolní populace xxxxx.
1.3 PODSTATA XXXXXXXX XXXXXX
Xxxxx, xxxxx x xxxxxxxx xxxxxx XX+/-® XX— /- xxxxxxxxxx xxxxxxxxxxxxxx (XX) xxxx xxxxxxxxxxx x cytotoxickým xxxxxxx analogu xxxxxxxxxx xxxxxxxxxxxxxxxxx (TFT). Xxxxx xxxxxxxxxxx xxxxxxxxxxxxxx xxxx xxxxxxx xx XXX, xxx způsobuje xxxxxxxx xxxxxxxxx metabolismu x xxxxxxxxx další xxxxxxx xxxxxx. Mutantní xxxxx xxxx xxxx schopny xxxxxxxxxxx xx xxxxxxxxxxx XXX, xxxxxxx normální xxxxx, xxxxx obsahují xxxxxxxxxxxxxx xxxx xxxxxxxxx xxxxxx. Podobně xxx x xxxxx s xxxxxxxxxxxx HPRT nebo XXXX xxxxxxx selekci xxxxxxxxxxxxxxx rezistence k 6-xxxxxxxxxxx (XX) xxxx 8-xxxxxxxxxx (XX). Xxxxxxxxxx xxxxxxxx látky xx xxxx xxx xxxxxxx xxxxxxx, jestliže xx xx xxxxxxx xx xxxxxx xxxxxx x xxxxxxx savců xxxxxxx xxxxxx xxxx nebo xxxxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxx. Xxxx by xxx například xxxxxxxxx xxxxxxxx xxxxxxxxx na xxxxxxxxxx xxxxxxxx zkoušené xxxxx pro mutantní xxxx xxxxxxxxxx buňky. Xxx xxxxxxxx xxxxxxxxxx xxxxx, xxxxx xxxx xxxxxxxx xxxxxxxxx jako xxxxxxxx xxxxxxx, xxxx xxxx být potvrzena xxxxxxxx systému xxxx xxxxxxx xxx xxxxxxx (8).
Xxxxx v xxxxxxxxx xxxx jednovrstevné kultuře xxxx xxxxxxx xxxx xxxxxxxxx xxxxxxxx látce xxx x metabolickou xxxxxxxx, tak xxx xx, a xxxxxxxxxxxxxx xx xxxxxx xxxxxxxxx xxxxxxxxxxxx a za xxxxxx xxxxxxx fenotypu xxxx selekcí xxxxxxx (9, 10, 11, 12, 13). Cytotoxicita xx xxxxxxx xxxxxx xxxxxxxxxx relativní xxxxxxxxx xxxxxxxxx (xxxxxxx) xxxx xxxxxxxxxx xxxxxxxxxxx xxxxxxxxx xxxxx xxxxxx po xxxxxxxx doby xxxxxxxx. Xxxxxxxxxx xxxxxxx xx xxxxxxx x xxxxxxxx xxxxx xx xxxxxxx xxxx xxxxxxxxxxxxxxxxx xxx xxxxx xxxxxxx xxxxx x typ xxxxx, xxx xxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxxx exprese xxxxxxxxxxxx xxxxxx. Xxxxxxx xxxxxxx xx xxxxxxx xxx, že xx xxxxxx xxxxx počet xxxxx xx média xxxxxxxxxxxx selekční činidlo xxx detekci xxxxxxxxxx xxxxx x do xxxxx bez selekčního xxxxxxx, xxx xxxx xxxxxxxxx xxxxxxxx klonování (xxxxxxxxxxxxxxx). Po xxxxxx xxxxxxxxx xxxx se xxxxxxxxx xxxxxxx. Četnost xxxxxxx se xxxxxxx x počtu mutantních xxxxxxx x selekčním xxxxx x počtu xxxxxxx x médiu xxx selekčního činidla.
1.4 XXXXX ZKUŠEBNÍ XXXXXX
1.4.1 Xxxxxxxxx
1.4.1.1 Xxxxx
Xxx použití x xxxx zkoušce xxxx x xxxxxxxxx xxxxx xxxx xxxxx, xxxxxx subklonů buněk X5171X, XXX, CHO-AS52, X79 xxxx TK6. Xxxx xxxxx x xxxx xxxxxxx xx xxxx xxxxxxxxx xxxxxxxxx x xxxxxxxxx xxxxxxxxx, xxxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxxx frekvenci xxxxxxxxxxx xxxxxx. Xxxxx xx xxxx být xxxxxxxxxxxx, xxx xxxxxx xxxxxxxxxxxxx mykoplasmaty, x x xxxxxxx kontaminace xx xxxxxx být xxxxxxx.
Xxxxxxx xx xxxx xxx xxxxxxxx tak, xxx xxxx xxxxxx xxxxxxxxxx xxxxxxxxx a xxxx. Xxxxx xxxxxxxxx xxxxx, xxxxxx x xxxxxxxxxxx zkoušené látky xx měl xxxx xxxxxxxxxx xxxxxxxxx xxxxxxx (14). Minimální xxxxx xxxxx, xxxxx přežijí xxxxxxxx x xxxxx xxxxx xxxxxxx x xxxxxx xxxxxx xxxxxxx, xx měl xxx xxxxxxx xx xxxxxxxx xxxxxxxxxxx xxxxxx. Obecným xxxxxxxxx xx, aby xxx xxxxxx počet xxxxx, xxxxx je xxxxxxxxxxxxxx xxxxxxxxxx hodnoty xxxxxxxx xxxxxxxxxxx xxxxxx. Xx xxxx xxxxxxxxxx, xxx xxxx použito xxxxxxx 106 buněk. Xxxx by xxx x xxxxxxxxx dostatečné xxxxxxxxx údaje x xxxxxxxx xxxxxxxx xxxxxxx, xxx xxxx xxxxxxxx xxxxxxxxxxxx xxxxxxxxx hodnota xxxxxxx.
1.4.1.2 Xxxxx x xxxxxxxxxx xxxxxxxx
Xxx udržování xxxxxx by xxxx xxx xxxxxxx xxxxxx xxxxxxxxxx média x xxxxxxxxx xxxxxxxx (xxxxxxxxxx xxxxxx, xxxxxxxxxxx XX2, xxxxxxx x vlhkost). Xxxxx xx měla xxx xxxxxxx xxxxx xxxxxxxxxx xxxxxxx x xxxx xxxxx xxxxxxxxx xxx xxxxxxx. Xx xxxxxxx xxxxxxxx, aby xxxxxxxxxx podmínky xxxx xxxxxxx xxx, xxx xxxx xxxxxxxxx optimální xxxx xxxxx xxxxx xxxxxx xxxxxxx a xxxxxxxxx xxx mutovaných, xxx xxxxxxxxxxxx xxxxx xxxxxx xxxxxxx.
1.4.1.3 Příprava xxxxxx
Xxxxx xx xxxx xxx získávány x xxxxxxxxx kultur, nasazeny xx kultivačního média x xxxxxxxxxx při 37 °X. Xxxx xxxxxxxx x xxxx xxxxxxx může být xxxxxxxx xxxxxxxxx x xxxxxxx xxx přítomné xxxxxxxx xxxxx.
1.4.1.4 Xxxxxxxxxxx xxxxxxxx
Xxxxx by xxxx xxx xxxxxxxxx xxxxxxxx xxxxx, a to x xxxxxxx xxxxxxxx xxxxxxxxxxx aktivace a xxx xxxx. Nejčastěji xxxxxxxxxx xxxxxxxx je xxxxxxxxxx dotovaná xxxxxxxxxxxxxxxxxxx xxxxxx (X9) připravená x xxxxx hlodavců xxxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxx, xxxx xx Xxxxxxx 1254 (15, 16, 17 a 18), xxxx xxxx xxxxxxxxxxxxx x β-xxxxxxxxxxxx (19, 20).
Xxxxxxxxxxxxxxxxxxx xxxxxx xx x xxxxxxxx xxxxxxxxxx xxxxx xxxxxxx xxxxxxxxx x koncentracích 1 — 10 % obj. Xxxxx x stav metabolického xxxxxxxxxxx systému xxxx xxxxxxx na xxxxx xxxxxxxx látky, xxxxx xx zkoušena. X xxxxxxxxx xxxxxxxxx xxxx xxx vhodné xxxxxx xxxx xxx xxxxx xxxxxxxxxxx xxxxxxxxxxxxxxxxxxx xxxxxx.
Xxxx xxxxxxxx xxxxxx, včetně xxxxxxxx xxxxxxxxx modifikovaných xxxxxxxxx xxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxx, xxxxxxxxx xxxxxxxx xxx xxxxxxxxx xxxxxxxx. Xxxxx xxxxxxxxx xxxxxxxxx xxxxx xx xxxx xxx xxxxxxx xxxxxxxxxx (např. xxxxxxxxxxx isoenzymu xxxxxxxxxx X450 xxx xxxxxxxxxxxx xxxxxxxx xxxxx).
1.4.1.5 Xxxxxxxx xxxxxxxx xxxxx
Xxxxx zkoušené xxxxx by xxxx xxx před xxxxxxxx xx xxxxx xxxxxxxxxx xxxx xxxxxxxxxxxx xx xxxxxxxx rozpouštědlech nebo xxxxxxxxxx x xxxxxxxxx xxxxxxx. Xxxxxxx xxxxxxxx xxxxx xxxxx být xxxxxxx xxxxx k xxxxxxxxxx xxxxxxxx x/xxxx xxxxx být xxxx xxxxxxxx zředěny. Xxxx xx xxx xxxxxxx xxxxxxx připravené zkoušené xxxxxxxx xxxxx, xxxxx xxxxx o xxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxxxxx.
1.4.2 Xxxxxxxx xxxxxxxx
1.4.2.1 Xxxxxxxxxxxx/xxxxxxxxx
Xxxxxxxxxxxx/xxxxxxxxx xx xxxx být xxxx xxxxxxxxx, xx xxxxxxx se xxxxxxxxx xxxxxx, a mělo xx xxx xxxxxxxxxx x přežitím xxxxx x s xxxxxxxxx X9. Xxxx-xx xxxxxxx xxxx xxx xxxxx xxxxxxxxxxxx/xxxxxxxx, mělo xx xxx jejich xxxxxxxx xxxxxxxxx údaji x xxxxxx xxxxxxxxxxxxx. Xxxxxxxxxx xx pokud xxxxx xxxxxxxx xxxxxx použití xxxxxxx rozpouštědel/vehikul. Při xxxxxxxx xxxxx xxxxxxxxx xx vodě xx xxxx xxx xxxxxxx xxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxxx xxxx. Xxxx xxx xxxxxxxxx přidáním molekulového xxxx.
1.4.2.2 Expoziční koncentrace
Mezi xxxxxxxx, která mají xxx xxxxxxxxxx při xxxxxxxxx xxxxxxxx koncentrace, xxxxx xxxxxxxxxxxx, xxxxxxxxxxx x xxxxxxxxxx systému x změny xX xxxx osmolality.
Cytotoxicita xx xxxx být xxxxxxxxx x xxxxxxxxxxxx xxxxxxxx x xxx xx x xxxxxxx xxxxxxxxxxx xx xxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxx x růstu, xxxx xxxx relativní xxxxxxxx xxxxxxxxx (xxxxxxx) xxxx xxxxxxxxx celkový růst. Xxxx xxx xxxxxxx xxxxxxxx xxxxxxxxxxxx a xxxxxxxxxxx x předběžném xxxxxxxxxxx.
Xxxx xx xxx xxxxxxx xxxxxxx xxxxx xxxxxxxxxxxxxx koncentrace. X xxxxxxx toxicity xx xxxx xxxx koncentrace xxxxxxxx rozmezí dané xxxxxxxxx x minimální xxxxxxxxx, xxxxxxxx xxxxxx xxxxxxxxx, xxx xxxx xxxxxxx xxxxxxxx, že xx xx xxxxxxxxxxx xxxx lišit xxxxxxxx 2 až Ö10. Xx-xx maximální xxxxxxxxxxx xxxxxxxx xx xxxxxxxxxxxx, xxxx by xxx xxxxxxxxx xxxxxxxxx 10 — 20 % (xxx xxxxxxx 10 %) přežití (xxxxxxxxx xxxxxxxx xxxxxxxxx) xxxx xxxxxxxxx xxxxxxx xxxx. X případě xxxxxxxxx xxxxxxxxxxxxxxx xxxxx by xxxx xxx xxxxxxxxx xxxxxxxx koncentrace 5 μx/xx, 5 xx/xx xxxx 0,01 X, xxxxx xxxx, xxxxx x xxxx xx xxxxxxxx.
Xxxxxxxxx xxxxxxxxxxx látky xx xxxx xxx xxxxxxxx až x xxxx xxxxxxxxxxxx xx xxxxxxxxxxxx xxxxxxxx, nebo xx xx xxxx xxx. Měla by xxx xxxxxxxxx xxxxxxxx xxxxxxxxxxxxx x konečném xxxxx, xx xxxxxxx xxxx xxxxx xxxxxxxxxx. Xxxx být výhodné xxxxxxxx rozpustnost xx xxxxxxx a xx xxxxx xxxxxxxx, xxxxx xxxxxxxxxxx xx může x xxxxxxx xxxxxxxx x testovacím xxxxxxx xxxxx v xxxxxxxx xxxxxxxxxxx xxxxx, X9 xxxx, xxx. Xxxxxxxxxxxxx xxx zjistit xxxxxxxx. Xxxxxxxxx by neměla xxxxx při vyšetřování.
1.4.2.3 Xxxxxxxx
Xxxxxxxx xxxxxxx experimentu xx xxxx xxx xxxxxxxxx x xxxxxxxxx (xxxxxxxxxxxx nebo xxxxxxxxx) xxxxxxxx jak x xxxxxxxxxxxx xxxxxxxx, tak xxx xx. Při xxxxxxx xxxxxxxxxxx xxxxxxxx xx xxxx xxx xxxxxxxxx xxxxxxxxx xxxxxxxx xxxxx, která x xxxxxxxxx odpovědi vyžaduje xxxxxxxx.
Xxxxxxxxx xxxxxxxxx xxxxxxxx xxxxx xxx xxxx xxxxx:
|
Xxxx metabolické aktivace |
Lokus |
Látka |
Číslo XXX |
Xxxxx xxxxx Xxxxxx |
|
Xxx xxxxxx xxxxxxxxxxx xxxxxxxx |
XXXX |
xxxxx-xxxxxxxxxxxxxx |
62–50–0 |
200–536–7 |
|
1-xxxxx-1-xxxxxxxxxxxxxxx |
759–73–9 |
212–072–2 |
||
|
XX (xxxx a velké xxxxxxx) |
xxxxxx-xxxxxxxxxxxxxx |
66–27–3 |
200–625–0 |
|
|
XXXX |
xxxxx-xxxxxxxxxxxxxx |
62–50–0 |
200–536–7 |
|
|
1-xxxxx-1-xxxxxxxxxxxxxxx |
759–73–9 |
212–072–2 |
||
|
X xxxxxx xxxxxxxxxxxx xxxxxxxx |
XXXX |
3-xxxxxxxxxxxxxxxxx |
56–49–5 |
200–276–4 |
|
X-xxxxxxxxxxxxxxxxxxx |
62–75–9 |
200–549–8 |
||
|
7,12-xxxxxxxxxxxxxxxxxxxxxx |
57–97–6 |
200–359–5 |
||
|
XX (xxxx a xxxxx xxxxxxx) |
xxxxxxxxxxxxx |
50–18–0 |
200–015–4 |
|
|
xxxxxxxxxxxxx xxxxxxxxxx |
6055–19–2 |
|||
|
xxxxx[x]xxxxx |
50–32–8 |
200–028–5 |
||
|
3-xxxxxxxxxxxxxxxxx |
56–49–5 |
200–276–5 |
||
|
XXXX |
X-xxxxxxxxxxxxxxxxxxx (xxx vysoké xxxxxx X9) |
62–75–9 |
200–549–8 |
|
|
xxxxx[x]xxxxx |
50–32–8 |
200–028–5 |
Xxxxx být xxxxxxx xxxx xxxx referenční xxxxx xxx pozitivní xxxxxxxx, např. xx-xx xxxxxxxxx xxxxxxxx dosavadních xxxxx x 5-xxxx-2′-xxxxxxxxxxxx (XXX 59–14–3, XXXXXX 200–415–9), xxxx xxx xxxx referenční látka xxxxxx použita. Xxx xxxxxxxxx xxxxxxxx xx xxxx xxx xxxxx x xxxxx xxxxxxx xxxxxxxxxx xxxxx xxxxx xxxxx xx xxxxxx xxxxxxxx xxxxx.
Xxxx by xxx xxxxxxx negativní xxxxxxxx xxxxxxx xxxxxx xxxxxxxxxxx xxxxxxx rozpouštědlo xxxx xxxxxxxxx x xxxxxxxxxx xxxxx xxxxxxx xxxxxxxx xxxx xxxxxxxxxx xxxxxxx. Xxxxx xxxx xx xxxx být xxxxxxxxxxxx xxxxxxxx xxxxxxx xxxx xxxxx, xxxxxxxxxx-xx xxxxx kontrolní údaje xxxxxxxxxxx, xx xxxxxxx xxxxxxxxxxxx xxxxxxxxxx xxxxx xxxxxxx xxxx mutagenní xxxxxx.
1.4.3 Xxxxxx
1.4.3.1 Xxxxxxxx xxxxxxxx xxxxx
Xxxxxxxxxxxxx xxxxx xx xxxx xxx xxxxxxxxx xxxxxxxx xxxxx xxx xx xxxxxxxxxxx xxxxxxxxxxxxx aktivačního xxxxxxx, xxx bez xxxx. Xxxxxxxx by měla xxxxx xxxxxxx xxxx (xxxxxxx xx xxxxxx xxxx 3 xx 6 hodin). Expoziční xxxx xxxx xxx xxxxxxxxxxx xx xxxxx xxxx xxxx xxxxxxxxx xxxxx.
Xxx každou xxxxxxxx xxxxxxxxxxx mohou xxx xxxxxxx xxxxxxxxxx xxxxxxx xxxx jedna xxxxxxxxxx xxxxxxx. Je-li xxxxxxx xxxxx kultura, xxx xx být xxxxx xxxxxxxxxxx xxxxxx xxx, xxx xxx xxxxxxxx xxxxxxxxxxxx xxxxx kultur xxx analýzu (např. xxxxxxx xxx analyzovatelných xxxxxxxxxxx). Xxxx xx xxx xxxxxxx duplicitní xxxxxxxxx xxxxxxxxx kultury (xxxxxxxx xxxxxxxxxxxx).
Xxxxxx xxxx xxxxxx xxxxx xx xxxx být xxxxxxxx xxxxxxxx metodami, např. x těsně xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx (21, 22).
1.4.3.2 Xxxxxxxxx xxxxxxx, xxxxxxxxxxxxxxxx a xxxxxxxx xxxxxx
Xx xxxxx xxxxxxxxx xxxx se xxxxx xxxxxxx a xxxxxxxxx xx xxxxxx xxxxxxxxx xxxxxxx x xx xxxxxx umožnění exprese xxxxxxxx mutantu. Se xxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxx xxxxxxxxx účinnosti xxxxxxxxx (xxxxxxx) xxxx xxxxxxxxxxx celkového růstu xxxxxx xx xxxxxxx xxxxxxx xx xxxxxxxxx xxxx.
Xxxxx xxxxx má xxxxxxxxxx xxxxxxxxx xxxxxx xxxxxx, xxx umožnil xxxxxxxxx xxxxxxxxx xxxxxxxxxxx xxxxxxx nově xxxxxxxxxxxx xxxxxxx (XXXX a XXXX xxxxxxxx xxxxxxx 6 až 8 xxx, TK xxxxxxx xxx xxx). Buňky xxxx xxxxxxxxxxx v xxxxx se xxxxxxxxx xxxxxxxx (xxxxxxxxxx činidly) x bez něho (xxx xxxx) za xxxxxx stanovení xxxxx xxxxxxx x klonovací xxxxxxxxx. Xx stanovením xxxxxxxxxxxxxxxx (použité pro xxxxxxx xxxxxxxx mutantů) xx xxxxxxx xx xxxxx xxxx exprese xxxxxxxxx na xxxxx xxx xxxxxxxxxx xxxxxxx.
Xx-xx xxxxxxxx látka xxxxxxxxx xx xxxxxxx X5178X XX+/-, mělo xx xxx xxxxxxxxx xxxxxxx xx jedné xx xxxxxxxxxx xxxxxx (x xxxxxxxx pozitivní xxxxxxxxxxx) x na xxxxxxxxxxx x pozitivních xxxxxxxxxx xxxxxxxxx kultury podle xxxxxxxxx kolonií. Je-li xxxxxxxx xxxxx xx xxxxxxx X5178X XX+/- xxxxxxxxx, xxxx by xxx xxxxxxxxx kultury xxxxx velikosti kolonií xxxxxxxxx na negativních x pozitivních xxxxxxxxxx. Xxx xxxxxxxx xx xxxxxxx TK6 XX+/- xxxx xxx xxxx xxxxxxxxx xxxxxxxxx kultury xxxxx xxxxxxxxx xxxxxxx.
2. XXXXX
2.1 ZPRACOVÁNÍ XXXXXXXX
Xxxxx xx měly zahrnovat xxxxxxxxx xxxxxxxxxxxx a xxxxxxxxxxxxxxxx, xxxxx xxxxxxx x xxxxxxxx xxxxxxx xxx xxxxxxxxxx a xxxxxxxxx xxxxxxx. V xxxxxxx xxxxxxxxx xxxxxxxx xx xxxxxxx X5178X XX+/- xx kolonie xxxxxxxxx xxxxxxx u xxxxx xxxxxxxxxxx zkoušené xxxxx (xxxxxxxx xxxxxxxxx xxxxxxxxxxx) x x xxxxxxxxx x xxxxxxxxx xxxxxxxx za xxxxxxx xxxxxxxx xxxx kolonie — velká xxxxxxx. Xxxxxxxxxxx a xxxxxxxxxxxxx xxxxxx jak xxxxxxx xxxxxxxxx velké xxxxxxx, xxx xxxxxxx xxxxxxxxx xxxx xxxxxxx byla xxxxxxxx xxxxxxxx (23, 24). Xx zkoušce XX+/- xxxx xxxxxxx xxxxxxxxxxx xx použití xxxxxxxx xxxxxxx x xxxxxxxxx xxxxxx (xxxxx) x kolonie s xxxxxxx xxxxxx (malá) (25). U xxxxxxxxxx xxxxx, které xxxxxxx xxxxxxxxxxxxxx genetické xxxxxxxxx, xx xxxxxxxxxxx xxxx xxxxxxxx, a tvoří xxxx malé xxxxxxx. Xxxxxxxxx xx obvykle xxxxxx xx xxxxx xxxxxx genu až xx xxxxxxxxxxxx xxxxxxxxx xxxxxxxxxxxx aberace. Indukce xxxxxxx tvořících xxxx xxxxxxx se xxxxxxx x chemickými látkami, xxxxx indukují silné xxxxxxxxxxxx xxxxxxx (26). Xxxx xxxxxxx xxxxxxxxx xxxxx xxxxxxx rostou xxxxxxxx tempem xxxx xxxxxxxx buňky x xxxxx xxxxx kolonie.
Mělo xx xxx udáno xxxxxxx (xxxxxxxxx xxxxxxxx xxxxxxxxx) nebo xxxxxxxxx xxxxxxx růst. Xxxxxxx xxxxxxx xx xxxx xxx vyjádřena xxxx xxxxx xxxxxxx x xxxxx xxxxxxxxxx xxxxx.
Xxxx xx být xxxxxxx xxxxx xxx xxxxxxxxxx xxxxxxx. Xxxx by xxxx xxx všechny xxxxx shrnuty xx xxxxx xxxxxxx.
Xxxxxxx xxxxx xxxxxxxxx xxxxxxxx se xxxxxxxxxx. Dvojznačné xxxxxxxx xx měly být xxxxxxxxx xxxxxx xxxxxxxxx, xxxxxxx s xxxxxxx xxxxxxxxxxxxxxxx xxxxxxxx. Xxxxxxxxx xxxxxxxx xxxx xxx xxxxxxxxx xxxxxx xx xxxxxxx. Xxx, xxx xxxx xxxxxxxxx xxxxxxxxxxx xxxxxxxx považováno xx xxxxx, xx xxxxx xxxxx xxxxxxxxxx. Xxxxx xxxxxxxxx xxxxxx s xxxxx rozšířit rozsah xxxxxxxxxxxx podmínek by xxxx xxx xxxxxxx x xxxxxxxxxx experimentech xxx xxx dvojznačné xxxxxxxx, tak xxx xxxxxxxxx xxxxxxxx. X xxxxxxxxxx xxxxxx, xxxxx xx mohly být xxxxxxx, xxxxx xxxxxxx xxxxxxxxxxx x podmínky xxxxxxxxxxx xxxxxxxx.
2.2 HODNOCENÍ X INTERPRETACE VÝSLEDKŮ
Pro xxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxx xxxxxxxx, xxxx. xxxxxx xxxxxxxx xxxxxxx x xxxxxxxxxx xx xxxxxxxxxxx, xxxx xxxxxxxxxxxxxxxx xxxxxx této xxxxxxxx. Xxxxxxxx by xxxx xxx xxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxxx. Xxx xxxxxxxxx výsledků xxxxxxx xxxxx xxx xxxxxxx xxxx xxxxxxx xxxxxxxxxx statistické xxxxxx. Xxxxxxxxxxx významnost xx xxxxxx xxx jediným xxxxxxxxx faktorem pro xxxxxxxxx xxxxxxx.
Xxxxxxxx xxxxx, xxxxx xxxxxxxx nesplňují xxxx xxxxxxx xxxxxxxx, xx x tomto xxxxxxx xxxxxxxx xx xxxxxxxxxxx.
Xxxxxx většina experimentů xxxxxxxx jasně pozitivní xxxx negativní výsledky, x xxxxxxxxxxx případech xxxxxxxx xxxxxx údajů xxxxxxxx xxxxxxx xxxxx x xxxxxxxx xxxxxxxx xxxxx. Xxxxxxxx mohou xxxxxx xxxxxxxxxx nebo xxxxxx bez xxxxxx xx xx, xxxxxxxx xx experiment xxxxxxxx.
Xxxxxxxxx xxxxxxxx xxxxxxx na xxxxxx mutace x xxxxxxx savců xx xxxxx znamenají, xx xxxxxxxx xxxxx xxxxxxxx x použitých xxxxxxxxxxxxx xxxxxxx xxxxx xxxxxx xxxxxx. Xxxxxxxxxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxxx xx xxxxxxxxxxx xx xxxxx xxxxxxxx. Xxxxxxxxx výsledky xxxxxxxxx, že zkoušená xxxxx xx podmínek xxxxxxx xxxxxxxxxx v xxxxxxxxx xxxxxxxxxxxxx xxxxxxx xxxxx genové mutace.
3. XXXXXX
XXXXXXXX X XXXXXXX
Xxxxxxxx x xxxxxxx musí xxxxxxxxx xxxx xxxxxxxxx:
Xxxxxxxxxxxx/xxxxxxxxx:
- xxxxxxxxxx xxxxx rozpouštědla/vehikula,
- xxxxxxxxxxx x xxxxxxx xxxxxxxx xxxxx x xxxxxxxxxxxx/xxxxxxxx, xx-xx známa.
Buňky:
- xxx x xxxxx xxxxx,
- xxxxx buněčných xxxxxx,
- xxxxxxxx počet xxxxxx,
- xxxxxxxx metody xxxxxxxxx xxxxxxx xxxxxxx,
- xxxxxxxxxxxx xxxxxxxxxxx.
Xxxxxxxx podmínky:
- xxxxxxxxxx výběru xxxxxxxxxxx x xxxxx xxxxxx, xxxxxx xxxx. údajů x cytotoxicitě x xxxxxx xxxxxxxxxxxx, xxxx-xx x xxxxxxxxx,
- složení xxxxx, xxxxxxxx xxxxxxxxxxx XX2,
- xxxxxxxxxxx xxxxxxxx xxxxx,
- xxxxx vehikula x přidané xxxxxxxx xxxxx,
- xxxxxxxxx xxxxxxx,
- xxxxxxxxx xxxx,
- délka xxxxxxxx,
- xxxxxxxx xxxxxxx xxxxx xxxxx expozice,
- xxx x složení xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxx xxxxxxx, xxxxxx xxxxxxxx xxxxxxxxxxxxx,
- xxxxxxxxx x xxxxxxxxx xxxxxxxx,
- xxxxx xxxx xxxxxxx (xxxxxxxx xxxxxx xxxxx xxxxxxxxxx xxxxx, xxxxxxxxx x xxxxxx xxxxx),
- xxxxxxxx xxxxxxx,
- xxxxxxxx klasifikace xxxxxxx na xxxxxxxxx, xxxxxxxxx xxxx dvojznačnou,
- xxxxxx použité x xxxxxxxx životaschopných x xxxxxxxxxx xxxxx,
- definice xxxxxxx xxxxx xxxxxxxxx x xxxx (případně xxxxxx kriterií xxx "xxxx" a "xxxxx" xxxxxxx).
Xxxxxxxx:
- známky toxicity,
- xxxxxx xxxxxxx,
- údaje x xX a xxxxxxxxxx xxxxx expozice xxxxxxxx xxxxx, pokud xxxx stanoveny,
- velikost xxxxxxx, xxxx-xx xxxxxxxxxxx, xxxxxxx xxx xxxxxxxxx x pozitivní xxxxxxxx,
- xxxxxxxxx xxxxxxxxxxx laboratoře xxxxxxxxx xxxxxxx xxxxxxx xxxx xxxxxxx xxxxxxxx X5178X XX+/-,
- xxxxx xxxxxxxx xxxxxxxxx xxxxxxxx xx dávce,
- xxxxxxxx xxxxxxxxxxx xxxxxxx,
- xxxxx x xxxxxxxx negativní (xxxxxxxxxxxx/xxxxxxxxx) x xxxxxxxxx xxxxxxxx,
- xxxxxxxxx údaje x xxxxxxxxx (rozpouštědlo/vehikulum) x pozitivní xxxxxxxx x xxxxxxxxx, xxxxxxxxx xxxxxxxxx x xxxxxxxxxxxx xxxxxxxxxx,
- xxxxxxx mutantů.
Rozbor xxxxxxxx.
Xxxxxx.
4. LITERATURA
1) Moore, X. X., XxXxxxxx, X. X., XxXxxxxx, X. X., Xxxxxx, X. X. (eds.) (1987), Banbury Xxxxxx 28; Xxxxxxxxx Xxxx Xxxxxxxxxxx, Xxxx Xxxxxx Xxxxxx Xxxxxxxxxx, Xxx Xxxx.
2) Chu, E. X. X., Xxxxxxx X. X. (1968), Xxxxxxxxx Cell Genetics. XX. Chemical Xxxxxxxxx xx Xxxxxxxx Xxxxx Xxxxxxxxx xx Xxxxxxx Xxxxxxx Xxxxx In xxxxx, Xxxx. Xxxx. Xxxx. Xxx. X. X. X, 61, 1306-1312.
3) Liber, H. X., Xxxxxx, X. X. (1982), Xxxxxxxx Xxxxx at xxx Xxxxxxxxx Kinase Xxxxx xx Xxxxxxx Xxxxx Xxxxxxxxxxxx, Xxxxxxxx Xxx. 94, 467-485.
4) Moore, X. M., Xxxxxxxxx-Xxxxx, X., Doerr, X. X., Xxxxxxxxx, X. X. (1989), Xxxxxxxxxxxx Xxxxxx Quantitation at xxx Xxxxx Lymphoma XX xxx CHO XXXXX Xxxx, Xxxxxxxxxxx, 4, 394-403.
5) Xxxxx, X. X., Stankowski, Xx. X. X., (1989), Xxxxxxxxxx xx xxx XX52/XXXX and xxx CHO/HPRT Assays: Xxxxxxxxxx xx Six Xxxx Xxxxxxxxxx, Mutatation Xxx. 223, 121-128.
6) Xxxxx, X. S., Xxxxxxxxxx, X., Glatt, X. X., Moore, X., Nishi, X., Xxxxxxxxxx, Xx. X. X., Theiss, J., Xxxxxxxx, X. (1994), Xxxxxxxxx Xxxx Xxxx Xxxxxxxx Assays Working Xxxxx Xxxxxx. Xxxxxx xx the International Xxxxxxxx xx Xxxxxxxxxxxxxxx xx Xxxxxxxxxxxx Xxxx Xxxxxxxxxx. Xxxxxxxx Xxx. 312, 235-239.
7) Scott, X., Xxxxxxxx, X. X., Xxxxxxxx, R. X., Xxxxxxxx, M., Xxxxxxx, D., Ashby, X., Xxxx, X. X. (1991), Xxxxxxxxxxxx Xxxxx Xxxxxxx Xxxxxxx Xxxxxxxxxx. X report xxxx ICPEMC Xxxx Xxxxx 9, Mutation Xxx. 257, 147-204.
8) Xxxxx, X., McCuen, X., Spector, X. X. S., Piper, X., Xxxxxxxxx, X. X. (1983), Xxxxxxxx Xxxx Xxxxxxxxx xx X5178X Cells xx Xxxxxxx. X Report xx xxx X. X. Environmental Xxxxxxxxxx Xxxxxx Xxxx-Xxx Program, Xxxxxxxxxx Xxx., 115, 225-251.
9) Li, X. X., Xxxxx, R. X., Xxxxxxx, X. X., Xxxxxx, X. X. (1988), X Xxxxxx xxx Xxxxxxxx xx the Xxxxxxx Xxxxxxx Xxxxx/Xxxxxxxxxxxx Xxxxxxx Xxxxxxxxxxxxxx Xxxxxxxxxxx Xxxxxx xx Determine xxx Xxxxxxxxxxxx xx Xxxxxxxx Xxxxxx: A Xxxxxx xx Xxxxx III xx the X. X. Environmental Xxxxxxxxxxx Xxxxxx Xxxx-Xxx Xxxxxxx, Xxxxxxxxxx Res., 196, 17-36.
10) Xx, X. X., Xxxxxx, J. X., Choy, W. X., Xxxx, X. X., Xxxxx, R. X., Loveday, X. X., X'Νxxxx, X. X., Xxxxxx, X. X., Stankowski, X. X. Jr., Xxxx, X. L. (1987), X Xxxxx xxx xxx Xxxxxxxxxxx xx xxx Chinese Xxxxxxx Xxxxx Xxxx/Xxxxxxxxxxxx-Xxxxxxx Xxxxxxxxxxxxxx Xxxxxxxxxxx Xxxx Xxxxxxxx Xxxxx, Xxxxxxxxxx Res., 189, 135-141.
11) Xxxxx, X. L., Xxxxxxx, X. W., Xxxxxx, X. X. (1989), X Xxxxxxxxxx of Xxxxxxxx Xxxxxxxxx xx xxx XX xxx XXXX Xxxx xx Xxxxx Lymphoblastoid Xxxxx: Xxxxxxxxxxxx Differences are Xxx xx an Xxxxxxxxxx Xxxxx xx Xxxxxxxxx xx xxx Xxxxxxxxx XX Xxxxx, Xxxxxxxxxx Xxx., 216, 9-17.
12) Xxxxxxxxxx, X. X. Xx., Xxxxxx, X. X., Xxxx, X. X. (1986), Xxxxxxxxxxxx xxx Xxxxxxxxx Xxxxxxxx xx Xxxxx Xxxxxxxxxxxxxxxxx xxx XXX 191-Xxxxxxx Xxxxxxxxx Analyses xx Ethyl Xxxxxxxxxxxxxxxxx xxx XXX 191 Xxxxxxx Xxxxxxxx in XX52 Xxxxx, Mutatation Xxx., 160, 133-147.
13) Xxxxxx, N. X., Xxxxxx, X. X., Xxxxx, X. (1984), Xxxxxxxxx for xxx X5178X/XX+/--XX+/- Mouse Xxxxxxxx Xxxx Xxxxxxxxxxxx Xxxxx, xx: Kilbey, B. X. xx xx (xxx.) Handbook xx Xxxxxxxxxxxx Xxxx Procedures, Xxxxxxxx Xxxxxxx Xxxxxxxxxx, Xxx Xxxx, 239-268.
14) Xxxxxx, X. X., Xxxxx, X. X., Xxxxxx, X. X., Xxxxx, X. X. X., Xxxx, X., XxXxxxxx, D. X., Xxxxxxx X. X. (1989), Xxxxxxxxx Xxxx Xxxx Mutation Assays Xxxxx xxxx Xxxxxx Xxxxxxxxx, in: Xxxxxxxxxxx Xxxxxxxxxx xx Mutagenicity Xxxx Xxxx, Xxxxxxxx, X. X., ed., Xxxxxxxxx University Xxxxx, 66-101.
15) Abbondandolo, A., Xxxxxxx, S., Corti, X., Fiorio, X., Xxxxxxxx, X., Xxxxxxxxxx, X. (1977), Xxxxxxxxx xx 6-Xxxxxxxxxxx-Xxxxxxxxx Xxxxxxx xx X79 Chinese Xxxxxxx Xxxxx xx Xxxxx-Xxxxx Xxxxxxxxx-Xxxxxxxxx Xxxxxxxxxxxxxxxxxxx, Xxxxxxxxxx Xxx. 46, 365-373.
16) Xxxx, X. X., XxXxxx, X., Xxxxxxxx, X. (1975), Xxxxxxx xxx Detecting Xxxxxxxxxxx xxx Xxxxxxxx xxxx the Xxxxxxxxxx/Xxxxxxxxx-Xxxxxxxxx Xxxxxxxxxxxx Xxxx, Mutatation Xxx. 31, 347-364.
17) Xxxxx, X., Xxxxxxx, X. O., Spector, X. X. X., Xxxxxx X. G., Xxxxx X. X. X. (1979), Xxxxxxxxxx xxx Characterisation xx xxx X5178X/XX+/--Xxxxx Xxxxxxxx Xxxxxxx Xxxxx Xxxxxx, Xxxxx. Res. 59, 61-108.
18) Xxxxx, X. X., Xxxx, X. X. (1983), Xxxxxxx Xxxxxxx for xxx Xxxxxxxxxx Xxxxxxxxxxxx Xxxx, Xxxxxxxxxx Res. 113, 173-215.
19) Elliott, X. X., Combes, R. X., Elcombe, X. X., Xxxxxxxxx, X. X., Gibson, G. X., Xxxxxx, X. X., Xxxx, X. X. (1992), Alternatives xx Aroclor 1254-Induced X9 in: In xxxxx Xxxxxxxxxxxx Xxxxxx, Xxxxxxxxxxx 7, 175-177.
20) Xxxxxxxxxx, X., Xxxxxxxx, X., Hara, X., Xxxxxxxx, T. (1976), X Xxxx Substitute xxx Xxxxxxxxxxxxxxx Xxxxxxxxx x. x. xx Xxxxxxx xx Metabolic Xxxxxxxxxx Xxxxxxx, V: Xx vitro Xxxxxxxxx Xxxxxxxxxx in Mutagenesis Xxxxxxx, de Serres, X. X., Fouts, X. R., Xxxx, X. X., Xxxxxxx, X. X. (eds), Xxxxxxxx, Xxxxx-Xxxxxxx, 85-88.
21) Xxxxx, D. F., Xxxxxx, X. X., XxXxxxx, X. T. (1982), XXX/XXXXX Mutation Xxxxx: Evaluation of Xxxxx and Volatile Xxxxxxx, xx: Xxxx, X. R., Costa, X. L., Schaich, X. M. (xxx), Xxxxxxxxx Effects of Xxxxxxxx Xxxxxx, Xxx Xxxx, Xxxxxx, 91-103.
22) Xxxxxx, P. X., Xxxxxx, X. X., Xx, A. P., Xxxxxx, X. L. (1983), Xxxxxxxxxx of xx Xxxxxxxx System Xxxxx Xxxxx Xxxxx xx Collagen Xxxx xxx Xxxxxxxxx Highly Xxxxxxxx Xxxxxxxx xx xxx XXX/XXXXX Xxxxxxxx Xxxxx, Xxxxxxx. Xxxxxxxxxxx, 5, 795-801.
23) Xxxxxxxxx, X. X., Xxxxx, X. M., Xxxxxx, X. X., Burrell, X., Xxxxxx, X. X. (1990), Xxxxxxxxx Xxxxxxxxxx of Xxxxxxxxx xx the Xxxxxxxxxxxx Xxxxxxxxx Kinase Locus xx Mouse Xxxxxxxx Xxxxx, Xxxx. Xxxx. Xxxx. Sci. X. X. X, 87, 51-55.
24) Xxxxx, X. X., Clive, X., Xxxxxx, X. C., Xxxxxx, X. X., Xxxxxx, X. X., Xxxxxx, X. X., Xxxxxx, X. (1985), Xxxxxxxx xx Xxxxxxxxxxxxxxxxxx, Xxxxxxxxx (XXX+) Xxxxxxx xx X5178X/XX+/--Xxxxx Xxxxxxxx Xxxxx, Xxxxxxxxxx Xxx. 151, 161-174.
25) Yandell, X. X., Xxxxx, X. X., Xxxxxx, X. B. (1990), Xxxxxxxxx Genetic Xxxxxxxx xx Xxxxxxxxx Mutations xx x Heterozygous Xxxxxxxxx Xxxxx xx Xxxxx Cells, Xxxxxxxxxx Xxx. 229, 89-102.
26) Xxxxx, M. X., Xxxxx, C. L. (1990), Comparison xx Xxxxxxxxxx Aberration Xxxxxxxxx xxx Xxxxx Xxxxxx XX-Xxxxxxxxx Xxxxxx Xxxxxxxxx xx L5178Y/TK+/- 3.7.2X Xxxxx Lymphoma Xxxxx, Xxxxxxxxxxx, 5, 609-614."
XXXXXXX 4X
"X.23 XXXXXXX XX CHROMOZOMOVÉ ABERACE XX XXXXXXXXXXXXXXX SAVCŮ
1. XXXXXX
Xxxx xxxxxx xx xxxxxxxx xxxxxx XXXX XX 483 — Xxxxxxx xx xxxxxxxxxxxx xxxxxxx ve xxxxxxxxxxxxxxx xxxxx (1997).
1.1 XXXX
Xxxxxx xxxxxxx xx xxxxxxxxxxxx xxxxxxx xx xxxxxxxxxxxxxxx xxxxx xx xxxx xx xxxxxxxxxxxxx xxxxxx xxxxx, xxxxx způsobují xxxxxxxxxx xxxxxxxxxxxx xxxxxxx xx xxxxxxxxxxxxxxx xxxxx (1, 2, 3, 4, 5). Xxxxxxxxx xx xxx xxxx xxxxxxxxxxxx aberací: chromozomové x xxxxxxxxxxxx. X xxxxxxx xxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxx aberace xxxxxxxxxxxxxx typu, xxxxx xxxxxxxxxxxx aberace xx xxxxxx vyskytují. Xxxx xxxxxx xxxx xxxxxx xx xxxxxxxxx xxxxxxxxxxx xxxxxxx x xxxx x xxxxxx xxxxx xxxxxxx xxxxxxxxx. Chromozomové xxxxxx x podobné xxxx xxxx xxxxxxxx xxxxx xxxxxxxxx xxxxxxxxxxx xxxxxx x člověka.
Touto xxxxxxxx se stanovují xxxxxxxxxxxx xxxxx ve xxxxxxxxxxxxxxx x xxxxxxxxxxx xx tedy, že xxxx zkouška xxxxxxxx xxxxxxxxx indukce xxxxxxxxx xxxxxx x germinálních xxxxxxx.
X této xxxxxxx xxxx xxxxxxx xxxxxxxxx xxxxxxxx. Xxxxx cytogenetickou xxxxxxxx xx vivo xx xxxxxxxx xxxxxxxxxxxx xxxxxxx xxx xxxxxx xxxxxxxxxxxxx. Xxxx xxxxxx xxxxx xxxxxx xxxxxxxxx xxxx xxxxxxx.
Xxx xxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxx xx xxxxxxxxxxxxxxx by xxxx xxx — xxxxx než xxxxx xx xxxxxx xxxx — xxxxxxxxx první xxxxxxxxx xxxxxxx xxxxxx, xxxxx xxxxxxxxx xx xxxxxxxx. Xxxxx informace x exponovaných xxxxxxxxxxxxxxxxxx xxxxxxxxx xxxxx lze xxxxxx xxxxxxxxxx chromozomovou xxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxx v diakinese-metafázi X, kdy se xxxxxxxxxx xxxxx xxxxxxx xxxxxxxxxxxx.
Xxxx xxxxxxx xx xxxx xx xxxxxxxx xxx xxxxxxxxx, xxx xxxx mutageny somatických xxxxx xxxxxxx také x germinálních xxxxxxx. Xxxxx xx xxxx xxxxxxx se xxxxxxxxxxxxxxx xxxxxxxx pro xxxxxxxxx xxxxxxxxx xxxxxxxxxx, xxxxx xxxxxxxx zohlednit xxxxxxx xxxxxxxxxxx in xxxx, xxxxxxxxxxxxxxx x xxxxxxx xxxxxxxx DNA.
Ve varlatech xx xxxxxxxx xxxx xxxxxxxx spermatogonií s xxxxxx citlivostí na xxxxxxxx xxxxxxxx xxxxx. Xxxxxxxxxx xxxxxxx xxxx xxxxxxxxxxx xxxxxxxxx odpověď xxxxxxxxxx xxxxxxxx xxxxxxxxxxxxx x převládajícími xxxxxxxxxxxxxxx xxxxxxxxxxxxxxx. X závislosti xx xxx poloze xx varlatech, xxxxx xxxx xxxxxx xxx xxxxx xxxxxxxx spermatogonií xxxxxxxxxx xxxxxxxxx xxxxxxxx xxxxx x xxxxxxxx xxxxxxxxx x xxxxxxxxxxxx xxxxxxx Sertoliho buněk x bariéry xxxx xxxxxxx xxxxxx x xxxxxxx.
Xxxxxxxx xxxxxxxx xxxxx x xxx, xx xx xxxxxxxx látka xxxx xxxxxxxxx metabolity xxxxxxxxxx xx xxxxxx xxxxx, xxxx vhodné xxxx xxxxxxx použít.
Viz xxxx xxxxxx úvod, xxxx X.
1.2 DEFINICE
Chromatidová xxxxxxx : xxxxxxxxxx xxxxxxxxx chromozomu x xxxxxx xxxxx jednotlivých xxxxxxxxx xxxx xxxxx x xxxxxxxx xxxxxxx xxxxxxxxx.
Xxxxxxxxxxxx xxxxxxx : xxxxxxxxxx xxxxxxxxx xxxxxxxxxx x xxxxxx zlomu xxxx zlomu a xxxxxxx xxxx xxxxxxxxx x xxxxxx xxxxx.
Xxx : xxxxxxxxxxxx xxxx xxxxx než šířka xxxxx xxxxxxxxxx x x xxxxxxxxx odchylkou xxxxxxxxx.
Xxxxxxxxx xxxxxxx : xxxxxxxx xxxxx chromozomů xx xxxxxxxx xxxxxxx x použitých xxxxx.
Xxxxxxxxxxx : xxxxxxx xxxxxxxxxxx xxxxx xxxxxxxxxxxxxx xxx (x), jiný xxx xxxxxxxxx (tj. 3 x, 4 x xxx.).
Xxxxxxxxxx xxxxxxx : xxxxxxxxxxxxx xxxxxxxxxxxxx změny xxxxxxxxx chromozomů xxx xxxxxxxx xxxxxx xx xxxxxx xxxxxxxx pod xxxxxxxxxxx, xxxx xx xxxx delece x xxxxxxxxx, xxxxxxxxxxxxxxxxxx xxxx xxxxxxxxxxxxxxxxxx xxxxx.
1.3 XXXXXXXX XXXXXXXX METODY
Zvířata xxxx xxxxxxx způsobem exponována xxxxxxxx látce x xx vhodné xxxx xx xxxxxxxx xxxxxxxx. Xxxx xxxxxxxxx se xxxxxxxx podá xxxxx xxxxxxxxxxx xxxxxxxx (např. xxxxxxxxx nebo Xxxxxxxx®). X germinálních xxxxx xx xxxx xxxxxxxx xxxxxxxxx xxxxxxxxxx, xxxxxx xx a xxxxxxxxx xx chromozomové xxxxxxx xxxxxxxxxxxxxx buněk.
1.4 XXXXX XXXXXXXX METODY
1.4.1 Xxxxxxxxx
1.4.1.1 Xxxxx druhu xxxxxxx
Xxxxx xxxx používáni xxxxx xxxxxx xxxxxxxx a xxxx; xxx xxxx xxxxxx xxxxx jakéhokoli xxxxxx vhodného druhu xxxxx. Xxxx by xxx xxxxxxx xxxxx xxxxxxx xxxxxxxxxxx xxxxx xxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxx xxxxxx. V xxxxxxxx xxxxxxxx studie xx xxxx xxx xxxxxxxx x xxxxxxxxx xxxxxx xxxxxxxxx x xxxxxx xx xxxxxxxxx ± 20 % xxxxxxx xxxxxxx hmotnosti.
1.4.1.2 Xxxxxxxx xxxxx x xxxxxx
Xxxxx obecné xxxxxxxx xxxxx xxxxxxxx úvodu x xxxxx X, xxxxxxx by xxxx xxx dosaženo xxxxxxxx xxxxxxx 50 – 60 %.
1.4.1.3 Xxxxxxxx xxxxxx
Xxxxxx xxxxx xxxxxxxx xxxxxxx xxxxx xx xxxxxxxx xxxxxxx xxxxxxx xx xxxxxxxxx xxxxxxx x xxxxxxx, xxxxx xx exponuje. Klece xx xxxx xxx xxxxxxxxxx xxx, xxx xxx xxxx jejich xxxxxx minimalizován. Zvířata xx xxxxxxxxxxx xxxxxxxxxxxx. Xxxx xxxxxxxxx xxxxxx xx xxxxxxx x xxxxxxxxxxxxx podmínkách alespoň xxx xxx aklimatizovat.
1.4.1.4 Xxxxxxxx dávek
Pevné zkoušené xxxxx xx xxxx xxx xxxx xxxxxxxx xxxxxxxx xxxxxxxxxx xxxx xxxxxxxxxxxx xx xxxxxxxx xxxxxxxxxxxxxx xxxx vehikulech x xxxxxxxxx xxxxxxx. Xxxxxxx xxxxxxxx xxxxx xxxxx být podávány xxxxx xxxx xxxxx xxx xxxx podáním xxxxxxx. Xxxx xx xxx xxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxx xxxxx, xxxxx údaje x xxxxxxxx neprokazují xxxxxxx xxxxxxxxxx.
1.4.2 Xxxxxxxx xxxxxxxx
1.4.2.1 Xxxxxxxxxxxx/xxxxxxxxx
Xxxxxxxxxxxx/xxxxxxxxx xx xxxxxx xxx xxx xxxxxxxxx xxxxxxxxx dávek xxxxxxx xxxxxx x xxxx xx být xxxxxxxxx xxxxxxxxx, xx xxxxxxx xx xxxxxxxxx xxxxxx. Xxxx-xx použita xxxx xxx xxxxx xxxxxxxxxxxx/xxxxxxxx, xxxx xx xxx jejich zařazení xxxxxxxxx xxxxx x xxxxxx xxxxxxxxxxxxx. Doporučuje xx xxxxx možno xxxxxxxx xxxxxx xxxxxxx xxxxxxx xxxxxxxxxxxx/xxxxxxx.
1.4.2.2 Kontroly
Součástí xxxxxxx xxxxxxxxxxx xx xxxx xxx xxxxxxxx xxxxxxxxx x negativní (xxxxxxxxxxxx/xxxxxxxxx) xxxxxxxx. S xxxxxxxx aplikace zkoušené xxxxx xx měla xxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxx xxxx xxxxxxx xx xxxxxxxxx, v xxxxx xxxxx k expozici.
Pozitivní xxxxxxxx xx xxxx xxxxxxxxxx strukturní aberace xx xxxxxxxxxxxxxxx xx xxxx při expozičních xxxxxxxx, x xxxxx xx xxxxxxxxxxx, xx xxxxxxxxx detekovatelný xxxxxx xxx xxxxxx.
Xxxxx xxxxxxxxx xxxxxxxx xx xxxx xxx xxxxxxx tak, xxx byl xxxxxx xxxxxxxx, xxx xxx xxx odečtu xxxxxxx xxxxx najevo kódovaná xxxxxxxxxxxx xxxxxxxxx. Xx xxxxxxxxxx, xxx xxxx xxxxxxxxx xxxxxxxx xxxxxxxx xxxxx xxxxxxxx xxx xxxxxxxx látka a xxx xxx odběr x jejím případě xxxxxxxx xxx jednou. Xxx xxxxxxxxx kontrolu xxxx být navíc xxxxx x xxxxx xxxxxxx chemických látek xx stejné xxxxxxxx xxxxx, xxxx-xx k xxxxxxxxx. Příklady xxxxx xxx xxxxxxxxx kontrolu:
|
Látka |
Číslo XXX |
Xxxxx xxxxx Einecs |
|
cyklofosfamid |
50–18–0 |
200–015–4 |
|
cyklofosfamid xxxxxxxxxx |
6055–19–2 |
|
|
xxxxxxxxxxxxxx |
108–91–8 |
203–629–0 |
|
xxxxxxxxx X |
50–07–7 |
200–008–6 |
|
xxxxxxxxx (xxxxxxx) |
79–06–1 |
201–173–7 |
|
2,4,6-xxxx(xxxxxxxx-1-xx)-1,3,5-xxxxxxx |
51–18–3 |
200–083–5 |
X xxxxxxxx xxxxxxx xxxxxx xx xxx být xxxxxxxx odběr x xxxxxxx xxxxxxxxx xxxxxxxx, xxxxx xx aplikováno xxxxx xxxxxxxxxxxx xxxx xxxxxxxxx x která xxxxx podstupuje xxxxxx xxxxxx jako exponované xxxxxxx, pokud xxxxxx x dosavadních xxxxxxxxxxx xxxxx k xxxxxxxxx xxxxxxxxxx xxxxx o xxxxxxxxxxx xxxxxx x xxxxxxxx buněk x xxxxxxxxxxxxxx xxxxxxxxx. Kromě xxxx xx xxxx xxx xxxxxxxxxxxx xxxxxxxx xxxxxxx také xxxxx, xxxxxxxxxx-xx xxxxx kontrolní xxxxx xxxxxxxxxxx, že xxxxxxx xxxxxxxxxxxx/xxxxxxxxx nevyvolává xxxxx xxxxxxx xxxx xxxxxxxxx účinky.
1.5 XXXXXX
1.5.1 Xxxxx zvířat
Každá xxxxxxxxxx x kontrolní xxxxxxx xxxx zahrnovat xxxxxxx xxx xxxxxxxxxxxxxxxx xxxxx.
1.5.2 Xxxx xxxxxxxx
Xxxxxxxx xxxxx xx xxxx být xxxxx možno xxxxxxxx xxxxxxxxxxx nebo xxxxxxxxx (xx. xxx xxxxx xxxxxxxx nebo xxxx xxxxxxxxxx). Xxxxxxxx xxxxx xxxxx být podávány xxxx ve xxxx xxxxxxx, xxx. xxx xxxxx v týž xxx x xxxxxxx xx xxxx xxx xxxxxxxx hodin, aby xxxx xxxxxxxxx xxxxxxxx xxxxxxx xxxxxx xxxxxxxxx. Xxxx xxxxxx podávání xx xxxx být xxxxxxx zdůvodněny.
Ve skupině x nejvyšší xxxxxx xx xxxx být xx expozici xxxxxxxxx xxx odběry. Poněvadž xxxxxxxx xxxxxxxxx xxxxx xxxx xxx xxxxxxxxx xxxxxx xxxxxxxxx, provede xx xxxxx xxxxx xxxxx x jeden xxxxxxxx odběr xxxxxxxxx 24 x 48 xxxxx xx expozici. X xxxxxxx xxxx xxx nejvyšší xxxxx xx xxx být xxxxx xxxxxxxx xx 24 xxxxx xxxx xx xxxxxx době xxxxxxxx, xxxxx odpovídá 1,5xxxxxxx xxxxx xxxxxxxxx xxxxx, xxxxx není xxxxx xxxx xxxxxxxxx xxxx pro detekci xxxxxx (6).
Xxxxx xxxxx xxx odběry xxxxxxxxx xxxx x xxxx xxxx. Xxxxxxxxx x xxxxxxx xxxxxxxxxx látek, xxxxx mohou xxxxxxxxx xxxxxxxx replikace (xxxxxxx) xxxxxxxxxx nebo xxxxx xxxxxxxxxx X-xxxxxxxxx xxxxxx, xxxx xxx xxxxxxxxx xxxxxxxx xxxxx (1).
Xxxxxxxx xxxxx xxxxxxxxx xxxxxxxx xxxx být xxxxxx xxxxxx xx xxxxxxx. X xxxxxxx xxxxx x opakovanou xxxxxxxx xx xxxx xxx xxxxxxx xxxxxxxx 24 xxxxx (1,5xxxxxxx délky xxxxx) po xxxxxxxx xxxxxxxx. Xxxxx xxxxxxx xxxxx být xxxxxxxxx xxxxx odběry v xxxx xxxx.
Xxxx xxxxxxxxx xx xxxxxxxx xxxxxxxxxxxxxxxxx xxxx vhodná xxxxx xxxxx zastavující xxxxxxxx (xxxx. Xxxxxxxx® xxxx xxxxxxxxx). Poté se xx xxxxxx xxxx xxxxxxx u xxxxxx xxxxx. X xxxx xx xxxx doba xxxxxxxxx 3 — 5 xxxxx; x xxxxxx čínského xx xxxx xxxx xxxxxxxxx 4 — 5 xxxxx.
1.5.3 Dávkování
Provádí-li se xxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxx xxxxxx xxx zjištění xxxxxxx, xxxx xx být xxxxxxxxx xx xxxxxx xxxxxxxxxx, se stejným xxxxxx a xxxxxx x xx stejného xxxxxx expozice, xxxxx xx xxxxxxx v xxxxxx xxxxxx (7). X xxxxxxx xxxxxxxx xx xxx xxxxx xxxxx xxxxxxx tři xxxxxx dávky. Xxxx xxxxxx dávky by xxxx xxxxxxxx rozmezí xxxx xxxxxxxxx x xxxxxxxxx xxxxxxxxx, xxxxxxxx xxxxxx toxicitou. Xxx xxxxxxxxx xxxxxx xxxxx, xxxx xxxx xxxxxxx xxxxx nejvyšší dávka. Xxxxxxxx dávka xx xxxxxxxxxx xxxx xxxxx xxxxxxxxxxxx xxxxxx známky xxxxxxxx, xx xx xxxxx xxxxx xxxxx xxx xxxxxxx xxxxxx xxxxxxxxx xxxxx očekávání x letalitě.
Látky xx xxxxxxxxxxx biologickou xxxxxxxxx xxx nízkých xxxxxxxxxxx xxxxxxx (např. hormony x xxxxxxxx) nemusí xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxx x xxxx xx xxx xxxxxxxxx xxxxxx xx xxxxxxx. Xxxxxxxx dávka xxxx xxx xxxx xxxxxxxxxx xxxx xxxxx xxxxxxxxxxxx xx spermatogoniích xxxxxxx xxxxxx toxicity (např. xxxxxxx počtu xxxxxxxxxxxxx x mitose xxxxxxxx x první a xxxxx meiotické xxxxxxxx; xxxx snížení by xxxxxx překročit 50 %).
1.5.4 Xxxxxxx zkouška
Jestliže xxxxxxx x xxxxxx xxxxxx alespoň 2000 xx/xx xxxxxxx hmotnosti xxxxxxx xxxxxxxxxxx nebo xx dvou dávkách x xxxxxx xxx xxxxxxxxxx xxxxx xxxxxxxxxxxxx xxxxxxx xxxxxx x xxxx-xx na xxxxxxx xxxxx o xxxxxxx, xxxxx xxxx xxxxxxxx xxxxxxxxx, očekávána xxxxxxxxxxxx, xxxxxxxxxx xx xxxxx xxxxxx xx xxxxx xxxxxxxx dávky xx xxxxxxxxx. Xxxxxxxxx xxxxxxxx xxxxxxx může xxxxxxxx xxxxxxx použít x xxxxxxx xxxxxxx xxxxx xxxxxx xxxxx.
1.5.5 Xxxxxxxx xxxxx
Xxxxxxxx látka xx xxxxxxx podává xxxxxxxxxxxxxx, xxxxxxxxx xxxxxx nebo xxxxxxx xxxxxxxxx xxxxxxx, xxxx intraperitoneální xxxxxxx. Xxxx xxxxxxx xxxxxxxx xxxx xxxxxxxxxx, jsou-li xxxxxxxxxxxxx. Xxxxxxxxx objem xxxxxxxx, xxxxx xxxx xxx xxxxxxxx xxxxx xxxxxxxxx xxxxxx xxxx xxxxxxxx, xxxxxx xx xxxxxxxxx testovacího xxxxxxx. Xxxxx xx neměl xxxxxxxxx 2 xx/100 x xxxxxxx hmotnosti. Xxxxxxx vyšších xxxxxx, xxx xx xxxxxxx xxxxx, xxxx xxx xxxxxxxxxx. Až xx xxxxxxxx x xxxxxx xxxxx, které xxxxxxx xxx xxxxxxx xxxxxxxxxxxxx xxxxxxxx xxxxxxxx účinky, xx měla xxx xxxxxxxxxxx zkoušeného xxxxxx xxxxxxxxxxxxxx nastavením xxxxxxxxxxx xxxxxxxxxxx konstantní xxxxx xxx xxxxx úrovních xxxxx.
1.5.6 Xxxxxxxx xxxxxxxxx xx analýzu xxxxxxxxxx
Xxxxx xx xxxxxxxx se x xxxxxxx xxxx xxxx xxxxxx získá xxxxxxx suspenze, xxxxxxxxxxxx xx a xxxxxx. Xxxx se xxxxxx xx podložní sklíčka x xxxxxx xx.
1.5.7 Xxxxxxx
X xxxxxxx zvířete xx xxxx být xxxxxxxxxxx xxxxxxx 100 xxxxx x xxxxx xxxxxxxxxxxx xxxxxxxx (xx. xxxxxxxxx 500 xxxxxxxx xx xxxxxxx). Tento xxxxx lze xxxxxx, xx-xx xxxxxxxxx xxxxx xxxxx aberací. Všechny xxxxxxxxx xxxxxx xxxxxxxxx xxxxxxxxxxx a negativních xxxxxxx, by xxxx xxx xxxx mikroskopickou xxxxxxxx nezávisle kódovány. Xxxxxxxx xxx fixaci xxxxx xxxxxxx xx xxxxxxxxxxxxxx xxxxxx xxxx xxxxxx xxxxxxxxxx u xxxxx metafází, xxxx xx xxxxxxxxxxx buňky xxxxxxxxx xxxxxxxxxx x xxxxx xxxxxxxxxxxxxx xxxxx 2 x ± 2.
2. XXXXX
2.1 XXXXXXXXXX XXXXXXXX
Xxxxx xxx jednotlivá xxxxxxx xx xxxx xxx xxxxxxxxxx ve xxxxx xxxxxxx. Experimentální xxxxxxxxx xx xxxxx. Xxx xxxxx xxxxx xx xxx xxx xxxxxxxxxx xxxxx xxxxx xx xxxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx a xxxxx xxxxxxxxxxxxxx aberací na xxxxx. Xxx exponované x kontrolní xxxxxxx xx xxxx být xxxxxxx xxxxx xxxx xxxxxxxxxxxx chromozomových xxxxxxx x jejich xxxxxx x četností. Gapy xx xxxxxxxxxxxxx xxxxxxxx x xxxxxxx xx, xxx obecně se xxxxxxxxxx xx xxxxxxx xxxxxxxx xxxxxxx.
Xx-xx xxxxxxxxxx xxxxxx x xxxx xxxxxx, xxx by xxx xxx xxxxxxxxx xxxxxxx cytotoxických xxxxxx xxxx míra xxxxxxxxxxxx xxxxxxxx u xxxxx xxxxxxxxxxxx zvířat a xxxxxx xxxxxxxxxx jako xxxxxxxxx xxxxxxxx poměr xxxxxxxxxxxxx v xxxxxx xxxxxxxx k xxxxx x druhé xxxxxxxxx xxxxxxxx, x to x celkovém vzorku 100 xxxxxxxx xx xxxxx xx xxxxx xxxxx. Pokud xx xxxxxxxxx pouze mitosa, xxxxxxx x 1000 xxxxxxx na xxxxx xx xxx být xxxxxxxx mitotický index.
2.2 XXXXXXXXX A XXXXXXXXXXXX XXXXXXXX
Xxx xxxxxxxxx pozitivního xxxxxxxx xxxxxxxx xxxxxxx xxxxxxxx, např. xxxxxx xxxxx buněk x xxxxxxxxxxxxxx xxxxxxxxx x xxxxxxxxxx xx xxxxx xxxx xxxxx xxxxxx xxxxx buněk s xxxxxxxxx xxx skupinu x určitou dávkou x k xxxxxxxx xxxxxxxx xxxxxx. Nejdříve xx měla xxx xxxxxxx biologická xxxxxxxxx xxxxxxxx. Xxx hodnocení xxxxxxxx xxxxxxx mohou xxx xxxxxxx xxxx xxxxxxx prostředek statistické xxxxxx (8). Xxxxxxxxxxx xxxxxxxxxx by xxxxxx xxx xxxxxxx xxxxxxxxx xxxxxxxx pro xxxxxxxxx xxxxxxx. Xxxxxxxxxx výsledky xx xxxx xxx xxxxxxxxx dalším zkoušením, xxxxxxx x xxxxxxxx xxxxxxxxxxxxxxxx xxxxxxxx.
Xxxxxxxx xxxxx, xxxxx výsledky xxxxxxxxx xxxx uvedená xxxxxxxx, xx v xxxxx xxxxxxx xxxxxxxx xx xxxxxxxxxxx.
Xxxxxx xxxxxxx xxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxxx xxxx xxxxxxxxx xxxxxxxx, x xxxxxxxxxxx případech xxxxxxxx xxxxxx xxxxx xxxxxxxx xxxxxxx výrok x xxxxxxxx xxxxxxxx xxxxx. Xxxxxxxx xxxxx xxxxxx dvojznačné nebo xxxxxx xxx xxxxxx xx xx, xxxxxxxx xx experiment opakován.
Pozitivní xxxxxxxx zkoušky xx xxxxxxxxxxxx xxxxxxx xx xxxxxxxxxxxxxxx savců in xxxx znamenají, xx xxxxxxxx látka xxxxxxxx x xxxxxxxxxxxx xxxxxxx xxxxxxxxxxx druhu strukturní xxxxxxxxxxxx xxxxxxx. Negativní xxxxxxxx xxxxxxxxx, xx xxxxxxxx látka xx xxxxxxxx zkoušky xxxxxxxxxx x germinálních xxxxxxx xxxxxxxxxxx druhu xxxxxxxxxxxx xxxxxxx.
Xxxx xx xxx xxxxxxxxxxx xxxxxxxxxxxxxxx, x xxxxx xx xxxxxxxx xxxxx nebo její xxxxxxxxxx xxxxxxxx xx xxxxxx tkáně.
3. ZPRÁVY
PROTOKOL X XXXXXXX
Xxxxxxxx o xxxxxxx musí obsahovat xxxx xxxxxxxxx:
Xxxxxxxxxxxx/xxxxxxxxx:
- zdůvodnění xxxxx xxxxxxxx,
- xxxxxxxxxxx x xxxxxxx zkoušené xxxxx x rozpouštědle/vehikulu, xx-xx xxxxx.
Xxxxxxxxx xxxxxxx:
- xxxxxxx druh/kmen,
- xxxxx x xxxxx xxxxxx,
- xxxxx, xxxxxxxx xxxxx, xxxxxx xxx.,
- individuální xxxxxxxx zvířat xx xxxxxxx zkoušky, xxxxxx xxxxxxx xxxxxxx hmotnosti, xxxxxxx xxxxxxx x xxxxxxxxxx odchylky xxx xxxxxx xxxxxxx.
Xxxxxxxx xxxxxxxx:
- xxxxx xx xxxxxx xxx xxxxxxxx xxxxxxx, xxxxx xxxx provedena,
- xxxxxxxxxx xxxxxxxxx xxxxxx xxxxx,
- xxxxxxxxxx xxxxxxx xxxxxxxx,
- xxxxx o xxxxxxxx zkoušené xxxxx,
- xxxxx x xxxxxxxx xxxxxxxx xxxxx,
- xxxxxxxxxx xxx xxxxxxxx,
- xxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx xxxxxxxx xxxxx v xxxxxx xxxx xxxx (xxx) xx xxxxxxxxxxxx xxxxx (xx/xx tělesné xxxxxxxxx/xxx),
- xxxxxxxx xxxxx x kvalitě xxxxxx x xxxx,
- xxxxxxxx xxxxx xxxxxxx xxxxxxxx x xxxxxx,
- xxxxxx xxxxxxxxx toxicity,
- identifikace xxxxx xxxxxxxxxxx xxxxxxxx, xxxx xxxxxxxxxxx x xxxxx xxxxxxxx,
- metody xxxxxxxx xxxxxxxxx,
- kritéria xxxxxxxxx xxxxxxx,
- xxxxx xxxxxxxxxxxxx buněk xx xxxxx zvíře,
- kritéria xxxxxxxxxxx xxxxxx na xxxxxxxxx, xxxxxxxxx xxxx xxxxxxxxxxx.
Xxxxxxxx:
- známky toxicity,
- xxxxxxxxx xxxxx,
- xxxxx xxxxxxxxxxxxx x xxxxxx xxxxxxxx k xxxxx x xxxxx metafázi xxxxxx,
- xxx a xxxxx xxxxxxx uvedený xxxxxxxxxx xxx každé xxxxx,
- xxxxxxx xxxxx xxxxxxx xx skupině,
- xxxxx xxxxx x xxxxxxxxx xx xxxxxxx,
- xxxxx možnosti xxxxxxxxx xxxxxxxx na xxxxx,
- xxxxxxxx statistické xxxxxxx,
- xxxxx x souběžné xxxxxxxxx kontrole,
- dosavadní xxxxx x xxxxxxxxx xxxxxxxx s xxxxxxxxx, xxxxxxxxx hodnotami x xxxxxxxxxxxx xxxxxxxxxx,
- údaje x xxxxxxxx xxxxxxxxx xxxxxxxx,
- xxxxx xxxxxxx, xxxxx xxxx pozorovány.
Rozbor xxxxxxxx.
Xxxxxx.
4. XXXXXXXXXX
1) Xxxxx, X. X., (1986), Xxxxxxxxxxx Potential in Xxxxx Xxxxxxxxxxxxx xx Xxxxxxxx Mutagens Xxxxxxx xx xxxxx Xxxx-Xxxxx Xxxxxxxxxxxxxx, in: Xxxxxxx Xxxxxxxxxx xx Xxxxxxxxxxxxx Xxxxxxxxx, Xxxx B: Xxxxxxx Xxxxxxx xxx Xxxxxxx Xxxxxxxxxxx, Xxxxx, X., Xxxxxxx, B., Xxxxxxxxx, J. (eds) Xxxx, Xxx York, 477-484.
2) Xxxxx, I. X., (1984), Cytogenetic xxxxx xx Mammals, xx: Xxxxxxxxxxxx Xxxxxxx: x Practical Approach, (xx.) X. Xxxxxx, X. X. Xxxxx, XXX Xxxxx, Xxxxxx, Xxxxxxxxxx XX, 275-306.
3) Xxxxx, X. X., Xxxxxxx, G., Xxxx, X. X. (1964), Xx Xxx-xxxxxx Method xxx Xxxxxxx Xxxxxxxxxxxx xxxx Xxxxxxxxx Xxxxxx, Xxxxxxxxxxxx Cell Xxxxxxxx, 3, 289-294.
4) Richold, X., Xxxxx, X., Xxxxxxxx, X., Xxxxxxxxx, X. X., Henderson, X. (1990), Xx xxxx Xxxxxxxxxxx Assays, xx: D. X. Xxxxxxxx (xx.), Xxxxx Xxxxxxxxxxxx Xxxxx, UKEMS Xxxxxxxxxxx Procedures. UKEMS Xxxxxxxxxxxx xx Xxxxxxxxxx xxx Mutagenicity Testing. Xxxxxx. Xxxx X xxxxxxx, Cambridge Xxxxxxxxxx Xxxxx, Xxxxxxxxx, Xxx Xxxx, Xxxx Xxxxxxx, Xxxxxxxxx, Xxxxxx, 115-141.
5) Xxxxxxxx, X., Kikuchi, X. (1978), X Xxx Xxxxxx for Xxxxxxxxxxx xx Xxxxxxxxx Xxxxxxxxxxxxxx Xxxxxxxxxxx, Xxxxxxxxxx Xxx., 52, 207-209.
6) Xxxxx, I. X., Xxxxxx X. X., Xxxxxxx, X., Favor, X., Xxxxxxxx, X., Xxxxxxxxxxxx, F., Xxxxxxx, X., Xxxxxx N. (1994), Xxxxxxxxxxxxx Xxxxxxxx xx Standardisation xx Xxxxxxxxxxxx Xxxx Procedures. Xxxxxxx Xxxxxx of xxx Xxxxxxx Group xx Xxxxxxxxx Xxxx Xxxx Xxxxx, Xxxxxxxxxx Xxx., 312, 313-318.
7) Xxxxxxx, R. J., Xxxxx, X. X., Xxxxxx, X. X., Xxxxxx, X. X., Xxx, X., Xxxxxxx, X. J., Xxxxxxxxx, X. G., Xxxxxx-Xxxxxx, X., Xxxxxx, X. X., Xxxxxxxx, X. X., Xxxxxxx, X. (1992), Report xx Xxxxxxx Toxicology Xxxxxxx/XX Xxxxxxxxxxxxx Xxxxxxx Xxxxxxx Xxxxxxx Group: Xxxx Xxxxxxx xx Xx xxxx Mutagenicity Assays, Xxxxxxxxxxx, 7, 313-319.
8) Xxxxxx, X. X., Xxxxxxxx, X., Albanese, X., Amphlett, X. X., Clarc, X., Xxxxxxxx, R., Xxxxxxx, X., Papworth, X. X., Xxxxxx X. X. X. (1989), Xxxxxxxxxxx Xxxxxxxx xx Xx vivo Xxxxxxxxxxx Xxxxxx, xx: X. X. Xxxxxxxx (ed.), Xxxxxxxxxxx Evaluation xx Xxxxxxxxxxxx Xxxx Xxxx. XXXXX Xxxxxxxxxxxx xx Xxxxxxxxxx for Xxxxxxxxxxxx Xxxxxxx, Xxxxxx, Part XXX. Xxxxxxxxx Xxxxxxxxxx Xxxxx, Cambridge, New Xxxx, Xxxx Xxxxxxx, Xxxxxxxxx, Xxxxxx, 184-232."
PŘÍLOHA 4X
"X.39 XXXXXXX XX XXXXXXXXXXXX XXXXXXX XXX (UDS) X XXXXXXXXX XXXXXXX XXXXX XX XXXX
1. XXXXXX
Xxxx xxxxxx je xxxxxxxx xxxxxx XXXX TG 486 — Zkouška xx xxxxxxxxxxxx xxxxxxx XXX (UDS) v xxxxxxxxx xxxxxxx savců xx xxxx (1997).
1.1 XXXX
Xxxxxx zkoušky na xxxxxxxxxxxx xxxxxxx XXX (XXX) v xxxxxxxxx xxxxxxx savců xx xxxx xx xxxxxxxxxxxxx xxxxxxxx xxxxx, které xxxxxxxx xxxxxxxx XXX x jaterních xxxxxxx xxxxxxxxxxxx xxxxxx (1, 2, 3, 4).
Tato xxxxxxx xx vivo xxxxxxxxx xxxxxx vyšetření xxxxxxxxxxxxx účinků chemických xxxxx x xxxxxxx. Xxxxxxxxxxx xxx xx xxxxxxxxxx xxxxxxxxx XXX x následné xxxxxxxx x jaterních xxxxxxx. Xxxxx jsou xxxxxxx xxxxxxx xxxxxx, xxx xxxx xxxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxxx. Jsou xxxx xxxxxxx xxxxxx pro xxxxxxxxx xxxx xxxxxxxxx XXX in xxxx.
Xxxxxxxx xxxxxxxx xxxxx x xxx, xx xx xxxxxxxx xxxxx xxxxxxxxx xx xxxxxx tkáně, xxxx xxxxxx xxxx xxxxxxx použít.
Rozsah xxxxxxxxxxx xxxxxxx DNA (XXX) xx zhodnotí stanovením xxxxxxxxxxx xxxxxxxxx xxxxxxxxxx xx buněk, které xxxxxxxx xxxxxxxxxx xxxxxxxx XXX (S-fází). Nejrozšířenější xxxxxxxxx xx xxxxxxxxxxxxxxxxx xxxxxxxxx xxxxxxxxxxx xxxxxxxxx xxxxxxxxx tritiem (3H-TdR). Xxx xxxxxxx na XXX in xxxx xx xxxxxxxxxx xxxxxxxxx xxxxx xxxxxxx. Jiné xxxxx xxx xxxxx xxxxx být xxxxxx xxxxxxx, xxxxxx xxxx xxxxxxxxx xxxx xxxxxx.
Xxxxxxx xxxxxxxx XXX závisí xx počtu xxxx XXX vyštěpených x xxxxxxxxxxx x místě xxxxxxxxx. Zkouška xx XXX je xxxx xxxxxx zvláště pro xxxxxxx xxxxxxxx reparací ("xxxx-xxxxx repair") (20 xx 30 xxxx) xxxxxxxxxxxx xxxxxx. Krátké xxxxxx ("short-patch repair") (xxxxx xx tři xxxx) xxxx xxxxxxx xxxx xxxxxxxxxx x xxxxxx xxxxx citlivostí. Xxxxx může xxxxxxxxx xxxxxxxxxxxxx reparace, xxxxxx xxxxxxxx xxxx xxxxxx xxxxxxxxx lézí XXX xxxxx k xxxxxxxxxx xxxxxxxxx. Xxxxxx xxxxxxxx XXX neposkytuje xxxxxx xxxxxxxxx x věrnosti xxxxxxxxxxx xxxxxxx. Xxxxx xx možné, xx xxxxxxx reaguje s XXX, ale xxxxxxxxx XXX xxxx opraveno xxxxxxxxxxx xxxxxxxx. Nedostatek xxxxxxxxxxxx informací, xxxxx xxxx xxxxxxx poskytuje x xxxxxxxxx xxxxxxxx, xx xxxxxxx xxxxxxxxxxx xxxxxxxxxx tohoto jevu, xxxxx xx vyšetřován x xxxxx xxxxxx.
Xxx xxxx xxxxxx xxxx, xxxx X.
1.2 XXXXXXXX
Xxxxxxxxxx xxxxx : xxxxx xxxxx xxx odpovídajících xxxxxxxx xxxxxx (XXX), xxxxx xxx xxxxxxxxxx xxxxxxx xxxxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxxx.
Xxxxx xxxxx xxx odpovídajících xxxxxxxx xxxxxx (XXX) : xxxxxxxxxxxxx xxxx XXX xxxxxxxx xxxxx x xxxxxxxxxxxxxxxxx zkoušce na XXX, xxxxxxxxx odečtením xxxxxxxxxx xxxxx xxx x xxxxxxxxxxxxxxxxx xxxxxxxxx (XX) xxxxxxxxxxxxxx xxxxxx xx počtu zrn xxxxxxxxxxxxxx xxxxxxxx xxxxxx (XX): XXX = XX — XX. Xxxxxxx NNG xx xxxxxxx xxx jednotlivé xxxxx, xxxx xxxxxxxx xxx xxxxx x xxxxxxx, x xxxxxxxxxxx xxxxxxxxx xxx.
Xxxxxxxxxxx xxxxxxx XXX (XXX) : Xxxxxxx xxxxxxxx XXX xx xxxxxxxxx a xxxxxxxxxx úseku XXX xxxxxxxxxxxx xxxxxx x xxxxxxxxxx indukovaným xxxxxxxxxx xxxxxxx xxxx xxxxxxxxxxx xxxxxxxx.
1.3 XXXXXXXX XXXXXXXX XXXXXX
Xxxxxxx na XXX x jaterních xxxxxxx xxxxx xx vivo xxxxxxxx syntézu reparací XXX po xxxxxxxxx x odstranění xxxxx XXX obsahujícího xxxxxx x poškozením xxxxxxxxxxx xxxxxxxxxx látkami nebo xxxxxxxxxxx činiteli. Zkouška xx xxxxxxx xxxxxxxx xx xxxxxxxxxxx 3X-XxX xx XXX jaterních xxxxx, xxx xx xxxx xxxxxxx xxxxx x X-xxxx xxxxxxxxx xxxxx. Xxxxxxxxxxx 3H-TdR xx xxxxxxx stanoveno xxxxxxxxxxxxxxx, xxxxxxx xxxx xxxxxxxx není xxx xxxxxxx xx xxxx X-xxxx xxxxx xxxx xxxx. kapalná xxxxxxxxxxx xxxxxxxxxxxxx.
1.4 XXXXX METODY
1.4.1 Xxxxxxxxx
1.4.1.1 Xxxxx xxxxx xxxxxxx
Xxxxx je xxxxxxxx xxxxxx, xxxxxx xxx xxxxxx xxxxxxxx vhodný xxxx savce. Xxxx xx xxx xxxxxxx xxxxx používané xxxxxxxxxxx xxxxx mladých zdravých xxxxxxxx xxxxxxxxx xxxxxx. X xxxxxxxx zahájení xxxxxx by měla xxx odchylka x xxxxxxxxx zvířat minimální x neměla xx xxxxxxxxx ± 20 % střední xxxxxxx xxxxxxxxx xxx xxx xxxxxxx.
1.4.1.2 Xxxxxxxx chovu x strava
Platí xxxxxx xxxxxxxx podle xxxxxxxx xxxxx x xxxxx X, xxxxxxx by xxxx xxx dosaženo xxxxxxxx xxxxxxx 50 - 60 %.
1.4.1.3 Xxxxxxxx zvířat
Zdravá xxxxxxxx xxxxxxx zvířata se xxxxxxxx xxxxxxx xxxxxxx xx xxxxxxxxx xxxxxxx x xxxxxxx, xxxxx xx xxxxxxxx. Xxxxx xx xxxx být xxxxxxxxxx tak, xxx xxx vliv jejich xxxxxx xxxxxxxxxxxxx. Zvířata xx xxxxxxxxxxx identifikují x před xxxxxxxxx xxxxxx xx nechají x laboratorních xxxxxxxxxx xxxxxxx xxx dní xxxxxxxxxxxxx.
1.4.1.4 Příprava zkoušené xxxxx
Xxxxx xxxxxxxx xxxxx xx xxxx xxx xxxx xxxxxxxx xxxxxxxx xxxxxxxxxx xxxx xxxxxxxxxxxx xx xxxxxxxx rozpouštědlech xxxx xxxxxxxxxx x xxxxxxxxx xxxxxxx. Kapalné xxxxxxxx xxxxx xxxxx xxx xxxxxxxx xxxxx xxxx xxxxx být xxxx xxxxxxx zředěny. Xxxx by xxx xxxxxxx xxxxxxx připravené xxxxxxxx chemické xxxxx, xxxxx xxxxx o xxxxxxxx xxxxxxxxxxx možnost xxxxxxxxxx.
1.4.2 Zkušební podmínky
1.4.2.1 Xxxxxxxxxxxx/xxxxxxxxx
Xxxxxxxxxxxx/xxxxxxxxx xx xxxxxx xxx xxx použitých xxxxxxxx dávek xxxxxxx xxxxxx x xxxx xx být xxxxxxxxx xxxxxxxxx, že xxxxxxx xx zkoušenou xxxxxx. Xxxx-xx xxxxxxx xxxx xxx xxxxx rozpouštědla/vehikula, xxxx by xxx xxxxxx zařazení xxxxxxxxx xxxxx x xxxxxx xxxxxxxxxxxxx. Xxxxxxxxxx xx xxxxxxxx zvážit xxxxxxx xxxxx možno xxxxxxx xxxxxxxxxxxx/xxxxxxx.
1.4.2.2 Xxxxxxxx
Xxxxxxxx každé xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxxxx xx xxxx xxx xxxxxxxx xxxxxxxxx x xxxxxxxxx (xxxxxxxxxxxx/xxxxxxxxx) xxxxxxxx. S výjimkou xxxxxxxx xxxxxxxx xxxxx xx xxxx xxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxx xxxxxx xxxxxx xxxx xxxxxxx xx xxxxxxxxx, x nichž dojde x expozici.
Pozitivními xxxxxxxxxx xx xxxx být xxxxx, x xxxxx xx xxxxx, xx xxxxxx podávání x xxxxxxxxxxx expozičních koncentracích xxxx x xxxxxxx XXX detekovatelnému xxx xxxxxxx. Xxxxxxxxx kontroly xxxxxxxxxx metabolickou xxxxxxxx xx xxxx xxx xxxxxxx x xxxxxxx xxxxxxxxxxxx mírnou xxxxxxx (4). Dávky xxxxx xxx xxxxxxx xxx, xxx byl účinek xxxxxxxx, xxx xxx xxx odečtu nevyšla xxxxx xxxxxx xxxxxxxx xxxxxxxxxxxx preparátu. Xxxxxxxx xxxxx pro xxxxxxxxx xxxxxxxx:
|
Xxxx xxxxxx |
Xxxxx |
Xxxxx CAS |
Číslo xxxxx Xxxxxx |
|
Xxxxx doby xxxxxx (2 xx 4 x) |
X-xxxxxxxxxxxxxxxxxxx |
62–75–9 |
200–249–8 |
|
Xxxxxx doby xxxxxx (12 až 16 h) |
N-(fluoren-2-yl)acetamid (2-AAF) |
53–96–3 |
200–188–6 |
Mohou xxx xxxxxxx také xxxx xxxxx xxx xxxxxxxxx kontrolu. Xx xxxxxxxxx, aby xxxx xxxxxxxxx kontrolní xxxxx xxxxxxxx xxxxx xxxxxxxx, xxx xxxxxxxx xxxxx.
1.5 XXXXXX
1.5.1 Xxxxx a xxxxxxx xxxxxx
Xxx by xxx xxxxxx dostatečný xxxxx zvířat, xxx xxxx xxxxxxxxxx xxxxxxxxx xxxxxxxxxx xxxxxxxx odpovědi xx zkoušku. Xxxxx xxxxxxx xx xx xxxx skládat xxxxxxx xx xxx analyzovatelných xxxxxx. Xxxxxxxx xxxx xxxxxxxxxxx dostatečné dosavadní xxxxx, xx pro xxxxxxxxx x pozitivní xxxxxxxxx skupiny xxxxxxxx xxxxx xxxxx xx xxx xxxxxxx.
Xxxxxxxx jsou x xxxx xxxxxx x xxxxxxxxx xxxxx xx xxxxxx xx xxxxxxx xxxxxx x xx xxxxxxx xxxxxxxx xxxxxxx xxxxxxxx, xxx xxxxxxxxx, že neexistuje xxxx xxxxxxxxx rozdíl x xxxxxxxx, xxxx xxxxxxxxxxx xxxxxxxx xxxxxxx xxxxxxx, xxxxxxx xxxxx. Xx-xx xxxxxxxx xxxxxxx xxxxxxxxxx xxx určité xxxxxxx, xxxx xx xxxx například x xxxxxxxxx farmaceutických látek, xxxx by xxx xxxxxxx provedena xx xxxxxxxx xxxxxxxxxxxxxx xxxxxxx.
1.5.2 Xxxx xxxxxxxx
Xxxxxxxx xxxxx xxxx zpravidla xxxxxxxx xxxxxxxxxxx.
1.5.3 Dávkování
Za xxxxxxxxxx xxxxxxxx xx xxxxxxxxx xxxxxxx xxx xxxxxx xxxxx. Nejvyšší xxxxx xx definována xxxx xxxxx xxxxxxxxxxxx xxxxxx xxxxxx xxxxxxxx, že xxxxx xxxxx xx xxxxx podle xxxxxxxxx xxx stejném xxxxxx xxxxxxxxx k letalitě. Xxxxx xxxxx xx xxxx být xxxxxxxxx 50 % xx 25 % xxxxx xxxxx.
Xxxxx se xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxx xxx xxxxxxx netoxických dávkách (xxxx. xxxxxxx a xxxxxxxx) nemusí xxxxxxxxx xxxxxxxxx dávky xxxxxxxxx x xxxx by xxx hodnoceny xxxxxx xx xxxxxxx. Xxxxxxx-xx xx xxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxxx údajů xxxxxx pro xxxxxxxx xxxxxxx, měla xx xxx provedena xx xxxxxx xxxxxxxxxx, xx xxxxxxx xxxxxx, kmenem, xxxxxxxx a xx xxxxxxxx režimu xxxxxxxx, xxx xx xxxxxxx x hlavní studii.
Nejvyšší xxxxx může být xxxxxxxxxx xxxx jako xxxxx vyvolávající xxxxxx xxxxxxxx x xxxxxxx (xxxx. xxxxxxxxxx jádra).
1.5.4 Xxxxxxx xxxxxxx
Xxxxxxxx zkouška x xxxxxx dávkou x xxxxxxx 2000 xx/xx xxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxxx xxxx xx xxxx xxxxxxx x xxxxxx xxx xxxxxxxxxx žádné xxxxxxxxxxxxx xxxxxxx účinky x xxxx-xx na základě xxxxx o látkách, xxxxx mají xxxxxxxx xxxxxxxxx, xxxxxxxxx genotoxicita, xxxxxx být xxxxx xxxxxx nezbytná. Xxxxxxxxx xxxxxxxx xxxxxxx může xxxxxxxx xxxxxxx použít x xxxxxxx zkoušce xxxxx úroveň xxxxx.
1.5.5 Xxxxxxxx dávek
Zkoušená xxxxx xx xxxxxxx xxxxxx xxxxxxxxxxxxxx, xxxxxxxxx xxxxxx xxxx xxxxxxx xxxxxxxxx xxxxxxx. Xxxx xxxxxxx xxxxxxxx jsou xxxxx, xxx-xx xx zdůvodnit. Xxxxxxxx xxxxxxxxxxxxxxxxx se xxxx nedoporučuje, neboť xx xxxxx mohla xxx xxxxxxxxxx xxxxxxxx xxxxx xxxxx x xxxxxx prostřednictvím xxxxxxxxx xxxxxxx. Maximální xxxxx xxxxxxxx, xxxxx xxxx xxx xxxxxxxx xxxxx xxxxxxxxx xxxxxx nebo xxxxxxxx, xxxxxx xx xxxxxxxxx xxxxxxxxxxx xxxxxxx. Xxxxx xx xxxxx xxxxxxxxx 2 ml/100 x xxxxxxx hmotnosti. Xxxxxxx vyšších objemů, xxx je xxxxxxx xxxxx, xxxx xxx xxxxxxxxxx. Xx na xxxxxxxx x žíravé xxxxx, xxxxx xxxxxxx xxx vyšších xxxxxxxxxxxxx xxxxxxxx xxxxxxxx xxxxxx, xx xxxx být xxxxxxxxxxx xxxxxxxxxx xxxxxx xxxxxxxxxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxx objem xxx xxxxx xxxxxxxx xxxxx.
1.5.6 Příprava xxxxxxxxx xxxxx
Xxxxxxx xxxxx xx xxxxxxxxxx x xxxxxxxxxxxx xxxxxx zpravidla 12 xx 16 hodin xx podání xxxxx. Xxxxxxxxxx xxxxxxxx xxxxxxxx xxxxxx (xxxxxx dvě xx xxxxx xxxxxx xx xxxxxxxx) xx xxxxxxxx, xxxx-xx xx 12 xx 16 xxxxxxxx xxxxx xxxxxxxxx xxxxxxx. Xxxxx však xxx použity xxxx xxxx xxxxxx, xxxx-xx xxxxxxxxxx xx xxxxxxx xxxxxxxxxxxxxxxxx xxxxx.
Xxxxxxxxxx kultury xxxxxxxxx xxxxx savců xx zpravidla xxxxxxxxx xxxxxxx xxxxx kolagenasou xx situ x xxxxxx se, aby xx xxxxxxx xxxxxxxxxxx xxxxxxx xxxxx zachytily xx vhodném xxxxxxx. Xxxxxxx buňky x xxxxxxxxx kontroly by xxxx xxxxxxxxx xxxxxxxxxxxxxxx (5) alespoň 50 %.
1.5.7 Xxxxxxxxx XXX
Xxxxxxx xxxxxxxxx xxxxxxx xxxxx xxxxx xx xxxxxxx xxxxxxx dobu, např. xxx xx xxx xxxxx, xxxxxxxx x xxxxxx xxxxxxxxxxx 3H-TdR. Xx konci xxxxxxxxx xxxx xx xxxx xxx xxxxxx z xxxxx xxxxxxxxxx x xxxxx xxxx xxxxx xxx xxxxxxxxxx s xxxxxx xxxxxxxxxxx přebytek xxxxxxxxxxx thymidinu, xxx xxxx snížena xxxxxxxxxxxxxxx xxxxxxxxxxxxx ("xxxx chase"). Xxxxx xx poté xxxxxxx, xxxxxx a xxxxxx. Xxx delší xxxxxxxxx xxxx xxxxxx xxx xxxxxxx xxxxxxxxxxxxx xxxxxxxx. Preparáty xx xxxxxx xx autoradiografické xxxxxx, xxxxxxxx xx x xxxxx (xxxx. x chladu 7 xx 14 dnů), xxxxxxxx xx, xxxxxx x xxxxxxxxx xx xxxxxxxxxx zrna stříbra. X každého xxxxxxx xx připraví dva xx tři xxxxxxxxx.
1.5.8 Xxxxxxx
Xxxxxxxxx xx měly xxxxxxxxx dostatečný xxxxx xxxxxxxxxxxx xxxxxxxxxx xxxxx, xxx mělo xxxxxxxxx XXX xxxxxxxxx xxxxxxx. Xxxxxxxxx xx pod xxxxxxxxxxx prohlédnou xx xxxxxx xxxxxx xxxxxxxxxxxx (xxxx. xx xxxxxxx, xxxxxxxx úroveň značení xxxxxxxxxxxxx xxxxxxxx).
Xxxx xxxxxxxxx xxx xx xxxx xxx preparáty xxxxxxxx. Xxxxxxxxx xx vyšetřuje 100 buněk xx xxxxx xxxxx alespoň xx xxxx preparátů; xxxxxxxxx xxxx xxx 100 xxxxx/xxxxx xx xxxx být xxxxxxxxxx. Xxx xxxxxxxx xxx xx xxxxx x X-xxxx xxxxxxxxxxx, xxx xxxxx buněk x X-xxxx xxxx xxx xxxxxxxxxx.
Xxxxxxxx 3X-XxX inkorporovaného xx jader x xxxxxxxxxx morfologicky xxxxxxxxxx xxxxx xxxxxxxx xxxxxxxxxxx xxx xxxxxxx by xxxx být xxxxxxxxx xxxxxxx xxxxxxx.
Xxxxx buněk xx xxxxxxx x xxxxx xxx xxxxxxxxxxxxxx xxxxxxxx xxxxŭx (xx) x x xxŭxxxxxxx xxxxx xxx x xxxxxxxxxxxxxxxxx xxxxxxxxx (xx) xxxxxxxxxxxxxx xxxxŭx. jako xxxxxxx xx xx xxxxxxx xxx počet xxxxx pro xxxxxxxxxx xxxxxxxxx xxxxxx cytoplasmy, xxxx xxŭxxxxx hodnota xxxx xx xxx xxxxxxx vybraných xxxxxxx x xxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxx. po xxxxxxxxxxxxx zdŮvodnění xxxxx xxx použity x xxxx xxxxxxx stanovení xxxxx xxxxx (např. xxxxxxxx xxxxxx xxxxx) (6).
2. XXXXX
2.1 XXXXXXXXXX XXXXXXXX
Xxxx xx xxx xxxxxxx údaje xxx xxxxxxxxxx preparáty a xxxxxxx. Údaje xx xxxx xxx xxxx xxxxxxx xx formě xxxxxxx. Xxxxxxxxx xxxxxxx XX xx hodnoty XX xx xxx xxx xxxxxxxx xxx xxxxxx xxxxx, xxx xxxxx xxxxx x xxx xxxxxx dávku x čas xxxxx xxxxx zrn odpovídajících xxxxxxxx xxxxxx (NNG). Xxxxxxxx jsou počítány "xxxxxxxxxx" xxxxx, xxxx xx xxx xxxxxxxx xxx xxxxxxxxxx "opravovaných" xxxxx odůvodněna x xxxxxxxx xx xxxxxxxxxxx xxxx xxxxxxxxxx xxxxxxx x negativních kontrolách. Xxxxxxxxx výsledky mohou xxx zhodnoceny xxxxxxxxxxxxx xxxxxxxx. Xxxx-xx být xxxxxxx, xxxx by xxx xxxxxxxxxxx xxxxx xxxxxxx x xxxxxxxxxx xxxx xxxxxxxxxx xxxxxx.
2.2 XXXXXXXXX X INTERPRETACE XXXXXXXX
Xxxx xxxxxxxx xxxxxxxx xxx pozitivní xxxx xxxxxxxxx xxxxxxx patří:
|
pozitivní |
i) |
hodnota XXX xxxx xxx xxxxxxxx xxxxxx, xxxxx xx zdůvodněna xx xxxxxxx xxxxxxxxxxx údajů xxxxxxxxxx; |
|
xxxx |
xx) |
xxxxxxx NNG je xxxxxxxx xxxxx xxx xxxxxxx xxx xxxxxxxxx xxxxxxxx; |
|
xxxxxxxxx |
x) |
xxxxxxx XXX leží xx xxxxxxxxx prahové xxxxxxx xxxx pod xx; |
|
xxxx |
xx) |
xxxxxxx NNG xxxx xxxxxxxx xxxxx xxx xxxxxxx pro souběžnou xxxxxxxx. |
Xxxx xx xxx xxxxxxxxx biologická xxxxxxxxx xxxxx, xx. měly xx být xxxxx x xxxxx parametry, xxxx xxxx xxxxxxxxxxx xxxxxx, xxxxx xxxxx x odpovědi x xxxxxxxxxxxx. Při xxxxxxxxx xxxxxxxx xxxxxxx xxxxx xxx použity xxxx xxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxx. Xxxxxxxxxxx xxxxxxxxxx xx však xxxxxx xxx jediným určujícím xxxxxxxx pro xxxxxxxxx xxxxxxx.
Xxxxxx xxxxxxx xxxxxxxxxxx xxxxxxxx jasně pozitivní xxxx xxxxxxxxx výsledky, x xxxxxxxxxxx případech xxxxxxxx xxxxxx xxxxx xxxxxxxx konečný výrok x aktivitě xxxxxxxx xxxxx. Xxxxxxxx xxxxx xxxxxx xxxxxxxxxx xxxx xxxxxx xxx ohledu xx to, xxxxxxxx xx xxxxxxxxxx opakován.
Pozitivní xxxxxxxx xxxxxxx xx XXX v xxxxxxxxx xxxxxxx xxxxx in xxxx znamenají, že xxxxxxxx xxxxx xxxxxxxx x jaterních xxxxxxx xxxxx in xxxx xxxxxxxxx XXX, xxxxx xxx xxxxxxx xxxxxxxxxxxx xxxxxxxx XXX xx xxxxx. Xxxxxxxxx výsledky xxxxxxxxx, xx xxxxxxxx xxxxx za xxxxxxxx xxxxxxx xxxxxxxxxx poškození XXX, xxxxx lze xxxxxxxxx xxxxx xxxxxxxx.
Xxxx xx být xxxxxxxxxxx xxxxxxxxxxxxxxx, x jakou xx xxxxxxxx xxxxx xxxxxxx do krevního xxxxx popř. xx xxxxxx xxxxx (xxxx. xxxxxxxxx toxicita).
3. XXXXXX
XXXXXXXX X XXXXXXX
Xxxxxxxx o xxxxxxx xxxx obsahovat xxxx xxxxxxxxx:
Xxxxxxxxxxxx/xxxxxxxxx:
- xxxxxxxxxx xxxxx xxxxxxxx,
- xxxxxxxxxxx x xxxxxxx xxxxxxxx xxxxx v xxxxxxxxxxxx/xxxxxxxx, xx-xx xxxxx.
Xxxxxxxxx xxxxxxx:
- xxxxxxx xxxx/xxxx,
- xxxxx, xxxxx x xxxxxxx xxxxxx,
- xxxxx, xxxxxxxx xxxxx, strava atd.,
- xxxxxxxxxxxx xxxxxxxx xxxxxx xx xxxxxxx xxxxxxx, xxxxxx xxxxxxx xxxxxxx xxxxxxxxx, xxxxxxx hodnoty x xxxxxxxxxx odchylky xxx každou xxxxxxx.
Xxxxxxxx xxxxxxxx:
- pozitivní x xxxxxxxxx (xxxxxxxxx/xxxxxxxxxxxx) xxxxxxxx,
- xxxxx xx studie xxx xxxxxxxx rozsahu, xxxxx byla xxxxxxxxx,
- xxxxxxxxxx xxxxxxxxx xxxxxx xxxxx,
- xxxxx o xxxxxxxx xxxxxxxx xxxxx,
- xxxxx x xxxxxxxx xxxxxxxx látky,
- xxxxxxxxxx xxxxxxx podávání,
- xxxxxxxxx xxxxxx xxxxxxx, xxx xx xxxxxxxx xxxxx xxxxxxx xx xxxxxxxx xxxxx xxxx xx xxxxxx tkáně,
- xxxxxxxx xxxxxxxx mezi koncentrací xxxxxxxx xxxxx x xxxxxx xxxx xxxx (xxx) xx xxxxxxxxxxxx xxxxx (xx/xx xxxxxxx xxxxxxxxx/xxx),
- podrobné údaje x kvalitě krmiva x vody,
- xxxxxxxx xxxxx xxxxxxx expozice x xxxxxx,
- xxxxxx xxxxxxxxx toxicity,
- xxxxxx xxxxxxxx a xxxxxxxxx xxxxxxxxx buněk,
- xxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxx,
- xxxxx xxxxxxxxx a počet xxxxxxxxxxx buněk,
- kritéria xxxxxxxxx,
- kritéria klasifikace xxxxxx xx xxxxxxxxx, xxxxxxxxx nebo xxxxxxxxxxx.
Xxxxxxxx:
- xxxxxxx hodnoty xxxxx xxx odpovídajících xxxxxxxx xxxxxx a xxxxx xxx odpovídajících xxxxxxxxxx, x xxxxx počet xxx, jednotlivě xxx xxxxxxxxx, xxxxxxx x xxxxxxx,
- podle xxxxxxxx xxxxxxxxx odpovědi xx xxxxx,
- xxxxxxxx xxxxxxxxxxx xxxxxxxxx,
- xxxxxx toxicity,
- xxxxx x souběžné xxxxxxxxx (xxxxxxxxxxxx/xxxxxxxxx) x xxxxxxxxx xxxxxxxx,
- xxxxxxxxx xxxxx o negativní (xxxxxxxxxxxx/xxxxxxxxx) x xxxxxxxxx xxxxxxxx s xxxxxxxxx, xxxxxxxxx hodnotami a xxxxxxxxxxxx xxxxxxxxxx,
- počet xxxxx "opravovaných" xxxxx, xx-xx stanoven,
- xxxxx xxxxx x S-fázi, xx-xx xxxxxxxx,
- xxxxxxxxxxxxxxx xxxxx.
Xxxxxx xxxxxxxx.
Xxxxxx.
4. XXXXXXXXXX
1) Xxxxx, X. Xxxxxxx, X. X., Xxxxxxxxx, X., Xxxxxx, X. X. (1985), Xx Xxxxxxxxxx xx xxx Xx xxxx Xxx. Xxxxxxxxxx DNA Xxxxxx Xxxxx, Xxxxxxxxxx Xxx., 156, 1-18.
2) Butterworth, X. X., Xxxxx, X., Xxxxxxxx, X., Xxxxxxxx, X., Xxxxxxxx, X., Xxxxxx, G., Xxxxxxxx, X. (1987), X Xxxxxxxx xxx Xxxxx xxx xxx Xx xxxx Xxx Xxxxxxxxxx XXX Repair Xxxxx, Xxxxxxxxxx Res., 189, 123-133.
3) Xxxxxxxx, X. X., Xxxxxx, X., Xxxxx, X., Xxxxxxx, X. X., Xxxxxxxxx, B., Xxxxxxx, X. X., Xxxx, X. W., Mitchell, X. xx X. (1993), In xxxx Xxx Liver XXX Xxxxx, in: Kirkland X. J., Xxx X., (xxx), Xxxxxxxxxxxxx Xxxxxxxxxxxx Tests: XXXX Xxxxxxxxxxx Xxxxxxxxxx. UKEMS Xxxxxxxxxxxx xx Xxxxxxxxxx xxx Xxxxxxxxxxxx Xxxxxxx. Xxxxxx. Part II xxxxxxx, Cambridge Xxxxxxxxxx Xxxxx, Cambridge, Xxx Xxxx, Xxxx Xxxxxxx, Xxxxxxxxx, Xxxxxx, 52-77.
4) Xxxxx, X., Xxxx, X. X., Xxxxxx, X., Xxxxxxxxx. X., Xxxxxxxxx, B., Doolittle, X. X., Furihata, X., Xxxxxxx, X., XxXxxxx, X. X., Xxxx, X. (1993), Xxxxxxxxxxxxxxx xxx xxx Xxxxxxxxxxx xx XXX Xxxxx In vitro xxx Xx xxxx, Xxxxx. Res., 312, 263-285.
5) Xxxxx, X., Xxxxxxx, X., Xxxxxxxxxx, X., Xxxxxxxxxxxx-Xxxxxx, X. (1993), Xxxxxxxxxx xx xxx Xxxxxxxx Xxxxxxx xxx Xxxxxxx Xxxxxxxxx xxx xxx Attachment xx Xxxxxxx Xxxxxxxx Xxx Xxxxxxxxxxx Used xxx xxx In xxxx/Xx xxxxx XXX Xxxxxx Xxxxx (XXX), Xxxxxxxxxx Xxx., 291, 21-27.
6) Xxxxxxxx, X. X., Tyson, X. X., Xxxxxxxxxxx, X. X. (1982), Xxxxxxxxx xx Genotoxic Xxxxxxxxxxx xx the In xxxx/Xx xxxxx Xxxxxxxxxx XXX Xxxxxx Xxxxx, Xxxxxxx.Xxxxxxx. 4, 553-562."
XXXXXXX 5
XXXXXX POŽADAVKY XX XXXXXXXXXXX X XXXXXXXXXX XXXXXXXXXXXX XXXXX X PŘÍPRAVKŮ
Viz xxxxxxxx Xxxxxx 2001/59/XX, Xx. xxxx. X 332, 28. 12. 2000, x. 81.
PŘÍLOHA 6
"
XXXXXXX XX
XXXX X
xxxxxxxx xxxxxxxx se xxxxxxx xxxxxxxx xxxxx xxxxxxxx dětmi
Kromě xxxxxxxxxx xx. 22 xxxx. 1 písm. x) xxxx xxxxxxxx, musí xxx xxxxx o xxxxxxxxx xxxxxx obsahující xxxxx, x nimiž xx xxxxxxx riziko xxx xxxxxxxxxx (Xx; X 65) x xxxxx jsou xxxxxxxxxxxxx x xxxxxxxx xxxxx xxxx 3.2.3 xxxxxxx XX této směrnice, x výjimkou xxxxx xxxxxxxxx xx trh xx formě xxxxxxxx xxxx v xxxxxxxx xxxxxxxxxx xxxxxxxxxxx rozprašovačem, xxxxxxxx xxxxxxx xxxxxxxx xxxxx xxxxxxxx xxxxx.
1. Xxxxxxxxx uzavíratelné obaly
Uzávěry xxxxxx xxxxx otevření xxxxx použité xx xxxxxxxxx xxxxxxxxxxxxxx xxxxxxx xxxx xxxxxxxx xxxxxxxxx xxxxx ISO 8317 (xxxxxx xx dne 1. xxxxxxxx 1989) "Xxxxx odolné dětem — Xxxxxxxxx xx xxxxxxxxx xxxxxxxxxxxx obaly x xxxxxx xxxxxx xxxxxxxx" přijatou Xxxxxxxxxxx xxxxxxxxxx xxx xxxxxxxxxxx (XXX).
2. Xxxxxxxxx xxxxxxxxxxxxxx xxxxx
Xxxxxxx xxxxxx xxxxx xxxxxxxx xxxxx použité xx xxxxxxxxx neuzavíratelných xxxxxxx musí splňovat xxxxxxxxx normy XXX XX 862 (xxxxxx x března 1997) "Xxxxx — Obaly xxxxxx dětem — Xxxxxxxxx x zkušební xxxxxxx xxx xxxxxxxxx xxxxxxxxxxxxxx xxxxx jiných xxx xxxxxxxxxxxxxxx výrobků" xxxxxxxx Xxxxxxxxx výborem xxx xxxxxxxxxxx (XXX).
3. Xxxxxxxx
1. Prokázání shody x xxxx uvedenými xxxxxxx xxxxx xxxxxxxxxx xxxxx xxxxxxxxxx, které xxxxxxx xxxxxxxx xxxxx xxxx XX 45000.
2. Xxxxxxxxxx xxxxxxx
Xx-xx xxxxxx, xx xxxx je xxxxxxxxxx xxxxxxxx pro xxxx, xxxxx xx xxxxxxx xxxxxx x xxxxxx bez pomoci xxxxxxxx, nemusí být xxxxxxx xxxxxxxxx.
Xx xxxxx xxxxxxxxx xxxxxxxxx x xxxxx existují xxxxxxxxx xxxxxx x xxxxxxxx x bezpečnosti xxxxxxx xxx xxxx, xxxx xxxxxxxxxxxx xxxxx xxxxxxxxx, xxx xxxxx odpovědná xx uvedení xxxxxxx xx xxx xxxxxxxxxx xxxxxxxxxx vydaný xxxxxxxxxx xxxxx xxxx. 3 xxxx 1 konstatující, xx xxx
- xxx xxxxxxx je xxxxxx, xx xxx xxxx xxxxxxxx zkoušet xxxxx xxxx xxxxxxxxx xxxxx XXX a XXX,
xxxx
- xx xxxxxx xxx xxxxxxx x xxx xxxxxxx xxxxxxxxxxx xxxxx xxxx xxxxxxxxx xxxxx.
XXXX X
Xxxxxxxx týkající se xxxxxxxxxxxx výstrah
Technické specifikace xxx xxxxxxxxxx výstrahy xxxx xxx v xxxxxxx x xxxxxx XX XXX 11683 (xxxxxx x xxxx 1997) "Xxxxx — Xxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxx — Požadavky".
"